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ABSTRACT 
In the United Kingdom, the number of patients waiting to receive a kidney transplant far 
outstrips the supply of donor organs, thereby making some form of rationing inevitable. The 
criteria for rationing can be made explicit in the design of a kidney allocation scheme, which 
typically aims to achieve a balance between efficiency, defined as maximising health 
benefits from a limited resource, and equity in the distribution of that resource. In the past, 
kidney allocation schemes have focussed on waiting time as one of the criteria to promote 
equity in access to transplantation. Over time, increasing emphasis has been placed on 
closer tissue matching between recipients and donors after this was shown to result in 
better post-transplant outcomes. More recently, there has been recognition of variability in 
the quality of donor kidneys such that not all donor kidneys will result in equally good 
survival outcomes and not all patients will derive the same benefit from a given donor 
kidney. This thesis describes the development of a patient-level simulation model that 
compares five different approaches to allocating kidneys from across the equity-efficiency 
spectrum. Emphasis is placed on characterising heterogeneity in the data inputs that are 
used to inform the simulation. This is achieved by using various regression modelling 
strategies to analyse patient-level data to facilitate prediction of costs, health-state utilities 
and survival conditional on covariates such as age, comorbidities and treatment modality. 
For each allocation scheme, the simulation model reports total costs, life years and quality-
adjusted life years across the patient population. The simulation model can be used to 
quantify not only the magnitude of health gains associated with moving from one kidney 
allocation approach to another, but also the impact in terms of equity in access to 
transplantation and the distribution of outcomes across different patient groups. The 
outputs of the simulation can be used to inform discussions about equity-efficiency trade-
offs in the design of a kidney allocation policy. 
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1. INTRODUCTION 
1.1. Background 
Established renal failure (ERF) is a condition of abnormal kidney structure or function 
defined by a glomerular filtration rate (GFR) persistently below 15 mL/min per 1.73m2.1 
Treatment of patients with ERF may involve renal replacement therapy (RRT) with dialysis 
or kidney transplantation. Mortality rates for patients with ERF are high, in part due to a 
lack of access to RRT.2 The number of patients awaiting a transplant far exceeds the 
number of available donor kidneys while the costs of dialysis consume a disproportionate 
amount of the healthcare budget.1 Because of this, interventions for the treatment of ERF 
are a frequent subject of interest for economic evaluation. There have been numerous 
comparisons of the costs and health outcomes associated with transplantation and dialysis 
(Appendix 1) and most of these have demonstrated that kidney transplantation results in 
improved survival and better quality of life at lower cost.3-13 However, given the shortage of 
donor kidneys, increasing the rate of kidney transplantation is not a straightforward 
endeavour. In the United Kingdom, the number of deceased donor transplants carried out 
between 1 April 2014 and 31 March 2015 was 2069, while the number of patients registered 
on the kidney transplant list was 5686.14  
1.2. Kidney allocation in the United Kingdom 
The scarce supply of donor kidneys has given rise to the need to ration for reasons other 
than the constraints of a finite healthcare budget. In many countries including the UK, the 
criteria for rationing of kidneys is made explicit through the design of a national allocation 
scheme.  
In 1989, transplant centres in the UK started to exchange kidneys retrieved from deceased 
adult donors to facilitate beneficial tissue matching on the basis of human leukocyte antigen 
(HLA) compatibility. The interest in tissue matching was motivated by evidence at the time 
that graft survival was superior in transplants with no mismatches between donors and 
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recipients on the three HLA groups (A, B and DR) or only one mismatch at the HLA-A or 
HLA-B loci and no mismatch at the HLA-DR locus.15 While the introduction of HLA matching 
could potentially improve survival gains through a shared scheme for kidney allocation, one 
possible consequence of the focus on immunological compatibility was that patients with 
rare HLA types, especially those occurring in minority ethnic groups, could end up waiting 
longer for a transplant.16  
A revised kidney allocation scheme was introduced at the national level in 1998. The 
emphasis on HLA matching was retained, but the scheme was expanded to include a 
number of other factors.17 It included the introduction of three tiers based on the degree of 
HLA matching (zero mismatched, favourably matched, non-favourably matched). Within 
the first and second tiers, the scheme gave priority to paediatric patients and patients with 
rare HLA types. Other factors that formed part of the points-based scoring system were 
donor-recipient age difference, waiting time and a factor to control for the balance of 
exchange of kidneys between transplant centres. Approximately 50% of kidneys from 
deceased donors (following brain-stem death) were allocated through the 1998 national 
scheme.17 However, improved data collection in the period following implementation of the 
1998 scheme provided evidence of the unintended consequences of HLA matching on 
equity in access to transplantation. For example, a review of patients registered on the 
waiting list between January 1998 and December 2000 showed variations in median 
waiting times of patients from different ethnic groups, with Asian and black patients waiting 
approximately twice as long (4 years) as white patients (2 years).18 
In 2006, a new national scheme was introduced, through which all kidneys from deceased 
donors following brain-stem death are now allocated. The primary objective of the 2006 
scheme was to improve equity of access to transplant among all patients regardless  of 
geographical location, ethnicity and rareness of HLA type and, so far as biologically 
possible, blood group and degree of sensitisation to HLA specificities.19 The number of tiers 
under the 2006 scheme was expanded to five. Tiers A and B are designated for zero 
mismatched paediatric patients (with highly sensitised patients and HLA-DR homozygous 
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patients in Tier A). Within Tiers A and B, patients are prioritised on the basis of waiting time. 
Tier C includes zero mismatched adult patients (highly sensitised and HLA-DR 
homozygous), while remaining zero mismatched adult patients and favourably matched 
paediatric patients are in Tier D. Tier E contains all other patients. Within Tiers C through 
E, patients are prioritised using a points system based on seven factors19: 
1. Waiting time 
2. HLA match and age combined 
3. Donor-recipient age difference 
4. Location of patient relative to donor 
5. HLA-DR homozygosity 
6. HLA-B homozygosity 
7. Blood group match (to achieve equity between group O and B patients) 
Since 2014, kidneys from deceased donors following circulatory death which meet certain 
criteria are allocated regionally according to the same principles as the 2006 scheme for 
kidneys from deceased donors following brain-stem death.20 At the time of preparation of 
this thesis, the 2006 national kidney allocation scheme was undergoing a review to assess 
the scope for making changes with respect to its underpinning philosophy, design and the 
criteria for HLA matching.21 
1.3. Newer concepts in kidney allocation 
Historically, the deceased donor kidney allocation system in the United States was primarily 
based on the principle of “first-come, first-served,” in which candidates were prioritised 
based on waiting time.22 In 2003, the Organ Procurement and Transplantation Network 
(OPTN) charged the Kidney Transplantation Committee with reviewing the allocation 
system to better understand its limitations and identify possible approaches for 
improvement.23 This precipitated a 10-year period of intensive research and public 
consultation to debate proposals for new concepts in kidney allocation. Of the proposed 
new concepts, there were two that garnered the most attention and scrutiny: life years from 
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transplant (LYFT) and longevity matching. LYFT is the concept of ranking transplant 
candidates by the estimated incremental years of life that are expected to be achieved with 
a transplant from a specific donor. The underlying calculation is computed as the difference 
in median lifespan with the transplant compared with remaining on dialysis.24 Thus the 
objective of the LYFT concept is to achieve the best use of donated kidneys by allocating 
each one to the patient who is expected to gain the most. In contrast, the concept of 
longevity matching is meant to address the fact that donor kidneys are of variable quality, 
with organs from donors over the age of 60 at greater risk of graft failure.25 Allocating high 
quality kidneys with long potential longevity to candidates with shorter potential longevity 
and vice versa can result in unrealised graft years and high re-transplant rates. Under the 
concept of longevity matching, the Kidney Donor Profile Index (KDPI) uses information on 
ten donor factors to estimate the quality of the kidney relative to other donors. Similarly, the 
Estimated Post-Transplant Survival (EPTS) score is calculated to risk-stratify transplant 
candidates (Table 1.1). The 20% of candidates with the highest EPTS scores are prioritised 
to receive the best 20% of kidneys according to the KDPI.26,27   
Table 1.1 Variables included in the calculation of the KDPI and EPTS scores in the 
revised US kidney allocation system 
Kidney Donor Profile Index28 Estimated post-transplant survival29 
1. Age 
2. Height 
3. Weight  
4. Ethnicity 
5. History of hypertension 
6. History of diabetes 
7. Cause of death 
8. Serum creatinine 
9. Hepatitis C virus status 
10. Circulatory death 
1. Age 
2. Length of time on dialysis 
3. Prior transplant 
4. Diabetes status 
 
During the consultation process for the proposed new allocation concepts, the Committee 
received feedback and concerns that the LYFT approach was made up of too many 
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variables and that an allocation system which attempted to match each kidney and patient 
was too complicated and unpredictable to be feasible.30 Concerns were also raised that a 
LYFT approach to kidney allocation would result in fewer older patients and those with 
diabetes receiving transplants.31  
In June 2013, the OPTN Board of Directors approved a new kidney allocation policy for the 
US that incorporates the concept of longevity matching based on the KDPI and EPTS 
scores. This revised system became effective in December 2014.31 
1.4. Simulation as a tool to study kidney allocation schemes 
Given the complexity and far-reaching consequences of organ allocation schemes, it is 
useful to be able to test the impact of potential changes to a system prior to implementing 
a new policy. Computer-based simulation modelling offers a method of doing so. Using 
historical data, it is possible to imitate the process of kidney allocation and test the impact 
of making various changes to data inputs and assumptions on model outputs.  
To be feasible, simulation modelling requires making simplifying assumptions in 
comparison to the real system that it is attempting to imitate.19,32 Oversimplification of a 
model can give a misleading or inaccurate depiction of reality, but added complexity can 
lead to the requirement for more data. In the case of kidney allocation, where a randomised 
experimental study design is not possible to implement, simulation is potentially the only 
way to assess in advance the impact of making changes to the system.  
The application of simulation modelling to study kidney allocation schemes is well 
established. However, the majority of the published literature is presented as an exploration 
or investigation of the impact of a single clinical factor on the allocation process or a 
description of a new allocation policy in which simulation methods or results are not the 
main feature, but are reported as supporting evidence. A summary of this body of literature, 
including the methods used to identify these papers, can be found in Appendix 2. Only four 
studies were identified in which the development of a model to simulate different 
approaches to deceased donor kidney allocation was the primary focus. These simulation 
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exercises have explored a variety of conceptual approaches to kidney allocation, with a 
common stated objective of exploring trade-offs between equity and efficiency.33-36 Table 
1.2 summarises the allocation approaches that were considered and the key results 
presented in each of these four simulation examples.  
The most notable difference among these simulation studies is the extent to which they 
capture the consequences of the allocation process by reporting characteristics of patients 
who received a transplant by attempting to link these characteristics to post-transplant 
outcomes such as survival. The earliest of the studies by Yuan et al. was essentially a 
representation of the flow of patients through five different allocation algorithms. Results 
were presented as a snapshot of the number of patients arriving, the number of transplants 
performed and the number of patients still waiting at 1, 3, 6, and 10 years. Yuan et al. did 
not report individual patient characteristics such as age, but did report the distribution of 
HLA mismatches and the distribution of waiting time at each time point for each allocation 
algorithm.33 The study by Jacquelinet et al. compared the results of a simulated allocation 
process to observed data in terms of transplantation access rates, but also described the 
transplant recipient population in terms of median waiting time, distribution of HLA 
mismatches, the distribution of donor and recipient ages and a measure of matched donor 
potential. However, no attempt was made to link these characteristics to post-transplant 
outcomes.36  
The study by Higgins et al. compared three kidney allocation algorithms, including the 
national UK transplant algorithm that was introduced in 1998, an equality (lottery) algorithm 
and an efficiency algorithm that was designed to allocate kidneys based on greatest 
expected transplant survival time. Transplant survival was estimated as a prognostic risk 
score that reflected 5-year graft survival based on a Cox proportional hazards model and 
included recipient age, diabetes status and HLA mismatching as covariates. This results of 
this simulation study provided a more detailed comparison of patient characteristics for 
each of the three allocation schemes. For example, in addition to HLA matching and 
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Table 1.2 Summary of kidney allocation simulation models in the published literature 
Author, year and country Allocation concepts explored Main results or outcomes 
Yuan et al. 33 
1994, Canada 
Comparison of 5 approaches: 
1. HLA matching 
2. Equal weight to HLA matching and waiting time 
3. Equal weight to HLA matching and waiting time + priority if HLA match 
score above a certain threshold 
4. First come, first transplanted 
5. Minimum HLA match requirement + first come, first transplanted 
 Number of patients arriving 
 Number of transplantations performed 
 Number of patients still waiting for transplant 
 Number of discarded kidneys 
 Mean HLA-match scores 
 Number of days from registration to transplantation 
 Number of days from registration for patients still waiting 
Zenios et al. 34 
1999, United States 
Comparison of 4 approaches: 
1. First-come, first-transplanted 
2. United Network of Organ Sharing algorithm in 1995 (points based on 
waiting time, rank in the waiting list, tissue mismatch, panel reactivity, 
priority to paediatric patients) 
3. Efficiency-based algorithm to maximise quality-adjusted life 
expectancy 
4. Distributive efficiency to promote equitable allocation among African-
American candidates 
 Patient survival rates (5-year) 
 Quality-adjusted life expectancy (at 10 years) 
 Median waiting time 
 Likelihood of transplantation 
Higgins et al. 35 
2005, United Kingdom 
Comparison of 3 approaches: 
1. Equality method (lottery) 
2. Efficiency algorithm (prioritise patients based on risk score reflecting 5-
year graft survival) 
3. 1998 UK national kidney allocation algorithm 
 Characteristics of transplanted patients (e.g. HLA matching, 
waiting time, proportion paediatric, highly sensitised and 
diabetic) 
 Mean prognostic score (based on recipient age, diabetes and 
HLA match)  
Jacquelinet et al. 36 
2006, France 
Allocation according to a score based on: 
1. Waiting time 
2. Recipient matchability (prioritise patients with lowest potential to find a 
match) 
3. HLA matching 
4. Age match 
 Characteristics of transplanted patients (HLA mismatch level, 
matched donor potential, waiting time, donor-recipient age 
distribution)  
 Transplantation access rates (number of transplanted patients 
among total number of candidates) 
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median waiting time, this study reported the proportion of paediatric, diabetic and highly 
sensitised transplant recipients. Furthermore, for each allocation scheme, the mean   
prognostic risk score for the population of transplant recipients was reported. The results 
demonstrated that based on prognostic risk scores, the efficiency algorithm would result in 
significantly better outcomes than the national UK transplant algorithm, and the national UK 
transplant algorithm would result in significantly better outcomes than the equity approach. 
Notably however, diabetic patients did not receive transplants under the efficiency allocation 
algorithm.35  
Of the four simulation studies identified, Zenios et al. provided the most extensive 
exploration of post-transplant outcomes using United States Renal Data System (USRDS) 
reports to estimate 5-year survival and mean quality-adjusted life years (QALYs) in addition 
to median waiting time and likelihood of transplantation. However, in the base case, QALY 
estimates were restricted to the 10-year time horizon of the simulation rather than reflecting 
lifetime estimates. A 100-year simulation was performed as a sensitivity analysis. Both the 
10-year and 100-year analyses showed that the efficiency-based allocation algorithm 
yielded the highest average QALYs, followed by the distributive efficiency approach, with 
the national algorithm (at the time) and the first-come, first-transplanted approaches 
producing the lowest average QALYs. Another notable contribution of the paper by Zenios 
et al. is that it demonstrated the ability to present simulation results such as median waiting 
time and survival by patient subgroups based on age, gender and ethnicity.34 
1.5. Research problem and objective 
The objective of this thesis is to use simulation modelling to compare the consequences of 
alternative approaches to kidney allocation from across the equity-efficiency spectrum in 
the UK context. It will differ from previously published simulation studies in the following four 
ways: 
1. By exploring newer kidney allocation concepts of interest that have emerged since the 
simulation exercise reported by Higgins et al.  
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2. By estimating outcomes in terms of both life years and QALYs from a lifetime time 
horizon 
3. By estimating costs associated with different approaches to kidney allocation 
4. By quantifying the impact of the different allocation concepts in terms of equity in access 
to transplantation and equity in outcomes.  
The simulation model in this thesis will compare five different allocation concepts. The 
current UK national kidney allocation scheme introduced in 2006 has been described in the 
literature as a compromise between efficiency (maximisation of outcomes) and equity (fair 
access to transplant).19 Taking the current allocation scheme as a midpoint along the equity-
efficiency spectrum, the simulation model will explore two alternative allocation concepts 
towards the equity end of the spectrum, namely random allocation and allocation based on 
waiting time. The simulation model will also explore the consequences of newer allocation 
concepts towards the efficiency end of the spectrum, namely longevity matching and QALY-
maximisation. The five kidney allocation concepts of interest are briefly summarised in 
Table 1.3. By exploring different allocation concepts from opposite ends of the equity-
efficiency spectrum, it will be possible to quantify the minimum and maximum health benefit 
that can be derived from a scarce supply of kidneys as well as the costs and health gains  
Table 1.3 The five kidney allocation concepts that will be explored in the simulation 
exercise 
Scheme Allocation concept 
1 Random allocation: subject to blood group and tissue compatibility, the kidney 
is randomly allocated to a patient on the waiting list 
2 Waiting time: subject to blood group and tissue compatibility, the kidney is 
allocated to the patient with the longest waiting time 
3 Current (2006) national kidney allocation scheme 
4 Longevity matching: top 20% of patients with the longest expected post-
transplant survival are prioritised to receive top 20% kidneys based on risk 
score 
5 Utility-maximising: for each patient, calculate the difference between expected 
QALYs if the patient were to receive the transplant and expected QALYs if the 
patient were to remain on dialysis; allocate the kidney to the recipient with the 
greatest expected QALY gain 
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associated with moving from one allocation approach to another, while also considering the 
potential trade-off in terms of equity. It is anticipated that the results of this simulation 
exercise can be used to inform discussions about equity-efficiency trade-offs in the design 
of a national kidney allocation policy.  
The intended objective and outputs of this simulation exercise have several important 
implications for the methods and overall modelling approach. Firstly, the allocation process 
takes place at the level of individual donor kidneys and patients, and therefore this 
simulation exercise will ideally be based on recent UK-specific sources of patient and donor 
characteristics to inform the matching process. Secondly, the more data that are available 
on patient characteristics, the greater the potential to capture variability in costs, survival 
and health-state utilities across patients. This will necessitate the use of various regression 
modelling techniques to generate estimates of costs, survival and health-state utilities 
conditional on patient characteristics of interest. Thirdly, in order to estimate post-transplant 
outcomes in terms of life years, QALYs and costs from a lifetime time horizon, some form 
of extrapolation of survival data will be necessary and will require consideration of different 
survival analysis methods to those that have been described in previous simulation 
exercises.  
This emphasis of this thesis is on the application of data and methods from across a number 
of different disciplines to demonstrate the feasibility of modelling alternative approaches to 
kidney allocation and to estimate the consequences of these different approaches in terms 
of costs, health benefits and equity. It will draw on knowledge, concepts and methods from 
clinical transplantation, health economics, operations research and medical statistics. Given 
the interdisciplinary nature of this thesis, Box 1.1 provides clarification of some key terms 
with an explanation of how they will be used in context of this thesis.37 
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1.6. Data sources 
The inclusion of both costs and QALYs as outputs in this simulation has important 
repercussions for the data inputs required to inform the model. An individual patient 
simulation approach is necessary in this exercise because the process of kidney allocation 
takes place at the patient level. A number of different sources of patient-level data will be 
used to develop separate models to predict costs, survival and health-state utility values, 
as well as to simulate the transplant patient and donor kidney characteristics (Table 1.4). 
Each data source is described in more detail in subsequent chapters. A brief introduction to 
the Access to Transplantation and Transplant Outcome Measures (ATTOM) study is 
provided here. 
 
 
Box 1.1 Explanation of key terms used in this thesis 
Efficiency: this term has many different meanings in the published literature; in the 
context of this thesis, efficiency is used to refer to maximisation of health benefits 
(QALYs) from a scarce resource 
Equity: this term has many different meanings in published literature; in the context of 
this thesis, equity is used to refer to the distributive consequences of a resource 
allocation decision and will specifically be considered in terms of equity in access to 
transplantation and equity in outcomes (QALYs) resulting from transplantation 
QALY: the quality-adjusted life year is an outcome measure that combines mortality and 
morbidity into a single index and is a widely used measure of health improvement in the 
UK for guiding resource allocation decisions37 
Simulation: a computer-based modelling exercise to imitate the process of matching 
donor kidneys with recipients under different allocation algorithms and to estimate the 
consequences of that process 
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Table 1.4 Summary of key data sources for the simulation exercise 
Parameter Source 
Costs  
RRT costs (dialysis and 
transplantation) 
Payment by Results tariff 
Hospital costs for RRT patients UK Renal Registry / Hospital Episode Statistics 
linked dataset 
Survival   
Post-transplant survival UK Transplant Registry (historical cohort) 
Graft failure UK Transplant Registry (historical cohort) 
Waiting-list survival  UK Transplant Registry (historical cohort) with 
linkage to UK Renal Registry (for dialysis dates) 
Health-state utility values  
EQ-5D-5L index scores ATTOM study 
Simulation inputs  
Waiting-list patient characteristics ATTOM study 
Donor characteristics NHSBT (historical cohort)  
 
1.7. The ATTOM study 
The ATTOM study is a prospective observational study involving collection of demographic, 
treatment and health outcomes data from all 72 renal units (including 23 transplant units) in 
the UK.38 The study recruited incident transplant patients aged 18-75 years between 1 
November 2011 and 30 September 2013. Prevalent patients on the transplant waiting list 
were selected as matched controls on a 1:1 basis for every incident transplant patient 
according to the following criteria: transplant centre, age (within five years), time on the 
waiting list, type of transplant (kidney only or combined kidney and pancreas), diabetes 
status (as a primary renal diagnosis) and dialysis status at the time of listing.38 The ATTOM 
study is a key data source for the simulation exercise, providing information on patient 
characteristics, as well as health-state utility values derived from the administration of the 
EQ-5D-5L questionnaire. The ATTOM study did not include collection of patient-level cost 
data. In addition, the maximum duration of follow-up for patients in the study is 
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approximately 4 years, therefore alternative sources of historical data from the UK 
Transplant Registry were needed to estimate long-term survival for the simulation exercise. 
The work contained in this thesis forms the basis of one of the five main research aims of 
the ATTOM study.38 The other four aims of the study were to: 
1. Identify patient-specific and centre-specific factors that influence access to the 
transplant waiting list and to transplantation 
2. Identify patient-specific and centre-specific factors that influence survival on the waiting 
list and after transplantation 
3. Evaluate quality of life (QOL) for patients on dialysis and after transplantation and 
including detailed analysis of patient-reported outcomes measures in several patient 
subgroups 
4. Utilise survival, health status, QOL, treatment satisfaction and costs to determine an 
optimal organ allocation policy. 
The ATTOM study is led by a multidisciplinary team of researchers who have met 
approximately every 6 months throughout the study to discuss progress and share results 
for each of the five workstreams. Work on this PhD commenced in July 2012, after patient 
recruitment for the ATTOM study had already begun. I was not directly involved in primary 
data collection but led on all other aspects of the research described in this thesis. This 
included: 
1. Outlining the decision problem, including reviewing relevant literature and identifying 
which allocation concepts to include in the simulation exercise 
2. Identifying data sources (costs, historical survival data) beyond the ATTOM study that 
were required to inform the simulation model  
3. Conducting analyses of patient-level cost, survival and health-state utility data 
4. Conceptualising, designing and coding the simulation model  
5. Reporting results and drafting the research papers contained within this thesis. 
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1.8. Structure of the thesis 
This thesis has been written as a series of individual research papers that can each be read 
as stand-alone pieces of work but are integrated in this thesis into a single document. Figure 
1.1 provides an overview of what each chapter contributes to the development of the 
simulation model and to the overall thesis. 
 
Figure 1.1 Contribution of each chapter to the thesis 
 
 
The structure of the remainder of this thesis is as follows: Chapters 2, 3 and 4 describe the 
separate regression analyses of patient-level data to predict cost, survival and health-state 
utility values respectively. Estimates from these regression models are then used as data 
inputs in the simulation model. Chapter 5 describes the structure of the kidney allocation 
simulation model and presents key results in terms of total costs and QALYs associated 
with each allocation scheme. Chapter 6 highlights equity considerations, discusses the 
contributions, implications and limitations of this work and identifies potential areas for future 
research.  
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2. COST ESTIMATES 
2.1. Introduction   
The simulation model comparing alternative allocation schemes will estimate lifetime costs 
for each patient from the perspective of the NHS as one of its main outcomes. This chapter 
of the thesis describes the data source, methods and final regression models that will be 
used to estimate annual costs for each patient during their time spent on the waiting list and 
following transplantation in the simulation model, dependent on individual characteristics 
such as age, gender and comorbidities. 
2.2. Research Paper 1 
The increasing cost of managing patients with ERF has received considerable attention and 
is an issue that many health systems around the world are facing.1,39 A number of countries, 
including the UK, have developed systems of bundled payments or fixed tariffs for the 
reimbursement of dialysis services.40 Given the high rate of comorbidities among patients 
with ERF, they are likely to incur additional costs beyond the provision of dialysis or, in the 
case of transplant recipients, beyond the transplant surgery itself.41  
Robust patient-level data sources for analysing healthcare costs outside of the United 
States are somewhat scarce. Prospective collection of cost data is often prohibitively 
expensive or limited to short time periods and small sample sizes. However, one-time 
linkage of the UK Renal Registry and the Hospital Episode Statistics (HES) datasets in 
England presented a rare opportunity to analyse variations in hospital costs for a large 
cohort of patients starting RRT over a period of several years. The richness of the linked 
dataset has facilitated the development of regression models to predict variations in costs 
by treatment modality, number of years on treatment, age and comorbidities. Research 
Paper 1, entitled Predicting hospital costs for patients receiving renal replacement therapy 
to inform an economic evaluation, describes the characteristics of this dataset, highlights 
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some of the considerations and challenges encountered in the analysis of cost data and 
presents the final regression models.42  
Appendix 3 contains an additional research paper, entitled Understanding cost of care for 
patients on renal replacement therapy: looking beyond fixed tariffs, which combines 
estimates of hospital costs from Research Paper 1 with fixed costs of RRT and illustrates 
how total costs vary for three hypothetical patient examples.43 
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ABSTRACT 
Objective: To develop a model to predict annual hospital costs for patients with established 
renal failure, taking into account the effect of patient and treatment characteristics of 
potential relevance for conducting an economic evaluation, such as age, comorbidities and 
time on treatment. The analysis focuses on factors leading to variations in inpatient and 
outpatient costs and excludes fixed costs associated with dialysis, transplant surgery and 
high cost drugs. 
Methods: Annual costs of inpatient and outpatient hospital episodes for patients starting 
renal replacement therapy in England were obtained from a large retrospective dataset. 
Multiple imputation was performed to estimate missing costs due to administrative 
censoring. Two-part models were developed using logistic regression to first predict the 
probability of incurring any hospital costs before fitting generalised linear models to estimate 
the level of cost in patients with positive costs. Separate models were developed to predict 
inpatient and outpatient costs for each treatment modality. 
Results: Data on hospital costs were available for 15,869 incident dialysis patients and 
4,511 incident transplant patients. The two-part models showed a decreasing trend in costs 
with increasing number of years on treatment, with the exception of dialysis outpatient costs. 
Age did not have a consistent effect on hospital costs, however, comorbidities such as 
diabetes and peripheral vascular disease were strong predictors of higher hospital costs in 
all four models. 
Conclusion: Analysis of patient-level data can result in a deeper understanding of factors 
associated with variations in hospital costs and can improve the accuracy with which costs 
are estimated in the context of economic evaluations. 
Key words: hospital costs, established renal failure, regression, patient-level data, two-
part model 
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INTRODUCTION 
Analysts involved in carrying out economic evaluations in healthcare are accustomed to 
expending considerable effort and resources to identify, collect, extrapolate and synthesise 
data to fully quantify the health consequences associated with different treatment 
approaches. However, when it comes to estimating costs, it is not uncommon to rely on 
readily available average unit costs that are assumed to apply uniformly to all patients or 
remain constant over time. If appropriate data sources can be identified, it would be 
beneficial to develop more precise ways to estimate the costs of managing patients with 
specific diseases and to explore in greater detail whether costs vary with patient and 
treatment characteristics of interest.  
Treatment options for patients with established renal failure (ERF) include dialysis and 
transplantation. For many patients, transplantation can result in increased life expectancy 
and better quality of life compared to chronic dialysis [1]. Treatment of ERF is resource 
intensive for the health service. While costs of dialysis and transplantation may be 
comparable in the first year of treatment, costs for transplant recipients following surgery 
drop considerably in subsequent years, while the cost of maintenance dialysis sessions 
remains constant [2]. In England, payment to providers for dialysis is covered under a fixed 
national tariff as part of the Payment by Results (PbR) system. A similar approach is 
underway to introduce a fixed tariff for kidney transplant surgery. However beyond the 
provision of dialysis and transplant surgery, patients with ERF may incur additional hospital 
costs for monitoring of their condition, management of comorbidities or infections, 
maintenance of vascular access or post-operative follow-up. More than half of patients 
starting renal replacement therapy (RRT) have one or more comorbidities [3] which, 
alongside other factors such as age, may lead to variations in hospitalisation rates [4].  
As part of the Access to Transplantation and Transplant Outcome Measures (ATTOM) 
study, an economic evaluation is being developed to compare alternative schemes for 
allocating kidneys to patients with ERF who are awaiting transplantation in the United 
Kingdom. Different approaches to kidney allocation can impact the length of time that 
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patients with different characteristics will spend on dialysis. This in turn can have an impact 
on the level of costs incurred. The objective of the current analysis is to develop a model to 
predict hospital inpatient and outpatient costs for patients with ERF, taking into account 
relevant patient and treatment characteristics such as age, comorbidities and time on 
treatment. The analysis will focus on characterising variations in hospital costs and 
therefore exclude fixed costs associated with routine dialysis, transplant surgery and high 
cost drugs. The approach to this analysis is guided by the intended use of the results as 
inputs for an economic evaluation that will compare the costs and consequences of 
alternative kidney allocation schemes.  
METHODS 
Data source 
In England, all admissions to NHS hospitals are captured in the Hospital Episode Statistics 
(HES) dataset. Patient demographics and information about type and length of stay are 
collected during a patient's time at hospital and are submitted to allow hospitals to be paid 
for the care they deliver [5]. Data on inpatient admissions have been routinely captured in 
HES since 1998 and outpatient attendances since 2003 [6]. The UK Renal Registry (UKRR) 
collects data provided by renal centres on all incident renal replacement therapy (RRT) 
patients, including demographics, comorbidity and treatment information [7]. In 2011, a pilot 
study was carried out in which UKRR data was linked to HES data for incident patients ≥18 
years of age who started dialysis or received a kidney transplant between 2002 and 2006. 
HES only began collection of outpatient attendances in April 2003, therefore the sample for 
this analysis was restricted to those patients who started RRT between April 2003 and 
December 2006. The linked dataset captured hospital episodes until the end of December 
2009 [6].  
Linkage of HES data to UKRR data enhances the variables available in the separate 
datasets and facilitates analysis of hospital episodes by RRT modality.  Taking the start of 
dialysis or date of transplant surgery as the index date, annual costs for each patient were 
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generated by applying the appropriate 2011-12 PbR tariff to each inpatient admission 
(based on healthcare resource group) or outpatient appointment (based on treatment 
function code) [8]. Four separate datasets were created to capture dialysis inpatient, dialysis 
outpatient, transplant inpatient, and transplant outpatient costs in order to allow for the effect 
of explanatory variables to differ between regression models depending on treatment 
modality or type of hospital activity. The datasets included all inpatient admissions and 
outpatient appointments for any reason except routine dialysis or kidney transplant surgery. 
High cost drugs such as immunosuppressants following transplant surgery or drugs to treat 
renal anaemia were not captured in the dataset. The analysis therefore includes hospital 
costs that may not be specifically related to the management of patients’ ERF. It was not 
considered feasible to distinguish between hospital episodes that were related versus those 
that were unrelated to the management of ERF in the current analysis. However in 
economic evaluations, the focus is on the difference in costs between alternative strategies, 
therefore the inclusion of both related and potentially unrelated costs is appropriate, 
provided the same approach is taken for both the dialysis and transplant datasets. 
Administrative censoring 
Linkage of the HES and UKRR datasets came to an end in December 2009 and therefore 
no further data on hospital episodes were available beyond this date. This means that in 
any given year, some patients may only have observed costs for a portion of the year due 
to administrative censoring. Rather than exclude these patients from the analysis, multiple 
imputation was performed to predict costs in the year that administrative censoring occurred 
under an assumption that data were missing at random (MAR). In the first instance, costs 
were imputed for the full year in which administrative censoring took place. However, since 
observed costs were available in these patients for part of the year up until the day of 
censoring, an additional step was taken to generate a hybrid imputed cost in order to make 
use of as much observed data as possible. Hybrid imputed costs were generated by using 
the imputed cost for the full year to calculate an imputed cost per day and multiplying this 
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by the number of unobserved days for that year, to which the observed costs up until the 
day of censoring were then added.  
Model development 
Hospital costs in all four datasets were positively skewed with a varying proportion of zero-
cost patients who had no inpatient admissions or outpatient visits in a given year. In order 
to accommodate these characteristics of the data, a two-part model approach for the 
regression analyses was taken [9-11]. Part one involved using logistic regression analysis 
to predict whether or not patients would incur any hospital costs. Part two involved fitting a 
generalised linear model (GLM) for those patients with positive costs [12, 13]. The cluster 
option was used to take into account the dependence between multiple observations (years 
of cost data) for the same patient.   
Initially age, sex, treatment modality, year since starting RRT, and co-morbidities were all 
entered into the regression models. Dummy variables were also entered for events 
including renal recovery, transplant and death in the dialysis models and for graft failure 
and death in the transplant models.  Since costs are expected to be elevated for several 
months prior to death, inclusion of a dummy variable only in the year of death would not 
capture the full impact of this event on costs in patients who die at the beginning of the year. 
Therefore, an additional variable was created to indicate if death occurred in the first half of 
the following year. Backwards elimination was used to inform variable selection using a P-
value threshold of 0.2 [14]. 
Model performance was assessed by comparing predicted and observed mean costs and 
calculating the root-mean-square error (RMSE) [10]. In addition, models that were 
developed based on multiply imputed values were compared to the results of complete-
case analyses to provide reassurance of the validity of the MAR assumption. 
All analyses were conducted in Stata (Version 13, Stata Corp, College Station, Texas, 
USA). 
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RESULTS 
Data on inpatient admissions and outpatient appointments during the first year after 
initiation of RRT were available for 15,869 dialysis patients and 4,511 transplant patients. 
Administrative censoring occurred in approximately 11% of transplant patients in the first 
year after surgery and increased to more than 50% by year six. In contrast, no administrative 
censoring was present in the first three years of the dialysis patient sample, but ranged 
between 20% and 50% in years three through six. Tables 1a and 1b summarise the number 
of patients included in the dataset by number of years following initiation of RRT. 
 
Table 1a Dialysis dataset: number of patients by years on dialysis  
Dialysis patients 
Years 
on 
dialysis 
With complete 
year costs 
With part-year costs due to 
TOTAL 
PATIENTS Death Transplant Recovered  
Admin 
censoring  
1 11,894 (75%) 2,798 (17%) 750 (5%) 427 (3%) 0 (0%) 15,869 
2 9,472 (80%) 1,488 (12%) 803 (7%) 123 (1%) 0 (0%) 11,886 
3 7,501 (79%) 1,246 (13%) 634 (7%) 84 (1%) 0 (0%) 9,465 
4 4,205 (56%) 1,063 (14%) 476 (6%) 40 (1%) 1,713 (23%) 7,497 
5 1,932 (48%) 659 (16%) 248 (6%) 31 (1%)  1,188 (29%) 4,058 
6 596 (33%) 274 (15%) 101 (6%) 5 (0%) 823 (46%) 1,799 
 
 
Table 1b Transplant dataset: number of patients by years following transplant  
Transplant patients 
Years 
following 
transplant 
With complete 
year costs 
With part-year costs due to TOTAL 
PATIENTS Graft failure Death Admin censoring 
1 3,625 (80%) 266 (6%) 122 (3%) 498 (11%) 4,511 
2 2,881 (80%) 116 (3%) 33 (1%) 585 (16%) 3,615 
3 2,150 (75%) 48 (2%) 35 (1%) 644 (22%) 2,877 
4 1,355 (63%) 38 (2%) 22 (1%) 735 (34%) 2,150 
5 717 (53%) 16 (2%) 17 (1%) 605 (44%) 1,355 
6 239 (33%) 9 (1%) 21 (3%) 448 (63%) 717 
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Part one: logistic regression analyses 
Excluding patients with only part-year cost data, the proportion of patients with zero costs 
in the first year of RRT was lower in the outpatient setting (2% for dialysis patients and 1% 
for transplant patients) than in the inpatient setting (24% for dialysis patients and 27% for 
transplant patients). Logistic regression analyses showed that, compared to the first year of 
RRT, the odds of incurring any hospital costs in subsequent years was lower, with the 
exception of outpatient appointments for transplant patients (Tables 2a and 2b).  
The presence of comorbidities was associated with higher odds of incurring inpatient costs 
in both dialysis and transplant patients, but the association was less consistent in the 
outpatient setting.  
Part two: generalised linear models 
Generalised linear models with an identity link function and gamma distribution were fitted 
to the subset of patients with non-zero costs. The model results shown in Tables 3a and 3b 
include imputed values that were generated using the hybrid approach to predict missing 
costs due to administrative censoring.  
Mean inpatient costs were higher for dialysis patients compared to transplant patients with 
a trend towards decreasing costs in both patient groups over time. In contrast, mean 
outpatient costs were initially higher in the first year for transplant patients compared to 
dialysis patients, but decreased at a faster rate in subsequent years with dialysis outpatient 
costs overtaking those of transplant patients by the third year. 
For dialysis patients, cost differed by treatment modality; haemodialysis was associated 
with higher costs in the inpatient setting, whereas peritoneal dialysis was associated with 
higher costs in the outpatient setting. Similarly in the transplant datasets, living donor 
transplants were associated with lower costs in the inpatient setting (although not 
statistically significant) and higher costs in the outpatient setting.  
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Table 2a Logistic regression analysis to predict whether or not dialysis patients incur any 
hospital costs 
 
 n (%) 
patient-years 
Dialysis inpatient  Dialysis outpatient 
 
Odds ratio 95% CI  Odds ratio 95% CI 
Constant  2.34* (2.18, 2.51)  18.09* (15.62, 20.95) 
Age group       
< 50 years 10,608 (21%) Reference   Reference  
50-64 years 13,330 (26%) 0.98 (0.91, 1.05)  1.26* (1.08, 1.46) 
65-75 years 15,393 (30%) 0.91* (0.85, 0.97)  1.01 (0.88, 1.17) 
> 75 years 11,243 (22%) 0.87* (0.81, 0.94)  0.82* (0.70, 0.96) 
Sex       
Male 31,450 (62%) Reference   - - 
Female 19,124 (38%) 1.10* (1.05, 1.16)  - - 
Years on dialysis       
1 15,869 (31%) Reference   Reference  
2 11,886 (23%) 0.59* (0.56, 0.62)  0.80* (0.73, 0.88) 
3 9,465 (19%) 0.50* (0.47, 0.52)  0.69* (0.62, 0.76) 
4 7,497 (15%) 0.58* (0.54, 0.62)  0.76* (0.67, 0.85) 
5 4,058 (8%) 0.61* (0.56, 0.67)  0.71* (0.62, 0.82) 
6 1,799 (4%) 0.65* (0.57, 0.74)  0.72* (0.59, 0.89) 
Dialysis modality       
Haemodialysis 39,730 (79%) Reference   Reference  
Peritoneal dialysis 10,844 (21%) 0.83* (0.79, 0.88)  2.36* (2.07, 2.69) 
Comorbidities       
Myocardial infarction  8,347 (17%) 1.22* (1.14, 1.31)  - - 
Congestive heart 
failure  
8,801 (17%) 1.11* (1.04, 1.19)  0.88* (0.79, 0.98) 
Peripheral vascular 
disease 
8,204 (16%) 1.33* (1.24, 1.42)  1.25* (1.12, 1.41) 
Cerebrovascular 
disease 
5,459 (11%) 1.15* (1.07, 1.24)  0.86* (0.76, 0.97) 
Pulmonary 7,351 (15%) 1.26* (1.17, 1.35)  1.13* (1.01, 1.27) 
Liver 393 (1%) - -  - - 
Diabetes 19,167 (34%) 1.27* (1.21, 1.34)  1.64* (1.48, 1.81) 
Cancer 4,092 (8%) 1.22* (1.11, 1.33)  1.40* (1.20, 1.63) 
Hypertension 31,245 (62%) 1.09* (1.04, 1.14)  1.36* (1.23, 1.49) 
Transplant  3,012 (6%) 1.11* (1.02, 1.21)  0.25* (0.21, 0.29) 
Recovered renal function 710 (1%) 0.82* (0.69, 0.96)  0.12* (0.10, 0.15) 
Death 7,528 (15%) 1.94* (1.81, 2.07)  0.16* (0.15, 0.18) 
Death first half following 
year 
2,521 (5%) 2.61* (2.34, 2.92)  1.16 (0.93, 1.44) 
*p<0.05 
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Table 2b Logistic regression analysis to predict whether or not transplant patients incur 
any hospital costs 
 n (%) 
patient-years 
Transplant inpatient Transplant outpatient 
 
Odds 
ratio 
95% CI Odds ratio 95% CI 
Constant  1.89* (1.65, 2.16) 104.02* (72.08, 150.12) 
Age group      
< 35 years 3,352 (22%) Reference  - - 
36-45 years 3,950 (26%) 0.81* (0.72, 0.92) - - 
46-55 years 3,886 (25%) 0.73* (0.64, 0.82) - - 
> 55 years 4,037 (27%) 0.76* (0.67, 0.87) - - 
Sex      
Male 9,575 (63%) Reference  Reference  
Female 5,650 (37%) 1.35* (1.22, 1.49) 1.53* (1.09, 2.16) 
Years following 
transplant 
     
1 4,511 (29%) Reference  Reference  
2 3,615 (24%) 0.21* (0.19, 0.23) 1.17 (0.85, 1.62) 
3 2,877 (19%) 0.18* (0.16, 0.20) 1.60* (1.06, 2.43) 
4 2,150 (14%) 0.19* (0.17, 0.22) 1.79* (1.06, 3.04) 
5 1,355 (9%) 0.19* (0.16, 0.23) 1.08 (0.64, 1.84) 
6 717 (5%) 0.18* (0.14, 0.22) 1.06 (0.45, 2.51) 
Transplant type      
Deceased donor 9,874 (65%) Reference  Reference  
Living donor 5,351 (35%) 0.82* (0.75, 0.90) 0.71 (0.49, 1.03) 
Comorbidities      
Myocardial infarction 1,238 (8%) 1.47* (1.24, 1.73) - - 
Congestive heart 
failure  
932 (6%) 1.48* (1.22, 1.79) - - 
Peripheral vascular 
disease 
1,676 (11%) 1.87* (1.62, 2.16) 1.56* (1.00, 2.42) 
Cerebrovascular 
disease 
975 (6%) 1.38* (1.16, 1.65) - - 
Pulmonary 2,050 (13%) 1.24* (1.09, 1.40) - - 
Liver 119 (1%) 2.18* (1.37, 3.47) - - 
Diabetes 4,000 (26%) 1.62* (1.46. 1.80) 1.80* (1.21, 2.66) 
Cancer 614 (4%) 1.62* (1.31, 2.01) 3.45* (1.32, 8.99) 
Hypertension 11,251 (74%) 1.33* (1.21, 1.46) - - 
Graft failure 493 (3%) - - 0.02* (0.02, 0.03) 
Death 250 (2%) 1.62* (1.14, 2.31) 0.02* (0.01, 0.03) 
Death first half following 
year 
79 (0.5%) 4.55* (2.47, 8.39) - - 
*p<0.05 
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Table 3a Mean annual costs (£) for dialysis patients (generalised linear model)  
 Dialysis inpatient Dialysis outpatient 
 Coeff 95% CI Coeff 95% CI 
Constant 7782* (7423, 8140) 1379* (1331, 1428) 
Age group     
< 50 years Reference  Reference  
50-64 years -170 (-489, 149) -25 (-79, 29) 
65-75 years -181 (-513, 151) -167* (-219, -115) 
> 75 years -444* (-806, -83) -320* (-376, -264) 
Sex     
Male Reference  - - 
Female 208* (-23, 439) - - 
Years on dialysis     
1 Reference  Reference  
2 -1189* (-1487, -891) -159* (-186, -131) 
3 -1434* (-1729, -1140) -112* (-145, -80) 
4 -1848* (-2166, -1530) -438* (-85, -1) 
5 -1709* (-2099, -1319) -13 (-66, 40) 
6 -2270* (-2774, -1767) 134* (36, 232) 
Dialysis modality     
Haemodialysis Reference  Reference  
Peritoneal dialysis -612* (-838, -385) 334* (296, 373) 
Comorbidities     
Myocardial infarction 390* (96, 683) - - 
Congestive heart failure  321* (58, 584) -40 (-81, 0) 
Peripheral vascular disease 721* (423, 1019) 117* (66, 168) 
Cerebrovascular disease 506* (174, 838) - - 
Pulmonary 412* (128, 696) 46 (0, 93) 
Liver 1682* (-161, 3524) - - 
Diabetes 1191* (929, 1453) 248* (211, 284) 
Cancer - - 139* (72, 206) 
Hypertension - - - - 
Transplant  -1863* (-2140, -1585) -552* (-602, -501) 
Recovered renal function 1293* (513, 2073) -348* (-454, -243) 
Death 2403* (2152, 2654) -377* (-414, -341) 
Death first half following year 4415* (3926, 4904) 200* (138, 262) 
*p<0.05 
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Table 3b Mean annual costs (£) for transplant patients (generalised linear model) 
 
Transplant inpatient Transplant outpatient 
 Coeff 95% CI Coeff 95% CI 
Constant 4735* (4331, 5138) 4053* (3961, 4145) 
Age group     
< 35 years Reference  Reference  
36-45 years -318 (-664, 29) -123* (-193, -53) 
46-55 years -310 (-676, 56) -151* (-224, -78) 
> 55 years -91 (-487, 306) -126* (-195, -57) 
Sex     
Male Reference  Reference  
Female 190 (-76, 455) 126* (76, 175) 
Years following transplant     
1 Reference  Reference  
2 -1576* (-1881, -1271) -2671* (-2731, -2610) 
3 -1919* (-2228, -1611) -2935* (-3000, -2869) 
4 -2138* (-2485, -1790) -3018* (-3088, -2948) 
5 -2061* (-2502, -1620) -3089* (-3166, -3011) 
6 -2654* (-3212, -2096) -3105* (-3204, -3006) 
Transplant type     
Deceased donor Reference  Reference  
Living donor -223 (-486, 39) 130* (78, 182) 
Comorbidities     
Myocardial infarction 641* (145, 1138) 130* (17, 242) 
Congestive heart failure  1248* (646, 1851) 159* (35, 284) 
Peripheral vascular disease 1222* (729, 1715) 256* (157, 354) 
Cerebrovascular disease 898* (271, 1524) 88 (-21, 197) 
Pulmonary 264 (-87, 616) 179* (99, 258) 
Liver 2093* (30, 4155) 524* (200, 849) 
Diabetes 1046* (734, 1359) 593* (515, 671) 
Cancer 485* (2, 969) 273* (134, 411) 
Hypertension 324* (56, 592) 144* (91, 197) 
Graft failure 2438* (1723, 3152) -309* (-451, -167) 
Death 4924* (3726, 6123) -216* (-426, -5) 
Death first half following year 5725* (3350, 8100) 629* (321, 936) 
*p<0.05 
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The increase in mean annual costs associated with various comorbidities ranged between 
£321 - £1,682 in the dialysis inpatient setting and between £264 and £2,093 in the transplant 
inpatient setting. Of the comorbidities included in the final models, peripheral vascular 
disease and diabetes were the only two that were consistently associated with significantly 
higher costs in both dialysis and transplant patients as well as in both inpatient and 
outpatient settings. The proportion of patients in both the dialysis and transplant datasets 
who had peripheral vascular disease was approximately 12% and the proportion who had 
diabetes was approximately 30%. 
Model performance and predicted costs 
Table 4 summarises observed and predicted mean annual cost estimates for each of the 
final two-part models. The results were compared with models that were developed based 
on complete-case analyses, in which patients who were administratively censored were  
Table 4 Observed and predicted mean annual costs  
 
Number of 
observations 
(patient-years) 
Mean costs  
(std dev) 
RMSE 
Dialysis inpatient  
Observed   
46850 
£ 5581 (9440)  
Two-part model complete-case analysis £ 5576 (2120) 9202.92 
Two-part model hybrid imputed costs £ 5578 (2136) 9204.73 
Dialysis outpatient  
Observed   
46850 
£ 1202 (1348)  
Two-part model complete-case analysis £ 1196 (343) 1291.19 
Two-part model hybrid imputed costs £ 1203 (345) 1291.22 
Transplant inpatient  
Observed   
11710 
£ 2398 (4675)  
Two-part model complete-case analysis £ 2390 (1931) 4278.45 
Two-part model hybrid imputed costs £ 2468 (1958) 4279.87 
Transplant outpatient  
Observed   
11710 
£ 2388 (2007)  
Two-part model complete-case analysis £ 2383 (1332) 1459.10 
Two-part model hybrid imputed costs £ 2447 (1386) 1458.98 
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removed from the dataset. In each case, RMSE was found to be similar between the model 
based on complete-case analysis and the model that was developed using multiply imputed 
values.    
As the motivation for the analysis was to predict annual hospital costs that can be used as 
inputs in an economic evaluation, the appendix provides a worked example of how the 
regression results presented above can be used for this purpose. 
DISCUSSION 
Previous examples of economic evaluations that have compared dialysis and 
transplantation as treatment alternatives for patients with ERF have taken a variety 
approaches to estimating costs. For transplant costs, it is common practice to estimate a 
cost for the first year of treatment that reflects the cost of surgery, and then assume a 
constant annual cost to capture resource use such as immunosuppressive therapy or 
outpatient visits in subsequent years [15-20]. For dialysis costs, some studies restrict the 
analysis to the cost of routine dialysis only, while others include the cost of hospitalisations, 
management of complications or drugs. Other than taking into account the cost of vascular 
access at the start of dialysis, annual costs for dialysis patients are often assumed to be 
constant [16, 18]. However, there are examples of economic evaluations that have 
introduced an element of variation in costs among dialysis patients by considering factors 
such as age or time on treatment: de Wit et al [19] presented separate estimates of hospital 
costs by age group based on data collected at 13 Dutch dialysis centres; Haller et al [15] 
analysed patient-level cost data from a hospital in Austria and presented separate cost 
estimates for dialysis patients in the first year, second year and subsequent years of 
treatment.  None of these previous studies have simultaneously considered the impact of 
treatment modality, length of time on treatment, age and comorbidities on costs. 
Collection of patient-level cost data is a resource intensive exercise. The linkage of HES 
data to UKRR data provides a rare opportunity to analyse a large existing dataset to explore 
variations in hospital costs specifically among patients receiving RRT in England. HES is, 
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to our knowledge, the most complete source of routinely collected information on 
admissions and attendances at NHS hospitals in England and linkage to UKRR data 
facilitates simultaneous exploration of multiple patient and treatment-related factors that 
may affect costs. The approach to analysing the linked dataset was guided by both the 
features of the data and the intended use of the results. In this case, the primary objective 
of the analysis was to predict annual costs for patients with different characteristics for use 
as inputs in an economic evaluation.  Additionally, there were three main features of the 
cost data that needed to be addressed: 1) missing data due to administrative censoring, 2) 
the proportion of observations with zero costs and 3) positively skewed distributions.  
Multiple imputation was carried out to address the issue of administrative censoring. 
Multiple imputation has the advantage of making use of all available observed data, while 
allowing for uncertainty about the missing values [21, 22]. In this analysis, the models based 
on complete cases and the models that included imputed values were very similar, providing 
confidence that missing data due to administrative censoring did not bias the estimates of 
cost. This suggests that a complete-case analysis would have been sufficient, but it is 
unclear if this conclusion can be generalised beyond our dataset. There is a growing body 
of literature describing other methods to address the common issue of censoring of cost 
data [23-27]. However, given that the primary objective of the current analysis was to 
estimate annual (as opposed to lifetime) costs and that cost histories detailing the timing of 
individual hospital events were not available in the current extract of the dataset, 
approaches based on survival analysis techniques were not pursued.  
The issues of zero costs and positively skewed distributions were addressed by adopting a 
two-part approach in which a logistic regression was fitted to predict the probability of 
incurring any hospital costs, followed by fitting a GLM to estimate the level of cost for 
patients with at least one admission or visit. A potential advantage of the two-part approach 
is that covariates that are determined to be significant in part one of the model do not have 
to be the same as those that determine the level of cost in part two. In the present analyses, 
there was general consistency in terms of the covariates that were included in part one and 
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part two of the final inpatient cost models, but less agreement in the outpatient setting where 
the percentage of zero costs was lower.   
The results of this analysis highlight a number of findings that are relevant when considering 
variations in hospital costs for patients on RRT in the context of economic evaluation. Firstly, 
while the cost of transplant surgery can be viewed as a one-time event and the cost of 
maintenance dialysis sessions generally remains constant from week to week and year to 
year, hospital costs for patients on RRT showed a decreasing trend over time that extended 
beyond the first two years on RRT. A plausible explanation for this trend is that patients who 
survive longer on therapy are on average fitter and healthier and required fewer hospital 
visits. Secondly, age did not have a consistent effect on costs across all treatment 
modalities and hospital settings and, in contrast to the approach taken in the economic 
evaluation by de Wit et al [19], the current analysis suggests that, controlling for other 
factors, increasing age alone may be associated with lower rather than higher costs. Thirdly, 
many of the comorbidities included in the analysis were found to be significant predictors of 
hospital costs and had a bigger impact than age in the estimation of costs for patients on 
RRT.  
In the absence of evidence to the contrary, it is perhaps most natural to adopt an assumption 
that costs remain constant either over time or between subgroups of patients with different 
characteristics. However, if appropriate patient-level data sources can be identified, a more 
detailed understanding of patient characteristics and treatment factors that influence costs 
can help improve the accuracy with which costs are estimated in the context of economic 
evaluations.  
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APPENDIX: A WORKED EXAMPLE TO PREDICT HOSPITAL COSTS BASED ON THE 
FINAL TWO-PART MODEL 
To estimate annual inpatient costs for a 55-year-old male patient with diabetes who has 
been on haemodialysis for three years: 
Part 1: probability of incurring any inpatient cost > £0 
Taking the natural log of the odds ratios in Table 2a, calculate log odds of incurring any 
inpatient cost 
CONSTANT + (β1 ×  AGEGROUP50 − 64) + (β2 ×  YEAR3) + (β3 ×  DIABETES)  
= 0.850 + (−0.022 × 1) + (−0.702 × 1) + (0.242 × 1) = 0.368 
Calculate probability from log odds 
𝑒𝑥𝛽  (1 + 𝑒𝑥𝛽) =  𝑒0.368  (1 + 𝑒0.368) = 0.591⁄⁄  
Part 2: estimate level of inpatient cost based on coefficients in Table 3a  
CONSTANT + (β1 ×  AGEGROUP50 − 64) + (β2 ×  YEAR3) + (β3 ×  DIABETES) 
= 7782 + (−170 × 1) + (−1434 × 1) + (1191 × 1) = 7368 
Combine parts 1 and 2: multiply estimated level of inpatient cost by probability of incurring 
any cost 
7368 × 0.591 = £4,354 
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3. SURVIVAL ESTIMATES 
3.1. Introduction 
Survival estimates are the main building blocks for the simulation model in two important 
ways: 
1. The longevity matching and QALY-maximising allocation schemes both require a 
method to predict expected post-transplant survival for each patient on the waiting list 
in order to inform prioritisation of patients as part of the kidney allocation process 
2. For all allocation schemes, estimates of post-transplant survival and time to graft failure 
are required to calculate lifetime costs and QALYs for all transplant recipients and 
estimates of waiting-list survival are required to calculate lifetime costs and QALYs for 
all patients who do not receive a transplant. 
This chapter of the thesis describes the approach to fitting survival models to a historical 
cohort of patients from the UK Transplant Registry. Survival analysis in kidney 
transplantation is dominated by the use of Cox regression models.16,44-47 While this 
approach is useful for quantifying treatment effects or determining factors that influence 
relative survival, its usefulness in extrapolating survival beyond the period of observed data 
is limited. Methods to extrapolate and estimate mean patient survival using parametric 
models are becoming increasingly important for informing the development of prognostic 
models and conducting cost-effectiveness analyses.48 Depending on the shape of the 
hazard function, standard parametric models such as the Weibull or exponential may be 
appropriate, but early exploration of the UK Transplant Registry data revealed that standard 
parametric models were unlikely to provide an appropriate fit. This led to the decision to 
explore flexible parametric modelling techniques in order to predict post-transplant survival, 
time to graft failure and waiting-list survival.49 
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3.2. Research Paper 2 
Research Paper 2, entitled Predicting patient survival after deceased donor kidney 
transplantation using flexible parametric modelling, describes the dataset containing 20 
years of historical transplant data and discusses the methodological considerations that 
were encountered in the application of a flexible parametric modelling approach to analyse 
post-transplant survival.50 The richness of the dataset made it possible to develop a survival 
model that included both donor and recipient characteristics, meaning that predictions of 
post-transplant survival in the simulation model reflect the combination of each donor-
recipient pairing.  
The flexible parametric modelling approach described in Research Paper 2 was also used 
to analyse time to graft failure and waiting-list survival. The final fitted models for these 
events are provided in Appendix 4. 
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Background: The influence of donor and recipient factors on outcomes following kidney transplantation is
commonly analysed using Cox regression models, but this approach is not useful for predicting long-term
survival beyond observed data. We demonstrate the application of a flexible parametric approach to fit a
model that can be extrapolated for the purpose of predicting mean patient survival. The primary motivation
for this analysis is to develop a predictive model to estimate post-transplant survival based on individual
patient characteristics to inform the design of alternative approaches to allocating deceased donor kidneys
to those on the transplant waiting list in the United Kingdom.
Methods: We analysed data from over 12,000 recipients of deceased donor kidney or combined kidney and
pancreas transplants between 2003 and 2012. We fitted a flexible parametric model incorporating restricted cubic
splines to characterise the baseline hazard function and explored a range of covariates including recipient, donor and
transplant-related factors.
Results: Multivariable analysis showed the risk of death increased with recipient and donor age, diabetic nephropathy
as the recipient’s primary renal diagnosis and donor hypertension. The risk of death was lower in female
recipients, patients with polycystic kidney disease and recipients of pre-emptive transplants. The final model
was used to extrapolate survival curves in order to calculate mean survival times for patients with specific
characteristics.
Conclusion: The use of flexible parametric modelling techniques allowed us to address some of the
limitations of both the Cox regression approach and of standard parametric models when the goal is
to predict long-term survival.
Keywords: Kidney transplantation, Survival, Multivariable analysis, Flexible parametric model, Extrapolation
Background
Outcomes following kidney transplantation are com-
monly analysed using Cox regression models. Such ana-
lyses have been instrumental for understanding the
influence of both donor and recipient factors on post-
transplant events, such as graft failure and patient
mortality [1–5]. However, the Cox regression approach
places emphasis on estimating relative risk and does not
make any distributional assumptions about the absolute
risk of an event. Therefore, its usefulness in predicting
survival beyond the period of observed data is limited
[6]. Following kidney transplantation, the risk of death is
highest in the period immediately after surgery, but
decreases sharply and then changes direction when the
risk of death starts to gradually increase over time.
While a number of standard parametric models (such as
the exponential, Weibull or loglogistic) are available and
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could facilitate extrapolation of survival data, they are
not flexible enough to accommodate hazard functions
that change direction.
In some situations, we not only want to understand
what factors influence relative survival, but we also want
to predict long-term survival for patients with given
characteristics. Estimates of life expectancy following
transplant are important as a basis for having informed
discussions with individual patients and their relatives.
For decision-making at a population level, estimates of
mean survival are needed to inform cost-effectiveness
evaluations that compare two or more treatment alter-
natives in terms of both lifetime health gains and costs.
There has also been considerable interest in the develop-
ment of survival prediction models and scoring tools for
use in kidney allocation systems. A number of predictive
models have been proposed, such as the Recipient Risk
Score (RRS), Life Years From Transplant (LYFT) and the
Expected Post Transplant Survival (EPTS) score, the
latter which was adopted as a measure alongside the
Kidney Donor Profile Index (KDPI) to facilitate longevity
matching in the revised kidney allocation system ap-
proved by the Organ Procurement and Transplantation
Network in the United States in 2013 [7–11]. The pri-
mary motivation for the current analysis is to develop a
predictive model to estimate post-transplant survival as
a potential approach to inform the design alternative
allocation schemes for deceased donor kidneys in the
United Kingdom.
In order to estimate mean patient survival from ob-
served data, it is desirable to have complete information
about when most or all patients have died. If the data
are not complete, estimates of mean survival will not
reflect the full distribution of survival times and will
likely underestimate true survival [12]. For recipients of
kidney transplants, waiting to observe post-transplant
mortality for a complete cohort of patients would
require several decades of follow-up. To circumvent this
problem, predictive models such as the aforementioned
LYFT approach used estimates of median rather than
mean survival times [8]. In contrast to the mean, median
survival only requires sufficient follow-up to observe
when 50 % of patients have died. However, with gradual
improvements in post-transplant survival, even median
survival can exceed 15 years. The survival models for
LYFT were developed based on transplant recipient data
spanning the period 1987 to 2006, thus highlighting an-
other dilemma: predicting survival times based on data
from patients who received transplants as many as
20 years ago may not accurately reflect the current clin-
ical situation and the data often need to be further
adjusted to reflect improvements in survival over time.
For example, advances in surgical technique, organ pres-
ervation technology, immunosuppressive therapy and
changes in the age and comorbidity profiles of both
donors and recipients all have the potential to influence
post-transplant outcomes.
Unlike the Cox regression approach, flexible parametric
models characterise the baseline hazard directly and can
therefore provide smooth estimates of the hazard and sur-
vival functions for any combination of covariates and can
be used to extrapolate survival beyond the observed data
[6]. The ability to extrapolate also means that it is not ne-
cessary to rely on older historical data simply to have suffi-
cient long-term follow-up to observe enough deaths. By
choosing to focus on data from transplants that have been
carried out more recently, a parametric modelling ap-
proach offers the advantage of allowing us to generate pre-
dictions of mean patient survival that are more reflective
of the characteristics of the current transplant population
and of current clinical practice.
In this analysis, we demonstrate the application of the
flexible parametric modelling approach proposed by
Royston and Parmar [6, 13] to predict mean patient sur-
vival among recipients of kidney transplants from
deceased donors in the United Kingdom. We begin by
describing the dataset and explaining the approach we
took to determine how many years of historical data we
should use to inform model development. We then
present the fitted flexible parametric model and demon-
strate agreement between observed and predicted sur-
vival. Finally, we use the model to extrapolate beyond
the observed data in order to predict mean survival for
patients with a given set of characteristics.
Methods
Data source
NHS Blood and Transplant is the central authority re-
sponsible for managing the UK Transplant Registry, which
records mandatory data for kidney transplants performed
in all transplant centres across the UK [3]. Anonymised
data on all first-time kidney and combined kidney and
pancreas transplants performed between 1993 and 2012
were obtained from the registry. Patients <18 years old at
the time of transplant, recipients of kidneys from living
donors, en bloc and double transplants were excluded
from the analysis, as were recipients of kidneys trans-
planted with organs other than the pancreas.
Determining how many years of transplant data to
include in model development
Kaplan-Meier curves and log-rank tests were used to ex-
plore if there was any evidence of notable shifts in mortality
rates over the 20-year period that would justify controlling
for change over time or potentially restricting the analysis
to more recent years of data. Several approaches for divid-
ing the dataset into cohorts based on year of transplant
were explored, including 5-year intervals, 10-year intervals
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and intervals that coincided with changes to the UK na-
tional kidney allocation scheme in 1998 and 2006. The list
of variables that were routinely recorded in the UK Trans-
plant Registry changed between 1993 and 2012 and so the
availability of key variables was also an important consider-
ation in deciding whether to model survival using all of the
data or to limit the analysis to a more recent subset. Based
on a combination of the above factors, a decision was made
to restrict the development of the flexible parametric model
to patients who received transplants between 2003 and
2012; however, longer-term data from transplants performed
between 1993 and 2002 were used to check the plausibility
of extrapolated survival based on the fitted model.
Explanatory variables
Previous published analyses and prognostic models were
reviewed to identify potential factors for inclusion in the
development of the model to predict post-transplant patient
survival [3, 8, 9]. Recipient factors of interest included age,
gender, ethnicity, primary renal diagnosis, pre-emptive
transplant, waiting time, kidney only versus combined
kidney and pancreas transplant and the calculated reaction
frequency of antibodies to human leukocyte antigen (HLA).
Calculated reaction frequency (cRF) is a measure of the
sensitisation level for each patient and is calculated as the
percentage of donors in a pool of 10,000 UK donors with
whom the patient is HLA antibody incompatible, similar to
the concept of calculated panel reactive antibody [2].
Patients with a cRF between 0 and 9 % were considered non-
sensitised, whereas patients with a cRF ≥ 85 % were classed
as highly sensitised [14]. Donor factors of interest included
age, ethnicity, weight, history of hypertension, diabetes,
circulatory-death versus brain-death donor and cause of
death. Cold ischaemia time and the level of HLA mismatch
were also included. HLA mismatch was graded from level 1
(000-mismatched) to level 4 (poorly matched) as described in
the UK 2006 National Kidney Allocation Scheme [15].
Categorical variables were created for each of these
factors and the univariate effect of each factor on sur-
vival was explored using log-rank tests [16]. After mak-
ing the decision to restrict model development to
patients who received transplants between 2003 and
2012, most variables had either complete or only a small
amount of missing data (<2 %) and therefore we did not
perform imputation in order to facilitate the model fit-
ting process. However, data for two donor factors, hyper-
tension and diabetes, were missing in approximately 8 %
of cases. For these variables, two approaches to handling
missing data were explored. First, in order to retain
these cases during model fitting, additional categories
for missing donor hypertension and donor diabetes
status were created. Second, multiple imputation using
chained equations was performed and results were com-
pared for consistency with the non-imputed dataset.
Fitting the multivariable flexible parametric model
We followed the Royston-Parmar approach to fitting a
flexible parametric model, in which the baseline distribu-
tion is modelled as a restricted cubic spline function of log
time [6, 17]. The first step in the development of the prog-
nostic model was to determine the appropriate complexity
or number of knots to characterise the baseline spline
function and choose a suitable scale (proportional hazards,
proportional odds or probit) [6]. We initially fitted models
on each of the three scales while varying the number of
interior knots from 0 to 4 and inspected the Akaike infor-
mation criterion (AIC) to determine the optimal fit.
For the multivariable model, the data were then split 2:1
into derivation and validation subsets and variable selection
was performed on the derivation dataset using backward
elimination and a p-value threshold of 0.10. We tested select-
ively for clinically plausible interactions and explored the
possibility of time-dependent effects for specific covariates if
log-log plots suggested any departures from proportionality
of hazards over time. We used the model fitted to the
derivation subset to predict survival curves in the validation
subset and compared these graphically. The final model was
then refitted to the combined derivation and validation
dataset and results are reported with the index of concord-
ance (c index) as a measure of discrimination. The c index es-
timates the probability of concordance between predicted and
observed outcomes with a value of 0.5 indicating no predictive
discrimination and a value of 1.0 indicating perfect separation
of patients with different outcomes [18]. The fitted model was
then used to extrapolate survival curves for patients with
given characteristics in order to generate predictions
of mean survival by calculating the area under the curve.
All analyses were conducted in Stata (Version 13, Stata
Corp, College Station, Texas, USA). The flexible para-
metric model was fitted using the stpm2 command [17].
Results
Restricting model development to transplants carried out
between 2003 and 2012
The initial dataset included 23,729 patients who received
a transplant between 1993 and 2012. Kaplan-Meier curves
were plotted for groups defined by year of transplant to
explore if there have been any notable shifts in mortality
rates over the 20-year period of available data. Visual
inspection showed clear separation of survival curves for
patients who received a transplant between 1993 and 2002
versus patients who received a transplant between 2003
and 2012, and this difference was confirmed by a log-rank
test (Fig. 1a). Alternative approaches to dividing the time
period into 5-year intervals (Fig. 1b) or intervals that
coincided with changes to the national kidney allocation
scheme (Fig. 1c) confirmed that mortality rates did not
differ significantly within the last 10 years (between 2003
and 2012) of the dataset; however, improvements in
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survival were seen when comparing mortality rates within
the first 10 years (between 1993 and 2002). In addition to
shifts in survival curves, another important consideration
for the multivariable analysis was the availability of data for
key covariates of interest. For example, data on cold ischae-
mia time has only been consistently recorded in the registry
since 2000 and there were considerable differences in the
proportion of circulatory-death donors between the years
1993 and 2002 (3.7 %) and the years 2003 and 2012
(28.4 %). Therefore based on the observed improvements
in survival and availability of data, a decision was made to
restrict the development of the survival model to those
patients who received transplants between 2003 and 2012.
Univariate analysis
Table 1 summarises the results of univariate survival
analyses by recipient, donor and transplant factors. At a
p-value threshold of 0.05, only three of the factors inves-
tigated did not yield statistically significant differences in
patient survival: cRF, cold ischaemia time and whether
the patient received a kidney only or combined kidney
and pancreas transplant.
Shape of the hazard function and choice of spline
function
Based on AIC, the preliminary flexible parametric model
with the optimal fit was found to be on a proportional
Fig. 1 Kaplan-Meier curves and log-rank tests to explore changes in patient survival between different cohorts based on year of transplant:
(a) 10-year intervals (b) 5-year intervals and (c) intervals that coincide with changes to the national kidney allocation scheme
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Table 1 Univariate survival analysis by recipient, donor and transplant factors for transplants carried out between 2003 and
2012 (N = 12,307)
n % Observed deaths Crude mortality rate % p-value (log-rank test)
Recipient age
18-29 997 8.1 43 4.3 <0.001*
30-39 2034 16.5 115 5.7
40-49 3185 25.9 256 8.0
50-59 3110 25.3 407 13.1
> 60 2981 24.2 682 22.9
Recipient gender
Male 7628 62.0 984 12.9 0.002
Female 4673 38.0 517 11.1
Not reported 6 0.1 - -
Recipient ethnicity
White 9871 80.2 1248 12.6 0.033
Asian 1376 11.2 164 11.9
Other 1049 8.5 90 8.6
Not reported 11 0.1 - -
Transplanted organs
Kidney only 11013 89.5 1368 12.4 0.253
Kidney and pancreas 1294 10.5 135 10.4
Pre-emptive transplant
No 11019 89.5 1406 12.8 <0.001
Yes 1270 10.3 92 7.2
Not reported 18 0.2 - -
cRF
0-9 % 10026 81.5 1229 12.3 0.356
10-29 % 523 4.3 55 10.5
30-84 % 1357 11.0 171 12.6
85-100 % 401 3.3 48 12.0
Waiting time
< 6 months 1941 15.8 243 12.5 0.003*
6 months to <2 years 4129 33.6 538 13.0
> 2 years 6237 50.7 722 11.6
Primary renal disease
Glomerulonephritis 1849 15.0 186 10.1 <0.001
Diabetic nephropathy (type 1) 1705 13.9 230 13.5
Diabetic nephropathy (type 2) 380 3.1 71 18.7
Renal vascular disease 545 4.4 78 14.3
Polycystic kidney disease 1513 12.3 147 9.7
Pyelonephritis 804 6.5 95 11.8
Other 1573 12.8 181 11.5
Not reported 3938 32.0 515 13.1
Donor age
< 40 3650 29.7 306 8.4 <0.001*
40-49 2754 22.4 324 11.8
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hazards scale with 2 interior knots for the spline func-
tion. Before fitting the multivariable model, we com-
pared the preliminary model based on the chosen scale
and number of knots without covariates to the observed
data by examining the shape of the hazard and survival
functions.
The risk of death is highest in the period immedi-
ately following surgery, then drops sharply before it
starts to gradually increase at approximately 2 years
post-transplant. Figure 2 demonstrates the ability of
the flexible parametric model to accommodate a haz-
ard function that is consistent with the shape of the
observed data. This provides reassurance of the
improved fit that can be obtained when using splines
instead of standard parametric models such as the
Weibull or loglogistic shown in Fig. 2 for comparison.
Table 1 Univariate survival analysis by recipient, donor and transplant factors for transplants carried out between 2003 and
2012 (N = 12,307) (Continued)
50-59 3200 26.0 416 13.0
> 60 2703 22.0 457 16.9
Donor type
Brain-death donor 8812 71.6 1117 12.7 0.003
Circulatory-death donor 3495 28.4 386 11.0
Donor hypertension
No 8688 70.6 938 10.8 <0.001
Yes 2525 20.5 386 15.3
Not reported 1094 8.9 179 16.4
Donor diabetes
Negative 10790 87.7 1268 11.8 0.021
Positive 541 4.4 69 12.8
Not reported 976 7.9 166 17.0
Donor weight
< 55 kg 3150 25.6 380 12.1 0.036
55-65 kg 723 5.9 62 8.6
65-75 kg 1721 14.0 215 12.5
75-85 kg 3234 26.3 411 12.7
85-95 kg 1973 16.0 226 11.5
> 95 kg 1342 10.9 168 12.5
Not reported 164 1.3 - -
Donor cause of death
Trauma 1510 12.3 158 10.5 <0.001
Intracranial 7954 64.6 1059 13.3
Other 2843 23.1 286 10.1
HLA mismatch
Level 1 [000] 1485 12.1 193 13.0 0.001*
Level 2 [0 DR + 0/1 B] 4002 32.5 467 11.7
Level 3 [0 DR + 2 B] or [1 DR + 0/1 B] 5192 42.2 624 12.0
Level 4 [1 DR + 2 B] or [2 DR] 1628 13.2 219 13.5
Cold ischaemia time
< 12 hrs 2061 16.8 177 8.6 0.310*
12 to <18 hrs 5859 47.6 691 11.8
18 to <24 hrs 2930 23.8 427 14.6
> = 24 hrs 1264 10.3 186 14.7
Not reported 193 1.6 - -
*log-rank test for trend
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Fitting the multivariable flexible parametric model
The variable selection process to identify significant pre-
dictors of post-transplant survival resulted in the model
shown in Table 2. The results in Table 2 reflect the final
model fitted to the combined derivation and validation
subsets. The risk of death increased with increasing age
of both the recipient and the donor, with a primary renal
diagnosis of diabetic nephropathy (type 1 or type 2 dia-
betes) in the recipient and with the presence of hyper-
tension in the donor. The risk of death was lower for
female transplant recipients, patients with polycystic
kidney disease and patients who received a pre-emptive
transplant. Excluding age, type 1 diabetic nephropathy
was associated with the highest increase in the risk of
death among transplant recipients.
Interaction terms for recipient age and gender, recipi-
ent age and diabetic nephropathy as the primary renal
diagnosis, and donor age and hypertension history were
tested, but none were found to be significant. To allow
for the possibility of time-dependent effects for any of
the covariates in the model, we first examined log-log
plots for any potential departures from the proportional
hazards assumption and identified pre-emptive trans-
plant, type of transplant (kidney only versus combined
kidney and pancreas transplant) and cold ischaemia time
as potentially varying over time. We tested time-
dependent effects for these variables in the flexible para-
metric model, but again none were found to improve
the fit of the model.
Agreement between observed and predicted survival
The c index for the final model was 0.70, comparable to
the value reported in the development of the LYFT
model (0.68) [19]. To assess the predictive performance
of the model, we created five prognostic groups and
used the final flexible parametric model to generate a
mean survival curve for each group and compared this
to the Kaplan-Meier survival curves based on the ob-
served data. Figure 3 shows broad agreement between
predicted mean survival curves and the observed
Kaplan-Meier curves, although there is less agreement
in later years when heavier censoring occurs. The separ-
ation of the curves in Fig. 3 also provides insight into
the magnitude of survival differences among transplant
recipients across the risk spectrum.
Extrapolation beyond the observed time period to predict
mean survival
To demonstrate the value of flexible parametric models
for extrapolation beyond the period of observed data, we
created three hypothetical patient profiles and generated
complete survival curves for each of them. Figure 4
shows the differences in survival curves and predicted
mean survival by calculating the area under the curve
for each patient profile.
Discussion
There are many examples in the transplant literature of
analyses that have examined the influence of various
factors on patient survival following kidney transplant-
ation, most of which are based on Cox regression
models [3–5]. The objective of the current analysis was
to revisit post-transplant mortality using a different
modelling technique that facilitates extrapolation of
survival curves beyond the period of observed data and
allows us to predict mean patient survival times.
Fig. 2 Comparison of smoothed hazard function based on observed data and preliminary flexible parametric model (no covariates) fitted with
spline function (2 interior knots); Weibull and loglogistic models in the accelerated-failure time (AFT) metric are also shown for comparison
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Before fitting a flexible parametric model, we felt it
was important to first consider how much historical data
to include in the development of our model. A conven-
tional approach might be to try and maximise sample
size and number of years of follow-up in order to cap-
ture any changes in the hazard rate over as long a period
as possible; however, we felt that this needed to be
balanced with the objective of developing a predictive
model that reflects current expectations of post-transplant
survival. Although 20 years of historical data on trans-
plants were available for analysis, we chose to restrict
model development to the most recent 10 years for two
main reasons. First, our exploratory analysis of Kaplan-
Meier curves indicated that there had been significant
improvements in survival for patients who received trans-
plants between 2003 and 2012 in comparison to patients
who received transplants between 1993 and 2002. Second,
a wider number of variables that were of potential interest
as predictors in the survival model were only available in
the more recent subset of the data, including sufficient
sample sizes to facilitate a comparison between recipients
of organs from circulatory-death donors and brain-death
donors. Although restricting model development to trans-
plants performed between 2003 and 2012 reduced the
overall sample size and limited the maximum duration of
follow-up to 10 years, it was judged that on balance, an
analysis based on the more recent subset of data would be
a better reflection of current clinical practice and more
appropriate given the intended use of the model for pre-
dicting survival. Quite often the decision about how much
historical data to include in model development is deter-
mined primarily by availability of and access to informa-
tion sources. While the decision that we took to only use
the most recent 10 years of transplant data is not widely
generalisable beyond our analysis, we advocate consider-
ing changes in the clinical context that might influence
survival and using exploratory analysis to provide empir-
ical guidance to inform this decision prior to model
fitting.
A range of potential explanatory variables were consid-
ered during the model development process, but the
final model was reduced to just four recipient factors
(age, gender, primary renal diagnosis and pre-emptive
transplant) and two donor factors (age and hyperten-
sion). Notably, we found no difference in death rates
between recipients of kidneys from circulatory-death
donors in comparison to brain-death donors. In addition,
controlling for type 1 diabetic nephropathy as the primary
renal diagnosis, we found no difference in death rates for
recipients of kidney only transplants compared to recipi-
ents of combined kidney and pancreas transplants. These
findings are broadly consistent with previous UK analyses
based on Cox regression models. For example, Johnson et
al identified recipient age, donor age and diabetes to be
significant predictors of 5-year patient survival [3]. How-
ever, Johnson et al. found that a waiting time of 2 years or
more and hypertension as the primary renal diagnosis in
transplant recipients also significantly increased the risk of
death at 5 years. In the present analysis, hypertension was
grouped with other forms of renal vascular disease as a
Table 2 Final flexible parametric model fitted to combined
derivation and validation dataset showing coefficients for each
of the 3 spline terms for the baseline hazard function and
hazard ratios for significant predictors of post-transplant patient
survival (N = 12,283)
Baseline hazard (log hazard scale) Coefficient p-value 95 % CI
Restricted cubic spline 1 1.03 <0.001 0.97 - 1.09
Restricted cubic spline 2 -0.08 0.001 -0.12 - -0.03
Restricted cubic spline 3 -0.14 <0.001 -0.16 - -0.12
Constant -3.97 <0.001 -4.31 - -3.63
Hazard ratio p-value 95 % CI
Recipient age
18-29 Baseline
30-39 1.15 0.423 0.81 - 1.64
40-49 1.79 <0.001 1.29 - 2.48
50-59 3.22 <0.001 2.35 - 4.43
> = 60 6.56 <0.001 4.79 - 8.98
Recipient gender
Male Baseline
Female 0.89 0.028 0.80 - 0.99
Pre-emptive transplant
No Baseline
Yes 0.66 <0.001 0.53 - 0.82
Primary renal diagnosis
Glomerulonephritis Baseline
Diabetic nephropathy
(type 1)
2.24 <0.001 1.84 - 2.73
Diabetic nephropathy
(type 2)
1.59 0.001 1.21 - 2.09
Polycystic kidney disease 0.81 0.056 0.65 - 1.01
Other 1.28 0.007 1.07 - 1.53
Not reported 1.28 0.004 1.08 - 1.52
Donor hypertension
No Baseline
Yes 1.27 <0.001 1.12 - 1.44
Not reported 1.20 0.023 1.03 - 1.42
Donor age
< 40 Baseline
40-49 1.26 0.004 1.08 - 1.48
50-59 1.26 0.003 1.08 - 1.47
> = 60 1.48 <0.001 1.26 - 1.74
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primary diagnosis, the latter which was also not found
to be a significant predictor of survival by Johnson et al.
The analysis by Johnson et al. was based on a slightly
earlier time period and included patients who received
transplants in the UK between 1995 and 2001; it did not
include recipients of combined kidney and pancreas
transplants or recipients of organs from circulatory-
death donors. With respect to donor factors, the current
analysis reaches similar conclusions to the findings of
Watson et al. in the development of the UK Kidney
Donor Risk Index (KDRI), which identified donor age
group and donor hypertension as the two most
Fig. 3 Comparison of Kaplan-Meier curves based on observed data (solid lines) and predicted mean survival curves based on final flexible
parametric model (dotted lines) by prognostic group
Fig. 4 Extrapolated survival curves with mean predicted survival for three different patient profiles
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important variables with the largest influence on trans-
plant outcomes [20].
The UK Transplant Registry is a rich source of histor-
ical data and among patients who received transplants
after 2002, many of the variables that we explored in our
model had either complete or only small amounts of
missing data. However, the amount of missing data for
variables such as recipient primary renal diagnosis and
donor hypertension potentially introduce an additional
source of uncertainty into our final predictive model.
For donor hypertension, we performed multiple imput-
ation and confirmed that this did not change the effect
of this variable on post-transplant survival estimates.
Nonetheless, information on donor hypertension in the
registry is obtained from various sources, ranging from
medical records to family members, and we were unable
to control for consistency with respect to the definition
of donor hypertension in the dataset. The prominence of
donor hypertension in post-transplant survival models
highlights the importance of improving the completeness
and consistency with which this variable is recorded. In
addition, the registry does not contain information on
other factors such as comorbidities or dialysis history for
transplant recipients, so we were unable to explore the
potential effect of these variables on patient survival in the
current analysis.
Conclusion
The flexible parametric approach to modelling survival
offers several advantageous features. In comparison to
semi-parametric approaches such as the Cox regression
model, fully parametric models characterise the baseline
hazard, which facilitates extrapolation beyond the period
of observed data. In comparison to standard parametric
models such as the Weibull, the use of restricted cubic
splines allows for greater flexibility to accommodate
more complex hazard functions that increase and de-
crease over time and are commonly encountered in
medical research. The objective of this analysis was to
demonstrate the application of a flexible parametric
modelling approach to predict mean survival times for
recipients of kidney transplants. The application of flexible
parametric techniques to estimate mean survival in
patients who are receiving dialysis would facilitate compar-
isons of survival differences between alternative treatment
modalities. In addition to informing cost-effectiveness
analyses, this approach may have a variety of applications,
from the development of prognostic models for informing
discussions with patients about treatment outcomes to the
use of scoring tools as part of organ allocation schemes.
Given the advantages of flexible parametric models, we
feel that it is a particularly useful approach for conducting
multivariable analysis of patient-level observational data
when the goal is to predict long-term survival.
Abbreviations
AIC, Akaike information criterion; cRF, calculated reaction frequency; EPTS,
expected post transplant survival; HLA, human leukocyte antigen; KDPI,
kidney donor profile index; KDRI, kidney donor risk index; LYFT, life years
from transplant; RRS, recipient risk score.
Acknowledgments
The authors are grateful to all the transplant centres in the UK who
contributed data on which this article is based.
Funding
This article presents independent research commissioned by the National
Institute for Health Research(NIHR) under the Programme Grant for Applied
Research (RP-PG-0109-10116) entitled Access to Transplantation
andTransplant Outcome Measures (ATTOM). The views expressed in this
publication are those of the authors and not necessarily those of the NHS,
the NIHR or the Department of Health.
Availability of data and materials
Data for this analysis were obtained from the UK Transplant Registry held
by NHSBlood and Transplant, whose Data Access Policy is available from:
http://www.odt.nhs.uk/uk-transplantregistry/data/data-access-policy/
Authors’ contributions
All authors contributed to the design of the study. MLR obtained the registry
data. BL performedthe analysis and drafted the manuscript. All authors read,
revised and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Observational Research Ethics Committee of
the London School of Hygieneand Tropical Medicine (Ref 6383).
Author details
1Department of Health Services Research and Policy, London School of
Hygiene and Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH,
UK. 2NHS Blood and Transplant, Bristol, UK. 3Department of Surgery,
University of Cambridge and the NIHR Cambridge Biomedical Research
Centre, Cambridge, UK. 4Transplant Unit, Royal Infirmary of Edinburgh,
Edinburgh, UK. 5Richard Bright Renal Unit, Southmead Hospital, Bristol, UK.
6Primary Care and Population Sciences, Faculty of Medicine, University of
Southampton, Southampton, UK. 7Scottish Renal Registry, Glasgow, UK.
8Department of Renal Medicine, Freeman Hospital, Newcastle upon Tyne, UK.
Received: 22 January 2016 Accepted: 16 May 2016
References
1. Morris PJ, Johnson RJ, Fuggle SV, Belger MA, Briggs JD. Analysis of factors
that affect outcome of primary cadaveric renal transplantation in the UK.
HLA Task Force of the Kidney Advisory Group of the United Kingdom
Transplant Support Service Authority (UKTSSA). Lancet. 1999;354:1147–52.
2. Fuggle SV, Allen JE, Johnson RJ, Collett D, Mason PD, Dudley C, et al.
Factors affecting graft and patient survival after live donor kidney
transplantation in the UK. Transplantation. 2010;89:694–701.
3. Johnson RJ, Fuggle SV, O'Neill J, Start S, Bradley JA, Forsythe JL, et al.
Factors influencing outcome after deceased heart beating donor kidney
transplantation in the United Kingdom: an evidence base for a new
national kidney allocation policy. Transplantation. 2010;89:379–86.
4. Summers DM, Johnson RJ, Allen J, Fuggle SV, Collett D, Watson CJ, et al.
Analysis of factors that affect outcome after transplantation of kidneys
donated after cardiac death in the UK: a cohort study. Lancet.
2010;376:1303–11.
5. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA.
Effect of donor age and cold storage time on outcome in recipients of
Li et al. BMC Nephrology  (2016) 17:51 Page 10 of 11
kidneys donated after circulatory death in the UK: a cohort study.
Lancet. 2013;381:727–34.
6. Royston P, Lambert PC. Flexible Parametric Survival Analysis Using Stata:
Beyond the Cox Model. College Station, Texas: Stata Press; 2011.
7. Baskin-Bey ES, Kremers W, Nyberg SL. A recipient risk score for deceased
donor renal allocation. Am J Kidney Dis. 2007;49:284–93.
8. Wolfe RA, McCullough KP, Schaubel DE, Kalbfleisch JD, Murray S, Stegall MD,
et al. Calculating life years from transplant (LYFT): methods for kidney and
kidney-pancreas candidates. Am J Transplant. 2008;8:997–1011.
9. Concepts for kidney allocation 2011, Organ Procurement and Transplantation
Network.
10. A Guide to Calculating and Interpreting the Estimated Post-Transplant
Survival (EPTS) Score Used in the Kidney Allocation System (KAS).
https://optn.transplant.hrsa.gov/media/1511/guide_to_calculating_
interpreting_epts.pdf . Accessed 8 May 2014.
11. Israni AK, Salkowski N, Gustafson S, Snyder JJ, Friedewald JJ, Formica RN,
et al. New national allocation policy for deceased donor kidneys in the
United States and possible effect on patient outcomes. J Am Soc Nephrol.
2014;25:1842–8.
12. Latimer N, NICE DSU. Technical Support Document 14: Undertaking survival
analysis for economic evaluations alongside clinical trials - extrapolation with
patient-level data. 2011. http://www.nicedsu.org.uk. Accessed 8 Dec 2014.
13. Royston P, Parmar MK. Flexible parametric proportional-hazards and
proportional-odds models for censored survival data, with application to
prognostic modelling and estimation of treatment effects. Stat Med.
2002;21:2175–97.
14. Pruthi R, Hilton R, Pankhurst L, Mamode N, Hudson A, Roderick P, et al.
UK Renal Registry 16th annual report: chapter 4 demography of patients
waitlisted for renal transplantation in the UK: national and centre-specific
analyses. Nephron Clin Pract. 2013;125:81–98.
15. Johnson RJ, Fuggle SV, Mumford L, Bradley JA, Forsythe JL, Rudge CJ.
A New UK 2006 National Kidney Allocation Scheme for deceased heart-
beating donor kidneys. Transplantation. 2010;89:387–94.
16. Collett D. Modelling Survival Data in Medical Research 2nd edition ed.
London: Chapman & Hall/CRC; 2003.
17. Lambert PC, Royston P. Further development of flexible parametric models
for survival analysis. Stata J. 2009;9:265–90.
18. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and measuring
and reducing errors. Stat Med. 1996;15:361–87.
19. Wolfe RA, McCullough KP, Leichtman AB. Predictability of survival models
for waiting list and transplant patients: calculating LYFT. Am J Transplant.
2009;9:1523–7.
20. Watson CJ, Johnson RJ, Birch R, Collett D, Bradley JA. A simplified donor risk
index for predicting outcome after deceased donor kidney transplantation.
Transplantation. 2012;93:314–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Li et al. BMC Nephrology  (2016) 17:51 Page 11 of 11
66 
 
4. HEALTH-STATE UTILITY ESTIMATES  
4.1. Introduction  
A number of sources of health-state utility estimates among ERF patients have been 
reported in the published literature.51,52 As a large, prospective study involving all renal and 
transplant centres in the UK, the ATTOM study was an important opportunity to collect 
additional health-state utility estimates that can add to existing knowledge in the following 
ways: 
1. Collection of data using the newer 5-level version of the EQ-5D questionnaire, the EQ-
5D-5L 
2. Measurement of EQ-5D-5L responses in both transplant patients and matched 
controls from the waiting list 
3. Collection of patient and treatment characteristics to facilitate multivariable regression 
analysis to identify factors that may lead to variations in health-state utility values. 
4.2. Research Paper 3:  
Research Paper 3, entitled Estimating health-state utility values in kidney transplant 
recipients and waiting-list patients using the EQ-5D-5L, describes the characteristics of 
transplant recipients and matched controls recruited into the ATTOM study and their EQ-
5D-5L responses converted into index scores. In this paper, because of the structure of the 
simulation model, separate multivariable regression models were fitted to predict health-
state utility values for transplant recipients and matched controls. Note that due to the 
international audience of the target journal for Research Paper 3, the term end-stage renal 
disease (ESRD) is used in place of ERF. 
The health-state utility estimates captured in the ATTOM study will be used to quality adjust 
survival in the simulation model comparing alternative allocations schemes. These values 
will be used not only to estimate pre- and post-transplant QALYs for all patients under all 
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allocation schemes, but also to calculate QALY differences between transplantation and 
dialysis to inform prioritisation of patients on the waiting list under the QALY-maximising 
approach. Box 4.1 provides a worked example to demonstrate the application of the health-
state utility estimates presented in Research Paper 3 to the simulation model. This example 
calculates the expected QALY gain from transplant for two hypothetical patients and 
determines which patient will receive a given donor kidney under the QALY-maximising 
approach to allocation.  
In recognition of the fact that not all covariates captured in the ATTOM study will be relevant 
to other researchers wishing to undertake cost-effectiveness analyses in the ERF patient 
population, Appendix 5 provides a summary of alternate regression models that can be 
used for predicting health-state utility estimates with different combinations of predictor 
variables. 
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Box 4.1 Worked example to compare QALY gains from transplant for two 
hypothetical patients on the waiting list 
In this example, we consider how to allocate a kidney from a 45-year-old donor with no 
history of hypertension to one of two hypothetical patients on the transplant waiting list 
under the QALY-maximisation allocation scheme.  
Patient 1: 55-year-old Asian female, primary renal diagnosis diabetes 
Patient 2: 60-year-old White male, primary renal diagnosis pyelonephritis 
 
Expected post-transplant survival and expected survival on the waiting list for each 
patient can be derived using the predictive models described in Research Paper 2 and 
Appendix 4. Survival estimates in this example are rounded to the nearest full year for 
simplicity.  
Estimates of health-state utility values for each patient can be derived using the 
models presented in Research Paper 3.  
First, we calculate QALYs if Patient 1 receives the transplant: 
 
Expected post-transplant survival in years = 9 
 
Using the regression model from Table 4.3 in Research Paper 3: 
 
Calculate post-transplant health-state utility value: 
= Constant + (EQ-5D at 6 months) + Female + Asian + Diabetes 
= 0.809 + 0.053 – 0.019 – 0.030 – 0.086 
= 0.727  
 
Assuming post-transplant health-state utility remains constant over time, calculate total 
QALYs if patient receives the transplant: 
= 9 x 0.727   
= 6.543 
 
Next, we calculate QALYs if Patient 1 remains on the waiting list (dialysis): 
 
Expected survival on waiting list in years = 4 years 
 
Using the regression model from Table 4.4 in Research Paper 3: 
 
Calculate dialysis health-state utility < year 1: 
= Constant + (Time on dialysis < 1 year) + Female + Asian + Diabetes 
= 0.878 – 0.053 – 0.048 – 0.054 – 0.055 
= 0.668 
 
Calculate dialysis health-state utility year 1-3: 
= Constant + (Time on dialysis 1-3 years) + Female + Asian + Diabetes 
= 0.878 – 0.055 -0.048 -0.054 – 0.055 
= 0.666 
 
Calculate total QALYs if patient remains on the waiting list: 
= (1 x 0.668) + (3 x 0.666) 
= 2.666 
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Repeat the same process to calculate QALYs for Patient 2 and then compare the 
expected QALY gain from transplant for Patient 1 and Patient 2: 
 
Under a QALY-maximisation approach to kidney allocation, Patient 2 would be 
prioritised to receive the kidney. 
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ABSTRACT  
 
Objectives: Previous studies have shown that recipients of kidney transplants have higher 
health utility scores than patients receiving dialysis, but how scores vary in relation to 
patient-level characteristics or treatment factors such as comorbidities and time on dialysis 
has not been well characterized. 
Methods: As part of the prospective observational study entitled Access to Transplantation 
and Transplant Outcomes Measures (ATTOM), we captured information on patient and 
treatment characteristics for a cohort of incident adult kidney transplant recipients and a 
cohort of matched controls from the kidney transplant waiting list in the United Kingdom.  
We assessed patients’ health status using the EQ-5D-5L questionnaire and conducted 
multivariable regression analyses of index scores in each cohort.  
Results: EQ-5D-5L responses at study recruitment were available for 1807 transplant 
recipients and 1704 patients on the waiting list. Mean index scores were higher in transplant 
recipients at six months following transplant surgery (0.827) compared with patients on the 
waiting list (0.772). In multivariable analyses, age was not a significant predictor of index 
scores. Female gender, Asian ethnicity, a primary renal diagnosis of diabetic nephropathy, 
smoking and the presence of comorbidities such as mental illness or ischemic heart disease 
were associated with lower utility scores in both cohorts. For patients on the waiting list, 
increasing time on dialysis was associated with lower utility scores. 
Conclusions: The current study provides new insights into variations in health-state utility 
values from a single source that can be used to inform future cost-effectiveness evaluations 
in patients receiving kidney transplants or dialysis. 
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INTRODUCTION 
Estimates of health-state utility values are required to undertake cost-effectiveness 
evaluations in which quality-adjusted life years (QALYs) are the outcome of interest. Utility 
estimates can be captured using patient-reported questionnaires as part of a clinical trial or 
observational study but in the absence of primary data, estimates are often sourced from 
published literature    
End-stage renal disease (ESRD) is a chronic condition that has been shown to impact 
patients’ health status. Numerous studies have been conducted to measure utility values 
among patients receiving renal replacement therapy. Meta-analyses of published studies 
suggest that higher utility values are generally observed among patients who receive kidney 
transplants in comparison to dialysis [1, 2]. Pooling results across studies can be an 
appealing approach to obtain a summary estimate (weighted average with associated 
uncertainty) of a utility value for each health state of interest that can be used to quality 
adjust survival in a cost-effectiveness model. However caution is required when undertaking 
meta-analyses of health-state utility values because there is often considerable variability 
in utility scores as a result of using different valuation methods across studies [3]. A further 
limitation of pooled utility estimates is that they may not be able to take into account 
heterogeneity of patient characteristics, treatment or measurement factors that could 
explain variations in utility scores for a given condition. Individual utility studies often have 
small sample sizes and each study may collect only a limited number of covariates that are 
not comparable across studies. 
Datasets that enable analysis of the effect of covariates such as age, gender or 
comorbidities on health-state utility values are increasingly important in order to facilitate 
the use of patient-level simulation techniques in economic evaluations. The Access to 
Transplantation and Transplant Outcomes Measures (ATTOM) study is a prospective 
observational study that involved collection of demographic, treatment and health outcomes 
data from all 72 renal units in the United Kingdom. As part of this study, we recruited a 
cohort of incident kidney transplant and combined (simultaneous) pancreas and kidney 
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(SPK) transplant recipients as well as a cohort of prevalent waiting-list patients selected as 
controls for transplanted patients [4]. Collection of health-state utility values as part of the 
ATTOM study has facilitated the following objectives of the current analysis: 
1. To report health-state utility values for a large sample of kidney transplant recipients 
and prevalent waiting-list patients using the 5-level version of the EQ-5D questionnaire. 
2. To conduct multivariable regression analyses to understand patient and treatment 
factors that lead to variations in health-state utility values among kidney transplant 
recipients and patients on the waiting list that can then be used to inform quality 
adjustment of life years in cost-effectiveness evaluations. 
METHODS 
The EQ-5D is a widely used generic instrument for describing and valuing health in terms 
of five dimensions: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. The original version of the EQ-5D has three levels of response 
categories for each dimension, ranging from no problems to extreme problems [5]. More 
recently, a 5-level version of the questionnaire (EQ-5D-5L) has been developed in an 
attempt to improve the instrument’s sensitivity and to reduce ceiling effects [6].  
Patients aged 18-75 years who received a kidney or SPK transplant in the UK between 
November 1, 2011 and September 30, 2013 were approached for recruitment into the 
ATTOM study. EQ-5D-5L questionnaires were administered to transplant recipients at 
recruitment and were supposed to be captured within 90 days of transplantation, although 
we noted a proportion of patients completed the questionnaire prior to surgery. Transplant 
recipients who were recruited during the first 6 months of the study were asked to complete 
the EQ-5D-5L again approximately 6 months after transplantation. We aimed to collect EQ-
5D-5L assessments at 6 months in 50% of all transplant patients; we were unable to collect 
data at 6 months in all patients because study nurses were only on site and available to 
administer questionnaires over a total period of 12 months.  
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Prevalent patients on the waiting list were selected as matched controls on a 1:1 basis for 
every incident transplant recipient based on the following criteria: transplant center, age 
(within five years), time on the waiting list, type of transplant (kidney only or SPK), diabetes 
status (as a primary renal diagnosis) and dialysis status (at the time of listing) [4]. For 
matched controls, the EQ-5D-5L responses were captured within 90 days of recruitment. 
Matched controls were recruited from prevalent patients who had been on the waiting list 
and on dialysis for varying periods of time. Therefore, the EQ-5D-5L assessment at 
recruitment in matched control patients did not represent the start of dialysis as a treatment 
modality. 
Questionnaire responses were converted to index scores using the EQ-5D-5L value set for 
England reported by Devlin et al [7]. We used logistic regression to explore if there were 
any factors that increased the likelihood of having a missing EQ-5D-5L index score at 
recruitment in both the transplant and waiting-list cohorts and identified Asian ethnicity as a 
potential predictor of missing responses in both cohorts. We performed multiple imputation 
creating 20 imputed datasets using predictive mean matching drawing from 3 nearest 
neighbors for missing EQ-5D-5L index scores in transplant recipients at recruitment. Among 
patients on the waiting list, in addition to 13% with missing EQ-5D-5L index scores, 
approximately 30% had missing information about duration of dialysis and therefore multiple 
imputation in this cohort was performed using predictive mean matching and chained 
equations. Due to the extent of missing EQ-5D-5L responses at 6 months in the transplant 
cohort, we did not feel it was appropriate to attempt imputation of these scores; instead we 
performed chi-squared tests for equality of proportions to provide reassurance that the 
characteristics of the patients with EQ-5D-5L index scores at 6 months were broadly 
representative of the overall population of transplant recipients recruited into the study.  
For the multivariable regression analysis of EQ-5D-5L index scores in transplant patients, 
we considered the following covariates that were collected in the ATTOM study: age, 
gender, ethnicity, deceased versus living donor, kidney alone versus SPK transplant, 
primary renal diagnosis, smoking status and comorbidities that occurred in at least 5% of 
patients. Initially we fitted separate ordinary least squares (OLS) regression models to 
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estimate EQ-5D-5L index scores among transplant recipients at recruitment and at 6 
months. However, given the lower than expected number of EQ-5D-5L responses at 6 
months, we then conducted a combined analysis of EQ-5D-5L index scores using an 
indicator variable for time of assessment (recruitment versus 6 months) and the cluster 
option to take into account dependence between multiple EQ-5D-5L responses in the same 
patient. For patients on the transplant waiting list, the multivariable regression model 
explored the following covariates: age, gender, ethnicity, dialysis modality, primary renal 
diagnosis, smoking status, comorbidities that occurred in at least 5% of patients and time 
on dialysis. Backwards elimination was used to inform variable selection using a threshold 
P-value of 0.15 as a proxy to performing an all-subsets procedure and selecting the model 
based on the Akaike Information Criterion (AIC) [8].    
As the main objective of this analysis is to estimate health-state utility values for use as 
inputs in cost-effectiveness models, we compared mean predicted index scores based on 
the final fitted multivariable regression models to mean observed index scores in various 
subgroups containing at least 20 patients each. 
Previous studies have reported that OLS regression models tend to overestimate index 
scores at low values and underestimate index scores at high values. Using complete cases 
only, we explored a number of alternative approaches including Tobit regression and fitting 
an adjusted limited dependent variable mixture model. However, neither of these 
approaches led to notable reductions in root mean squared error (RMSE) and were not 
pursued any further within the current analysis. 
All analyses were conducted in Stata (Version 13, Stata Corp, College Station, Texas, 
USA). 
RESULTS 
A total of 2252 transplant recipients and 1959 patients on the transplant waiting list were 
recruited into the ATTOM study. Figure 1 shows the number of completed EQ-5D-5L 
assessments that were available for analysis for each cohort. The proportion of patients 
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who completed the questionnaire at recruitment was 80% and 87% in the transplant 
recipient and waiting-list cohorts respectively. Among transplant recipients, the proportion 
of patients who completed the questionnaire at 6 months was 23%, less than half of the 
target of 50%.  
Among transplant recipients who completed the EQ-5D-5L at recruitment, 134 (7.4%) 
completed the questionnaire prior to transplantation rather than in the 90-day period 
following transplantation. Of the 134 patients who completed the questionnaire prior to 
transplantation, 117 were recipients of kidneys from living donors. Mean EQ-5D-5L index 
scores in patients who completed the questionnaire prior to transplantation were higher than 
those who completed the questionnaire after transplantation, although the difference we 
observed was not statistically significant (0.803 vs. 0.772, P-value = 0.078). When we 
simultaneously controlled for other patient and treatment characteristics, the timing of the 
EQ-5D-5L assessment (before versus after transplantation) was not found to be a 
significant predictor of index score. Therefore, we retained the 134 questionnaire responses 
that had been completed prior to transplantation in our analysis of index scores at 
recruitment so as not to bias the sample by removing a large number of recipients of living 
donor transplants. 
Table 1 provides a univariate summary of EQ-5D-5L index scores by patient and treatment 
characteristics in each cohort. Among transplant recipients, we observed a statistically 
significant difference between mean EQ-5D-5L index scores at recruitment and at 6 months 
(0.774 vs. 0.827, P-value < 0.001). For the multivariable analysis in the transplant cohort, 
we initially fit separate regression models to estimate index scores at recruitment and at 6 
months. We noted consistency between the two models in the direction and magnitude of 
coefficients for most covariates before proceeding to a combined analysis of scores from 
both time-points. Table 2 shows the variables that were retained in the final model fitted to 
the combined sample. The following variables were associated with lower index scores in 
transplant recipients: female gender, Asian ethnicity, a primary renal diagnosis of diabetic 
nephropathy, current or ex-smoking status and the presence of comorbidities including 
ischemic heart disease, respiratory disease, malignancy or mental illness, which included 
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psychosis, bipolar disorder or depression as recorded in case notes. Higher index scores 
were seen in recipients of living donor transplants compared with deceased donor 
transplants. 
The final multivariable regression model of EQ-5D-5L index scores for patients on the 
transplant waiting list is shown in Table 3. Similar to the findings of the analysis for transplant 
recipients, female gender, Asian ethnicity, a primary diagnosis of diabetic nephropathy and 
the presence of ischemic heart disease or mental illness were significant predictors of lower 
scores among patients on the waiting list. In addition, the model showed that patients who 
were pre-emptively listed for transplantation before starting dialysis had higher utility scores 
and health status appeared to decline the longer patients remain on dialysis.  
To assess the performance of the final multivariable regression models, Table 4 
summarizes mean predicted and mean observed EQ-5D-5L index scores for each cohort 
in all possible subgroups with a sample size of at least 20 patients. For transplant recipients, 
we only summarized comparisons of scores at 6 months post-transplant as these are more 
likely to be of relevance for use in cost-effectiveness models than scores measured at 
recruitment. Table 4 shows that the magnitude of error between predicted and observed 
mean scores varies across subgroups up to a maximum of ±0.042.  
DISCUSSION 
Primary collection of data on health-state utility values to inform cost-effectiveness 
evaluations can be a time consuming and resource-intensive exercise. In situations where 
primary data collection is not feasible, estimates of health-state utility values are often 
sourced from the published literature. As the volume of published utility estimates for many 
disease areas continues to grow, analysts undertaking cost-effectiveness evaluations 
increasingly need to justify their approach for selecting what values to use as inputs in their 
models [9, 10]. One strategy is to select a single study from the published literature that 
most closely reflects the patient population (inclusion/exclusion criteria), disease stage and 
health states defined in the model. In contrast, if multiple studies estimating health-state 
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utility values for the same disease state have been published, another strategy is to pool 
estimates across studies using meta-analytic techniques. However in some cases, neither 
of these strategies is entirely satisfactory; a single study may not report utility estimates for 
the full range of health states of interest in the cost-effectiveness model but meta-analysis 
may be unsuitable due to high levels of heterogeneity arising from differences in the 
methods used to elicit and value health states [3, 11]. This has given rise to the practice of 
selecting health-state utility estimates from separate studies to inform the different 
comparator arms in a cost-effectiveness model, to distinguish between patient subgroups 
or to capture decrements in utility due to adverse events and comorbidities. Drawing on 
data from disparate sources to inform the same cost-effectiveness model can potentially 
lead to inconsistent or implausible values and raises additional questions about how utility 
values should be combined [11, 12].  
Published systematic reviews have identified a large number of studies capturing health-
state utility values among patients receiving renal replacement therapy. In both Liem et al. 
and Wyld et al., health-state utility values were more extensively studied in dialysis than in 
transplant patients and only a minority of studies evaluated health status in both dialysis 
and transplant patients at the same time [1, 2]. Both reviews concluded that higher utility 
values are seen in transplant recipients compared to dialysis patients but these pooled 
comparisons do not explicitly take into account adjustments between these groups for 
potential differences in patient demographics such as age, gender and ethnicity or 
comorbidities.  
The ATTOM study recruited incident kidney and SPK transplant recipients and also 
identified a cohort of prevalent patients on the transplant waiting list as matched controls. 
In addition to administering the EQ-5D-5L questionnaire, we collected data on a range of 
patient and treatment characteristics to allow us to explore their effects on utility scores. Our 
analysis confirms previous findings that transplant recipients have higher utility scores than 
dialysis patients. The mean utility score at 6 months for transplant recipients in our study 
was similar to the values reported in meta-analyses by Liem at al. (0.81) and Wyld et al. 
(0.82) [1, 2]. Where longitudinal studies were available, both of these meta-analyses 
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examined utility scores that were measured at or closest to 12 months post-transplant rather 
than 6 months. Our study also provides a source of utility estimates for a cohort of patients 
on the transplant waiting list that reflects the subset of ESRD patients who were considered 
suitable candidates for transplantation. The mean utility score for patients on the transplant 
waiting list in our study was 0.772, higher than the mean values reported among dialysis 
patients by Liem et al. (0.56 for hemodialysis, 0.68 for peritoneal dialysis patients) and Wyld 
et al. (0.71) [1, 2]. The waiting-list population in our study was a prevalent cohort that 
included patients who had been receiving dialysis for varying periods of time and also 
included some patients who had not yet commenced dialysis. This provided an important 
opportunity to quantify the magnitude of decline in health status associated with time spent 
on dialysis. 
We made a number of other notable observations based on multivariable regression 
analyses: Firstly, age was not found to be a significant predictor of index scores. Although 
the background effect of age on health state valuations using the time trade-off method has 
been established [13], the current analysis suggests that when controlling for other factors 
affecting health status such as comorbidities, primary renal diagnosis and time on 
treatment, age did not appear to have any additional explanatory effect. Secondly, gender 
and Asian ethnicity were associated with lower scores among both transplant recipients and 
patients on the waiting list, although the effect was more pronounced for those on the 
waiting list.  Thirdly, diabetic nephropathy as a primary renal diagnosis was associated with 
lower index scores in both cohorts. Taken together, these results provide insight into how 
much health status can vary, particularly for patients on the transplant waiting list. In our 
comparison of mean utility scores across patient subgroups, we observed differences in 
index scores of almost 0.20 and this does not even include subgroups of patients with 
comorbidities such as mental illness that were shown to be associated with the largest 
decrements in health status. A greater understanding of which types of patients experience 
poorer health status while on the transplant waiting list compared to health status following 
transplant could provide a basis for assessing the impact of prioritizing different types of 
patients for transplantation within the context of organ allocation schemes.  
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The main strengths of this study are the large sample sizes combined with comprehensive 
collection of data on patient and treatment factors that allowed us to explore their influence 
on health status among both transplant recipients and patients on the transplant waiting list. 
In the meta-analysis conducted by Liem et al., EQ-5D scores for a given treatment modality 
were based on studies with sample sizes ranging from as few as 27 patients to a maximum 
of 455 patients [1]. In our analysis, we assessed the final multivariable regression models 
by comparing mean observed and mean predicted index scores and demonstrated that they 
performed satisfactorily overall across most patient subgroups.  
A limitation of the present study is the lower number of EQ-5D-5L responses captured 
among transplant recipients at 6 months. Although we were primarily interested in 
estimating health status at 6 months rather than at the time of transplant surgery, we 
included questionnaire responses collected at both time-points in the multivariable analysis 
because the large sample size at recruitment could help improve the precision of the 
coefficient estimates in the regression model. More complete data at 6 months as well as 
additional longitudinal assessments would have been desirable to explore if utility values 
change over time. For the multivariable analyses, we restricted our approach to the use of 
OLS regression. While several regression modelling approaches have been proposed in 
the literature to deal with the bounded and skewed nature of health state utility data [14-17], 
we believe that OLS regression is justified in this case because the primary objective was 
to estimate mean  utility scores and, even with missing EQ-5D-5L responses, the sample 
sizes were relatively large. Exploration of alternative modelling approaches using Tobit 
regression or mixture models did not appear to reduce RMSE. Nonetheless, there are a 
number of other approaches that could be applied to our dataset to facilitate a more 
comprehensive comparison of different methods in future research. 
When conducting cost-effectiveness evaluations of ESRD patients receiving dialysis or 
transplantation, careful consideration should be given to the treatment strategies under 
comparison and selection of the most appropriate utility values that reflect the 
characteristics of the patient populations of interest. The current study provides new insights 
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into variations in health-state utility values from a single source that can be used to inform 
such evaluations in the future.  
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Table 1 Univariate summary of EQ-5D-5L index scores by patient and treatment characteristics 
 
 Incident transplant recipients at 
recruitment 
Incident transplant recipients at 6 
months 
Prevalent waiting list patients at 
recruitment 
Patients with EQ-5D-5L responses 1807 512 1704 
EQ-5D-5L index score 
  
 
  
 
  
 
Mean (SD) 0.774 (0.192) 0.827 (0.213) 0.772 (0.219) 
Interquartile range 0.698 - 0.898 0.766 -1.003 0.682 - 0.944 
          
 n (%) 
EQ-5D-5L index 
Mean (SD)* 
n (%) 
EQ-5D-5L index 
Mean (SD)* 
n (%) 
EQ-5D-5L index 
Mean (SD)* 
Age group   
 
  
 
  
 
18-29 187 (10.4%) 0.805 (0.179) 41 (8.0%) 0.910 (0.167) 137 (8.0%) 0.801 (0.209) 
30-39 253 (14.0%) 0.770 (0.206) 62 (12.1%) 0.854 (0.192) 224 (13.2%) 0.757 (0.193) 
40-49 441 (24.4%) 0.769 (0.187) 128 (25.0%) 0.817 (0.222) 412 (24.2%) 0.766 (0.230) 
50-59 473 (26.2%) 0.767 (0.196) 140 (27.3%) 0.809 (0.225) 481 (28.2%) 0.757 (0.232) 
>60 453 (25.0%) 0.778 (0.189) 141 (27.5%) 0.818 (0.212) 450 (26.4%) 0.792 (0.207) 
Gender          
Male 1,127 (62.4%) 0.783 (0.193) 307 (60.0%) 0.827 (0.221) 984 (57.8%) 0.791 (0.211) 
Female 680 (37.6%) 0.761 (0.190) 205 (40.0%) 0.827 (0.202) 720 (42.3%) 0.747 (0.227) 
Ethnicity          
White 1,523 (84.3%) 0.778 (0.188) 452 (88.3%) 0.827 (0.212) 1,299 (76.2%) 0.780 (0.213) 
Asian 146 (8.1%) 0.737 (0.213) 28 (5.5%) 0.848 (0.166) 192 (11.3%) 0.725 (0.257) 
Black 104 (5.8%) 0.781 (0.206) 24 (4.7%) 0.800 (0.277) 178 (10.5%) 0.768 (0.208) 
Other 34 (1.9%) 0.745 (0.212) 8 (1.6%) 0.824 (0.237) 35 (2.1%) 0.764 (0.227) 
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Primary renal diagnosis          
Glomerulonephritis 318 (17.6%) 0.791 (0.190) 96 (18.7%) 0.865 (0.176) 251 (14.7%) 0.792 (0.210) 
Diabetic nephropathy 248 (13.7%) 0.691 (0.226) 60 (11.7%) 0.718 (0.267) 195 (11.5%) 0.708 (0.228) 
Renal vascular disease  111 (6.2%) 0.801 (0.165) 26 (5.1%) 0.856 (0.180) 112 (6.6%) 0.769 (0.236) 
Polycystic kidney disease 275 (15.2%) 0.797 (0.160) 67 (13.1%) 0.851 (0.195) 288 (16.9%) 0.793 (0.200) 
Pyelonephritis 217 (12.0%) 0.783 (0.186) 63 (12.3%) 0.828 (0.208) 195 (11.4%) 0.770 (0.239) 
Other 638 (35.3%) 0.781 (0.190) 200 (39.1%) 0.829 (0.216) 663 (38.9%) 0.776 (0.215) 
Transplanted organs       
   
Kidney only 1,694 (93.7%) 0.779 (0.189) 489 (95.5%) 0.830 (0.210) - 
 - 
Kidney and pancreas 113 (6.3%) 0.706 (0.221) 23 (4.5%) 0.756 (0.273) - 
 - 
Donor type       
   
Brain-death donor 579 (32.0%) 0.746 (0.201) 155 (30.3%) 0.784 (0.236) - 
 - 
Circulatory-death donor 562 (31.1%) 0.765 (0.195) 165 (32.2%) 0.818 (0.205) - 
 - 
Living donor 666 (36.9%) 0.808 (0.176) 192 (37.5%) 0.868 (0.195) - 
 - 
Dialysis modality (at listing)      
 
  
 
Haemodialysis - 
 - -  - 1,140 (66.9%) 0.753 (0.228) 
Peritoneal dialysis - 
 - -  - 255 (15.0%) 0.786 (0.201) 
Pre-dialysis - 
 - -  - 298 (17.5%) 0.833 (0.188) 
Missing - 
 - -  - 11 (0.7%) 0.824 (0.167) 
Time on dialysis (at EQ-5D completion)       
 
Pre-dialysis -  - -  - 98 (5.8%) 0.827 (0.213) 
<1 year -  - -  - 224 (13.2%) 0.777 (0.220) 
1-3 years -  - -  - 389 (22.8%) 0.768 (0.219) 
>3 years -  - -  - 457 (26.8%) 0.741 (0.228) 
Missing -  - -  - 536 (31.5%) 0.789 (0.208) 
Ischemic heart disease      
 
   
No 1,646 (91.1%) 0.778 (0.189) 462 (90.2%) 0.838 (0.195) 1,519 (89.1%) 0.779 (0.217) 
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Yes 154 (8.5%) 0.735 (0.224) 48 (9.4%) 0.730 (0.321) 166 (9.7%) 0.716 (0.220) 
Missing 7 (0.4%) 0.777 (0.092) 2 (0.4%) 0.616 (0.547) 19 (1.1%) 0.703 (0.309) 
Respiratory disease          
No 1,651 (91.4%) 0.779 (0.188) 464 (90.6%) 0.830 (0.209) 1,565 (91.8%) 0.773 (0.219) 
Yes 150 (8.3%) 0.728 (0.227) 47 (9.2%) 0.794 (0.255) 119 (7.0%) 0.772 (0.203) 
Missing 6 (0.3%) 0.773 (0.100) 1 (0.2%) 1.003 (0.000) 20 (1.2%) 0.707 (0.301) 
Malignancy          
No 1,687 (93.4%) 0.777 (0.190) 466 (91.0%) 0.829 (0.214) 1,563 (91.7%) 0.773 (0.218) 
Yes 114 (6.3%) 0.731 (0.225) 45 (8.8%) 0.807 (0.210) 122 (7.2%) 0.770 (0.213) 
Missing 6 (0.3%) 0.773 (0.100) 1 (0.2%) 1.003 (0.000) 19 (1.1%) 0.703 (0.309) 
Mental illness          
No 1,697 (93.9%) 0.781 (0.189) 483 (94.3%) 0.835 (0.209) 1,559 (91.5%) 0.783 (0.211) 
Yes 104 (5.8%) 0.673 (0.214) 28 (5.5%) 0.685 (0.248) 125 (7.3%) 0.654 (0.264) 
Missing 6 (0.3%) 0.773 (0.100) 1 (0.2%) 1.003 (0.000) 20 (1.2%) 0.695 (0.303) 
Smoking status          
Non-smoker 970 (53.7%) 0.785 (0.181) 277 (54.1%) 0.848 (0.201) 854 (50.1%) 0.785 (0.222) 
Current smoker 184 (10.2%) 0.759 (0.209) 43 (8.4%) 0.778 (0.242) 238 (14.0%) 0.743 (0.226) 
Unknown  156 (8.6%) 0.791 (0.181) 41 (8.0%) 0.877 (0.175) 225 (13.2%) 0.756 (0.220) 
Ex-smoker 497 (27.5%) 0.755 (0.208) 151 (29.5%) 0.788 (0.230) 387 (22.7%) 0.772 (0.204) 
*Bold / italics denote P<0.05 for comparison of means using two-sample t-test / one-way analysis of variance. SD, standard deviation. 
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Table 2 Multivariable regression model for EQ-5D-5L index scores in transplant recipients 
at study recruitment and at 6 months (multiply imputed dataset at baseline only, n = 2,241 
patients with 2,750 observations) 
 
 Coefficient Std. Error P-value 95% CI 
     
Constant 0.809 0.008 <0.001 (0.793, 0.824) 
     
EQ-5D assessment at study recruitment Reference    
EQ-5D assessment at 6 months 0.053 0.009 <0.001 (0.035, 0.071) 
     
Male Reference    
Female -0.019 0.009 0.026 (-0.036, -0.002) 
     
Ethnicity White, Black or Other Reference    
Ethnicity Asian -0.030 0.017 0.092 (-0.064, 0.005) 
     
Deceased donor transplant Reference    
Living donor transplant 0.034 0.009 <0.001 (0.017, 0.051) 
     
Primary renal diagnosis other Reference    
Diabetic nephropathy -0.086 0.015 <0.001 (-0.115, -0.057) 
     
Presence of comorbidities     
Ischemic heart disease -0.040 0.020 0.052 (-0.079, 0.000) 
Respiratory disease -0.045 0.018 0.016 (-0.081, -0.008) 
Malignancy -0.040 0.018 0.026 (-0.075, -0.005) 
Mental illness -0.098 0.022 <0.001 (-0.141, -0.056) 
     
Non-smoker / unknown status  Reference    
Current smoker -0.025 0.015 0.099 (-0.056, 0.005) 
Ex-smoker -0.029 0.010 0.004 (-0.049, -0.009) 
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Table 3 Multivariable regression model for EQ-5D-5L index scores (multiply imputed 
dataset) in patients on the transplant waiting list (n=1931) 
 
 Coefficient Std. Error P-value 95% CI 
     
Constant 0.878 0.015 <0.001 (0.850, 0.907) 
     
Male Reference    
Female -0.048 0.010 <0.001 (-0.069, -0.028) 
     
Ethnicity White, Black or Other Reference    
Ethnicity Asian -0.054 0.017 0.002 (-0.088, -0.020) 
     
Primary renal diagnosis other Reference    
Diabetic nephropathy -0.055 0.016 0.001 (-0.087, -0.023) 
     
Time on dialysis      
Pre-dialysis Reference    
<1 year -0.053 0.019 0.005 (-0.090, -0.016) 
1-3 years -0.055 0.017 0.001 (-0.088, -0.022) 
>3 years -0.071 0.016 <0.001 (-0.103, -0.039) 
     
Presence of comorbidities     
Ischemic heart disease -0.048 0.018 0.007 (-0.082, -0.013) 
Mental illness -0.118 0.021 <0.001 (-0.158, -0.077) 
     
Non-smoker / ex-smoker / unknown  Reference    
Current smoker -0.027 0.012 0.029 (-0.051, -0.003) 
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Table 4 Mean predicted versus mean observed EQ-5D-5L index scores (all subgroups 
with ≥20 patients) 
 
(A) Transplant recipients 
 
 n Predicted Observed Error 
Male, non-Asian, deceased donor 
transplant, primary renal diagnosis other, 
none of listed comorbidities, non-smoker 
60 0.862 0.888 -0.026 
Male non-Asian, living donor transplant, 
primary renal diagnosis other, none of 
listed comorbidities, non-smoker 
61 0.896 0.900 -0.004 
Female, non-Asian, deceased donor 
transplant, primary renal diagnosis other, 
no ne of listed comorbidities, non-smoker 
44 0.843 0.844 -0.001 
Female non-Asian living donor transplant, 
primary renal diagnosis other, none of 
listed comorbidities, non-smoker 
34 0.877 0.889 -0.012 
 
(B) Waiting-list patients 
 
 n Predicted Observed Error 
Male, non-Asian, primary renal diagnosis 
other, pre-dialysis, none of listed 
comorbidities, non-smoker 
30 0.878 0.886 -0.008 
Male, non-Asian, primary renal diagnosis 
other, dialysis <1 year, none of listed 
comorbidities, non-smoker 
64 0.825 0.825 0.000 
Male, non-Asian, primary renal diagnosis 
other, dialysis 1-3 years, none of listed 
comorbidities, non-smoker 
87 0.824 0.864 -0.040 
Male, non-Asian, primary renal diagnosis 
other, dialysis >3 years, none of listed 
comorbidities, non-smoker 
112 0.808 0.816 -0.008 
Male, non-Asian, primary renal diagnosis 
other, dialysis 1-3 years, none of listed 
comorbidities, smoker 
55 0.797 0.755 0.042 
Male, non-Asian, primary renal diagnosis 
other, dialysis >3 years, none of listed 
comorbidities, smoker 
44 0.781 0.773 0.008 
Male, non-Asian, primary renal diagnosis 
diabetic nephropathy, dialysis 1-3 years, 
none of listed comorbidities, non-smoker 
20 0.769 0.750 0.019 
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Female, non-Asian, primary renal 
diagnosis other, pre-dialysis, none of 
listed comorbidities, non-smoker 
28 0.830 0.852 -0.022 
Female, non-Asian, primary renal 
diagnosis other, <1 year, none of listed 
comorbidities, non-smoker 
60 0.777 0.779 -0.002 
Female, non-Asian, primary renal 
diagnosis other, 1-3 years, none of listed 
comorbidities, non-smoker 
60 0.776 0.803 -0.027 
Female, non-Asian, primary renal 
diagnosis other, >3 years, none of listed 
comorbidities, non-smoker 
99 0.759 0.753 0.006 
Female, non-Asian, primary renal 
diagnosis other, 1-3 years, none of listed 
comorbidities, smoker 
34 0.749 0.728 0.021 
Female, non-Asian, primary renal 
diagnosis other, >3 years, none of listed 
comorbidities, smoker 
24 0.733 0.692 0.041 
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Figure 1 Number of completed EQ-5D-5L assessments in each cohort 
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5. KIDNEY ALLOCATION SIMULATION MODEL  
5.1. Introduction  
The main objective of this thesis is to compare the costs and consequences associated with 
alternative approaches to allocating kidneys from deceased donors to patients on the 
transplant waiting list in the UK. Previous chapters have described the sources of data used 
to characterise variations in costs, survival and health-state utility values at the patient level 
which will serve as inputs in the simulation model. This chapter describes the structure and 
key assumptions for the simulation model and reports total costs and QALYs across the 
patient population for each allocation scheme.  
5.2. Research Paper 4 
The simulation model described in Research Paper 4 was constructed in two phases. The 
first phase involved translating each of the allocation criteria into code to perform the 
matching process in which one patient from the waiting list is selected for every kidney that 
becomes available. Once all five allocation schemes had been coded and tested, the 
second phase was to incorporate the predictive regression models from Chapters 2, 3 and 
4 to estimate lifetime costs and QALYs for each patient who receives a transplant and then 
to sum these across all patients. The simulation model was constructed using the software 
package SIMUL8. A detailed explanation of the approach to structuring and coding the 
simulation model is beyond the scope of Research Paper 4, however interested readers 
may wish to refer to Appendix 6, which provides additional documentation to describe how 
the model was constructed.  
Although the simulation exercise described in this thesis was designed to estimate total 
lifetime costs and QALYs associated with different approaches to kidney allocation, special 
care has been taken in Research Paper 4 not to draw any formal conclusions or 
recommendations about which of the five allocation schemes under comparison is 
considered optimal. Part of the reason for this will become more evident in Chapter 6, when 
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equity considerations are discussed. However, another challenge in trying to determine 
which allocation scheme is optimal is that it requires an informed answer to the following 
question: whose outcomes should we be seeking to maximise? Given a limited supply of 
kidneys, the different approaches to kidney allocation will result in different patients being 
prioritised to receive a transplant, while other patients will be more likely to remain on the 
waiting list for longer periods of time. Taking a lifetime time horizon for estimating costs and 
QALYs in the simulation model introduces a particular challenge, namely how to account 
for the lifetime costs and outcomes for those patients who do not receive a transplant during 
the simulation period. A number of approaches were considered, including: 
1. Continue to run the model with an infinite stream of donor kidneys, however this was 
not considered feasible because SIMUL8 requires the model to terminate in order to 
trigger code at the end of a run to produce results (total costs and QALYs)  
2. For all patients who remained on the waiting list at the end of the model run, predict 
which patients will receive a transplant in the future and estimate their costs and QALYs, 
however this would require a reliable method to predict which patients would receive a 
transplant (dependent on the characteristics of future donor kidneys) and when they 
would receive a transplant under each of the different allocation schemes 
3. Assume that all patients who remained on the waiting list at the end of the model run 
never receive a transplant and assign them costs and QALYs equivalent to remaining 
on the waiting list until death, however this assumption is unlikely to be met in practice.  
The first two options were not considered feasible to implement within the structure of the 
simulation model that had been developed or within the time constraints of the PhD. 
Consequently, the third approach outlined above was adopted. Given the limitations of the 
assumption that none of the patients on the waiting list would receive a transplant in the 
future, Research Paper 4 presents results (total costs and QALYs) for transplant recipients 
only as well as for the combined population of transplant recipients and patients who did 
not receive a transplant during the simulation. 
Note that due to the target journal and intended audience for Research Paper 4, the term 
utility-maximisation has been used interchangeably with the term QALY-maximisation. 
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ABSTRACT  
Introduction: In the United Kingdom, the number of patients waiting to receive a kidney 
transplant far outstrips the supply of donor organs thereby making some form of rationing 
inevitable. There is increasing recognition that not all donor kidneys will result in equally 
good survival outcomes and that not all patients will derive the same benefit from a given 
donor kidney. We sought to explore the feasibility of designing a kidney allocation scheme 
to match recipients and donors in a manner that would maximise the benefit derived from 
each donor organ.  
Methods: An individual patient simulation was developed to compare a utility-maximising 
approach to kidney allocation with alternative allocation concepts from across the equity-
efficiency spectrum. We used various sources of patient-level data to develop separate 
multivariable regression models to predict survival, health state utilities and costs. We 
simulated the allocation of kidneys from 2200 donors to a waiting list of 5500 patients and 
produced estimates of total lifetime costs and quality-adjusted life years (QALYs) for each 
allocation scheme.  
Results: Among patients who received a transplant, the utility-maximising approach to 
kidney allocation resulted in the highest total QALYs and costs (47,613 QALYs, £665 
million) while waiting-time allocation resulted in the lowest (39,496 QALYs, £584 million). 
However, when taking into consideration outcomes for those patients who did not receive a 
transplant, the utility-maximising scheme no longer produced the highest total QALYs 
across the entire patient population. 
Discussion: This simulation exercise demonstrates the feasibility of designing a utility-
maximising approach to kidney allocation and provides insight into the magnitude of QALY 
and cost differences to inform the discussion about trade-offs associated with alternative 
allocation concepts from across the equity-efficiency spectrum. 
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INTRODUCTION 
In 2015, there were approximately 5700 patients waiting to receive a kidney transplant in 
the United Kingdom [1]. Because the number of patients waiting to receive a transplant far 
outstrips the supply of organs from deceased donors, some form of rationing is inevitable. 
In many countries, the approach to rationing is made explicit through the design of a national 
kidney allocation scheme. In the UK, a matching system between recipients and donors has 
been in place since 1989 [2]. The approach to kidney allocation in this country is subject to 
continuous audit and review and over the decades, the national scheme has been revised 
twice in order to address and balance considerations of both improving transplant outcomes 
and promoting equity in access to transplant [3, 4].  
Simulation modelling is a practical tool that can be used to evaluate or prospectively test 
the impact of potential changes to kidney allocation schemes [5-7]. As part of the Access to 
Transplantation and Transplant Outcomes Measure (ATTOM) study, we conducted a 
simulation exercise to explore and compare alternative approaches to allocating kidneys in 
the UK context. Building a simulation model can be a time-consuming and data-intensive 
exercise. Before constructing a simulation, it is therefore important to define the decision 
problem and intended outputs of the model as these can influence the required data inputs 
and vice versa. We approached the development of the simulation model described in this 
paper with three key objectives in mind: 
1. To simulate a number of different approaches to kidney allocation that reflect varying 
degrees of emphasis on the competing objectives of maximising transplant outcomes 
on the one hand and promoting equity on the other 
2. To report outcomes for each kidney allocation scheme in terms of both quality-adjusted 
life years (QALYs) and costs 
3. To maximise use of information on individual patient and donor characteristics to inform 
the allocation process and to account for between-patient variability in the estimation of 
outcomes. 
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Kidney allocation concepts of interest 
The current UK kidney allocation scheme was introduced in 2006 [4]. In this simulation 
exercise, we compared the 2006 national kidney allocation scheme (NKAS) to several 
alternative approaches, with a particular interest in exploring the feasibility of designing an 
allocation scheme that would maximise health gains among transplant recipients from a 
fixed supply of donor kidneys. The design of a utility-maximising allocation scheme was 
predicated on the following assumptions: 
1. For patients awaiting a transplant, there is a treatment alternative, namely dialysis  
2. Not all donor kidneys will result in equally good survival outcomes 
3. Not all potential recipients will derive the same survival benefit from a given donor 
kidney. 
In the utility-maximising scheme, for each donor kidney that becomes available, the 
simulation model estimates expected QALYs following transplant for each patient on the 
waiting list given the characteristics of both that patient and the donor kidney to be allocated. 
Next, the simulation model estimates expected QALYs for each patient on the waiting list if 
that patient were to remain on dialysis. Taking the difference between expected QALYs 
following transplant and expected QALYs on dialysis, each kidney is allocated to the patient 
with the biggest expected QALY gain as a result of receiving the transplant. Over the 
population of transplant recipients, this approach to allocation should yield the maximum 
total QALY gains for a fixed number of donor kidneys. This utility-maximising scheme is 
conceptually similar to the Life Years from Transplant (LYFT) calculation previously 
described by Wolfe et al., however in the current simulation exercise, we applied different 
methods and used UK data sources to estimate survival and health state utilities in order to 
calculate QALY gains [8].  
Another allocation concept that we wanted to explore in our simulation exercise can be 
broadly referred to as longevity matching, which was a key feature of the new kidney 
allocation scheme implemented in the United States in 2014. Under this concept, donor 
kidneys are risk-stratified using a scoring system in order to identify which kidneys are 
associated with better post-transplant survival. Similarly, potential recipients on the waiting 
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list are risk-stratified based on estimates of their expected post-transplant survival (EPTS) 
score. The allocation policy then prioritises candidates in the top 20th percentile of EPTS 
scores to receive kidneys from the top 20% of donor kidneys [9]. To test the concept of 
longevity matching in the UK context, we used a UK-specific kidney donor risk index 
(UKKDRI) [10] and developed a multivariable parametric model to estimate mean post-
transplant survival for potential recipients based on an analysis of historical UK Transplant 
Registry data [11]. A key difference between our approach to estimating recipient post-
transplant survival and the EPTS score used in the US kidney allocation scheme is that our 
survival predictions also take into account relevant donor characteristics, namely age and 
history of hypertension. Thus, in our simulation exercise, recipient post-transplant survival 
estimates for both the utility-maximising and longevity matching allocation schemes are 
recalculated for each potential donor-recipient combination. 
In addition to exploring the concepts of utility-maximisation and longevity matching, we 
included two other allocation concepts in our simulation exercise that were intended to 
reflect greater emphasis on equity: random allocation and allocation based on waiting time. 
Table 1 provides an overview of all five allocation concepts explored in our simulation 
exercise.  
 
Table 1 Description of the five kidney allocation schemes included in the simulation 
exercise  
Allocation concept Description of allocation criteria considered in each scheme 
Scheme 1: random  Blood group compatibility and HLA match  
 Priority for HLA mismatch level 1 (000)  
 Taking the above criteria into account, allocate the kidney 
randomly  
Scheme 2: waiting time  Blood group compatibility and HLA match  
 Priority for HLA mismatch level 1 (000)  
 Taking the above criteria into account, allocate the kidney to the 
patient with the longest waiting time 
Scheme 3: 2006 NKAS [12]  Priority for HLA mismatch level 1 (000), taking into account 
whether or not patients are highly sensitised or HLA-DR 
homozygous 
 Within tiers, prioritise patients according to a points-based system 
based on: 
o waiting time 
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o HLA match and age combined 
o donor-recipient age difference 
o location of patient relative to donor 
o HLA-DR homozygosity 
o HLA-B homozygosity 
o blood group match  
Scheme 4: longevity matching  For each donor kidney, estimate expected post-transplant survival 
for each patient on the waiting list  
 If the donor kidney has a UKKDRI score in the top 20%, then 20% 
of patients with the longest expected post-transplant survival are 
prioritised to receive the kidney 
 Taking the above criteria into account, allocate the kidney 
according to the 2006 NKAS scheme points-based system 
Scheme 5: utility-maximising  Blood group compatibility and HLA match  
 Priority for HLA mismatch level 1 (000)  
 For each donor kidney, estimate expected post-transplant QALYs 
for each patient and expected QALYs if each patient were to 
remain on the waiting list 
 Taking the above criteria into account, allocate the kidney to the 
patient with the biggest expected QALY gain from transplant 
 
METHODS 
Characteristics of waiting list patients and donor kidneys 
To simulate the composition of the transplant waiting list, we obtained data on 1948 
prevalent listed patients who were recruited into the ATTOM study between November 2011 
and September 2013 [13]. Of these patients, 513 had received a previous transplant. In the 
absence of predictive survival models that would allow us to account for prior transplants, 
we excluded these patients from the simulation exercise leaving a sample of 1435 patients, 
whose characteristics were replicated to make up a total waiting list of 5500 patients. During 
the simulation exercise, each time a patient received a transplant, a replacement was added 
to the waiting list to keep it constant at 5500 patients. For the donor dataset, we obtained 
characteristics of 2200 donors (4400 kidneys) based on a representative historical cohort 
from NHS Blood and Transplant. 
Characteristics of individual patients and donors were assigned at the point of entry into the 
model so that these characteristics could be used throughout the simulation to inform the 
allocation process as well as to estimate survival, costs and health state utilities. Most 
patient characteristics, including comorbidities, were kept constant throughout the 
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simulation, however three characteristics were updated as simulation time progressed; 
waiting time and time on dialysis were incremented on a daily basis, while patient age was 
incremented annually. 
Model structure and assumptions 
The simulation model was constructed using the software package SIMUL8 2015 
Professional version (SIMUL8 Corporation, Boston, MA, USA). At the start of the simulation, 
prevalent waiting list patients are loaded and held in a queue while donor kidneys are 
assumed to arrive at a fixed rate equivalent to 1200 deceased donors per year (Figure 1).  
 
Figure 1 Structure of the simulation model  
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The allocation process is triggered by the arrival of each donor kidney. Using Visual Logic, 
SIMUL8’s internal programming language, we are able to loop through patients on the 
waiting list to evaluate blood group and tissue compatibility for each potential donor-
recipient combination and perform the necessary calculations and scoring algorithms 
relevant to each allocation scheme of interest. In the model, we allowed for the possibility 
that no appropriate match is identified for a donor kidney. This is expected to occur in only 
a small proportion of cases, usually due to incompatibility with a rare donor blood or tissue 
type. In the current UK allocation scheme, tissue matching between the donor and recipient 
is determined on the basis of human leukocyte antigens (HLA); patients are separated into 
one of four possible HLA mismatch levels from level 1 (000-mismatched) to level 4 (poorly 
matched). In current practice, patients with a level 4 HLA mismatch are not eligible to 
receive the donor kidney through the national allocation scheme [12]. In order to maintain 
consistency and comparability between allocation schemes, we applied this same criterion 
to all five allocation schemes in our simulation exercise.  
Once a match has been identified, the recipient and donor kidney are assembled into a 
single entity to simulate the transplantation event and moved to the next step in the 
simulation process to determine post-transplant survival and to estimate lifetime QALYs and 
costs. The model assumes only two events are possible following transplantation: graft 
failure, in which the transplanted kidney stops working, or patient death. These events are 
modelled as competing risks in which we randomly sample from the survival curve for each 
event and move the patient to the event with the earliest sampled time [14]. If a patient 
experiences graft failure, we have assumed the patient returns to dialysis and faces the 
same mortality risk as a patient who has been on the waiting list and receiving dialysis for 
>3 years. However, if the sampled value for time to death following graft failure is longer 
than the time the patient would have survived based on the previously sampled value to 
determine initial post-transplant outcomes, we replaced it with the lower value so as not to 
paradoxically award patients who experienced graft failure with better survival prospects 
than those who did not experience graft failure. We made a decision not to model repeat 
transplants in this simulation in the absence of survival models specific to these patients. 
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The model was built by developing separate sections of Visual Logic code for each step in 
the allocation process so that, for example, the same procedure to evaluate blood group 
compatibility could be called at any point in the simulation for any of the five allocation 
schemes. Internal spreadsheets were used extensively to perform interim calculations at 
the patient level, which also facilitated model checks and step-by-step verification of the 
simulation process.  
 
Estimating life years, QALYs and costs 
Survival models 
There are three survival models underpinning time-to-event calculations to estimate post-
transplant patient survival, post-transplant graft failure and waiting list survival at various 
points in the simulation. Each of these models was developed based on analysis of historical 
UK Transplant Registry data. Data on dialysis start dates were additionally obtained through 
linkage to the UK Renal Registry to inform the waiting list survival model. Models were fitted 
using flexible parametric survival analysis in order to facilitate [15]: 
1. Extrapolation of survival curves to allow calculation of mean survival in years 
2. Inclusion of relevant patient and donor characteristics as covariates to capture variability 
in our predictions of survival and by extension in our estimates of costs and QALYs. 
A more detailed description of the method used to fit the post-transplant patient survival 
model is described elsewhere [11]. Table 2 summarises the various points in the simulation 
where each of the survival models was applied and Table 3 summarises the patient and 
donor characteristics that were included as covariates in each of the models. When the 
survival models were used as part of the allocation process to match recipients and donor 
kidneys (longevity matching and utility-maximisation), they were applied deterministically to 
produce mean survival estimates. When the survival models were used to inform competing 
risks following transplantation in order to estimate lifetime QALYs and costs, we allowed for 
stochastic variation.  
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Table 2 Description of survival models used in the simulation 
Where used How used 
Post-transplant 
patient survival 
Waiting list 
survival 
Post-
transplant 
graft failure 
1. Allocation 
scheme 4: 
longevity 
matching 
 
To calculate expected 
post-transplant survival for 
each patient on the waiting 
list; 20% of patients with 
the longest expected post-
transplant survival are 
prioritised to receive 
kidneys with top 20% 
UKKDRI scores  
Deterministic - - 
2. Allocation 
scheme 5: 
utility-
maximisation 
To calculate expected 
QALYs for each patient on 
the waiting list if (1) the 
patient were to receive the 
transplant (2) the patient 
were to remain on the 
waiting list 
Deterministic Deterministic - 
3. Competing risk 
to determine 
post-transplant 
outcomes after 
the kidney has 
been allocated 
(all allocation 
schemes)  
Following allocation of the 
kidney to a recipient on the 
waiting list, sample times 
for (1) graft failure event 
and (2) patient death 
event; take the minimum  
Stochastic - Stochastic 
4. Time from graft 
failure to death 
(all allocation 
schemes) 
If the patient experiences 
graft failure, sample time 
from graft failure to death 
assuming the survival rate 
is equivalent to a patient on 
the waiting list who has 
been on dialysis >3 years; 
compare this with the 
difference between time to 
death less time to graft 
failure from #3; take the 
minimum 
- Stochastic - 
5. Waiting list 
survival for 
patients who 
did not receive 
a transplant (all 
allocation 
schemes) 
For patients on the waiting 
list at the end of the 
simulation, assume 
survival rate is equivalent 
to a patient who remains 
on the waiting list and does 
not receive a transplant   
- Deterministic - 
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Table 3 Summary of covariates in survival models used in the simulation 
Covariate Categories 
Post-
transplant 
patient 
survival 
Waiting 
list 
survival 
Post-
transplant 
graft 
failure 
Recipient age 18-29, 30-39, 40-49, 
50-59, >60 
✓ ✓ ✓ 
Recipient gender Male / Female ✓ ✓ - 
Recipient ethnicity White, Asian, Black, 
Other 
- ✓ - 
Recipient primary renal diagnosis      
Diabetic nephropathy Yes / No ✓ ✓ - 
Polycystic kidney disease Yes / No ✓ - ✓ 
Recipient years on dialysis at the 
time of listing for transplant 
Pre-dialysis, <1 year, 
1-3 years, > 3 years 
- ✓ - 
Pre-emptive transplant Yes / No ✓ - ✓ 
HLA mismatch level Level 1 [000], Level 2 
[0 DR + 0/1 B], Level 
3 [0 DR + 2 B] or [1 
DR + 0/1 B], Level 4 
[1 DR + 2B] or [2 DR] 
- - ✓ 
Donor age <40, 40-49, 50-59, 
>=60 
✓ - ✓ 
Donor history of hypertension Yes / No / Unknown ✓ - - 
 
 
Health-state utility estimates 
Health-state utility estimates for transplant recipient and patients on the waiting list were 
captured in the ATTOM study using the EQ-5D-5L questionnaire. We developed 
multivariable regression models to identify patient characteristics that led to variations in 
utility scores to inform quality-adjustment of survival estimates in the simulation model 
(citation to ATTOM EQ-5D paper pending publication). Table 4 provides a summary of 
characteristics that were included as covariates for each of the patient groups.  
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Table 4 Summary of covariates in regression models to predict health state utilities used 
in the simulation model 
Covariate Categories Waiting list Transplant 
Gender Male  / Female ✓ ✓ 
Ethnicity White, Black, Other, 
Asian ✓ ✓ 
Primary renal diagnosis: diabetic nephropathy Yes / No ✓ ✓ 
Comorbidities    
Ischaemic heart disease  Yes / No ✓ ✓ 
Respiratory disease  Yes / No - ✓ 
Malignancy Yes / No - ✓ 
Mental illness  Yes / No ✓ ✓ 
Smoking status Non-smoker. Ex-
smoker, Current 
smoker 
✓ ✓ 
Time on dialysis Pre-dialysis, <1 
year, 1-3 years,      
>3 years 
✓ - 
 
Costs 
The costs of maintenance dialysis and transplant surgery were estimated in the simulation 
by applying fixed national tariffs [16]. We estimated annual hospital costs using two-part 
regression models that were developed by analysing patient-level data from linkage of the 
Hospital Episode Statistics dataset to UK Renal Registry data [17]. Hospital costs were 
captured by treatment modality (dialysis vs. transplantation) and by hospital setting 
(inpatient vs. outpatient) and regression models included a number of patient characteristics 
as covariates summarised in Table 5. For transplant recipients, the annual cost of 
maintenance immunosuppression assumed that patients received a combination of 
corticosteroids, a calcineurin inhibitor (50/50 split between ciclosporin and tacrolimus) and 
an antiproliferative agent (50/50 split between mycophenolate mofetil and azathioprine) 
[18]. 
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Table 5a Summary of covariates in regression models to predict hospital costs for dialysis 
patients in the simulation model  
 
Covariate Categories 
Dialysis 
inpatient 
Dialysis 
outpatient 
Age < 50, 50-64, 65-75, >75 ✓ ✓ 
Gender Male / Female ✓ ✓ 
Years on dialysis 1 to 6 ✓ ✓ 
Dialysis modality Haemodialysis / 
Peritoneal dialysis 
✓ ✓ 
Comorbidities     
Myocardial infarction Yes / No ✓ - 
Congestive heart failure Yes / No ✓ ✓ 
Peripheral vascular disease Yes / No ✓ ✓ 
Cerebrovascular disease Yes / No ✓ ✓ 
Respiratory disease Yes / No ✓ ✓ 
Liver disease Yes / No ✓ - 
Diabetes Yes / No ✓ ✓ 
Malignancy Yes / No  ✓ ✓ 
Hypertension Yes / No ✓ ✓ 
Year of death Yes / No ✓ ✓ 
 
 
Table 5b Summary of covariates in regression models to predict hospital costs for 
transplant patients in the simulation model  
 
Covariate Categories 
Transplant 
inpatient 
Transplant 
outpatient 
Age <35, 36-45, 46-55, >55 ✓ ✓ 
Gender Male / Female ✓ ✓ 
Years following transplant 1 to 6 ✓ ✓ 
Comorbidities    
Myocardial infarction Yes / No ✓ ✓ 
Congestive heart failure Yes / No ✓ ✓ 
Peripheral vascular disease Yes / No ✓ ✓ 
Cerebrovascular disease Yes / No ✓ ✓ 
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Respiratory disease Yes / No ✓ ✓ 
Liver disease Yes / No ✓ ✓ 
Diabetes Yes / No ✓ ✓ 
Malignancy Yes / No  ✓ ✓ 
Hypertension Yes / No ✓ ✓ 
Year of graft failure Yes / No ✓ ✓ 
Year of transplant surgery Yes / No ✓ ✓ 
Year of death  Yes / No  ✓ ✓ 
 
Running the simulation 
For each allocation scheme, we performed three runs using a separate random number 
stream for each run. A single run ends when all 4400 donor kidneys have been allocated or 
removed from further consideration if no match has been identified. Although we are 
primarily interested in comparing total costs and QALYs across all transplant recipients 
resulting from the different allocation schemes, it is also important to consider the outcomes 
of those patients who did not receive a transplant within the time frame of the simulation. 
For these patients, we made a simplifying assumption that they face a mortality risk 
equivalent to remaining on the waiting list until death and used this as the basis for 
projecting their lifetime costs and QALYs at the end of the simulation. For each allocation 
scheme, we present total discounted life years, QALYs and costs for all transplant recipients 
averaged across the three runs (with 95% confidence intervals) using a discount rate of 
3.5%. 
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RESULTS  
A summary of the main results for all transplant recipients for each of the five allocation 
schemes is shown in Table 6. The proportion of donor kidneys for which no match was 
identified was approximately 1% across all simulation runs and therefore the number of 
patients who received a transplant was similar across allocation schemes. Reassuringly, 
the utility-maximising scheme generated the most QALYs for transplant recipients but also 
led to the highest costs. Waiting-time allocation resulted in the lowest total QALYs and 
costs. Table 7 orders the allocation schemes by increasing total costs relative to waiting-
time as the baseline option and reports incremental cost-effectiveness ratios (ICERs). 
Figure 2 plots the five allocation schemes on the cost-effectiveness plane, showing how 
closely all of them are positioned to the cost-effectiveness frontier.  
Given the objective of maximising health gains from a scarce resource, the utility-
maximising allocation scheme produced results that were in line with expectations for 
transplant recipients, but a complete assessment of the consequences of an allocation 
scheme should also consider the outcomes for those patients who did not receive a 
transplant. For the purposes of estimating lifetime QALYs and costs, we applied a 
simplifying assumption that all patients who did not receive a transplant during the 
simulation remained on the waiting list until death. If we add these estimates to the total 
QALYs and costs for transplant recipients (Table 8), we see that the relative positions of the 
allocation schemes on the cost-effectiveness plane change (Figure 3). Longevity matching 
now produces the lowest total QALYs and costs, while the 2006 NKAS leads to the highest 
total QALYs and costs. Incremental analysis (Table 9) shows that random allocation and 
waiting-time allocation are dominated as they produce both fewer QALYs and higher costs 
compared to the utility-maximising allocation scheme. While the longevity matching and 
utility-maximising schemes both generated more QALYs for transplant recipients than the 
current national allocation scheme, they generated far fewer QALYs for those patients who 
we have assumed remain on the waiting list. 
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Table 6 Total discounted life years, QALYs and costs for all transplant recipients 
averaged across 3 runs (with 95% confidence interval)  
 Total discounted life 
years 
Total discounted 
QALYs 
Total discounted 
costs (millions) 
Allocation scheme 1: 
random 
49,773 (48,860, 50,687) 40,236 (39,434, 41,038) £ 591 (574, 607) 
Allocation scheme 2: 
waiting time 
48,848 (47,464, 50,233) 39,496 (38,390, 40,602) £ 584 (568, 601) 
Allocation scheme 3: 
2006 NKAS 
54,320 (52,956, 55,684) 44,040 (42,882, 45,198) £ 625 (619, 631) 
Allocation scheme 4: 
longevity matching 
55,061 (53,476, 56,646) 44,704 (43,316, 46,092) £ 632 (627, 638) 
Allocation scheme 5: 
utility-maximising 
58,951 (58,276, 59,625) 48,045 (47,542, 48,549) £ 681 (667, 694) 
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Table 7 Incremental cost-effectiveness analysis based on total costs and QALYs for transplant recipients  
 
  
Discounted costs  Discounted QALYs Comparison Incremental  cost Incremental  QALY ICER 
Allocation scheme 2: 
waiting time 
£  0 0  - -  -  - 
Allocation scheme 1: 
random 
 £  6,167,585  739 1 vs. 2  £  6,167,585  739  £ 8,342 / QALY 
Allocation scheme 3: 
2006 NKAS 
 £  40,375,355  4544 3 vs. 2  £  34,207,771  3804 £ 8,992 / QALY 
Allocation scheme 4: 
longevity matching 
 £  47,893,249  5208 4 vs. 3  £  7,517,894  664 £ 11,317 / QALY 
Allocation scheme 5: 
utility-maximising 
 £  80,033,713  8117 5 vs. 4  £  48,170,081  3341 £ 14,418 / QALY 
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Figure 2 Cost-effectiveness plane showing incremental costs and QALYs for transplant 
recipients only 
 
 
 
Table 8 Total discounted life years, QALYs and costs for all transplant recipients and 
waiting-list patients who did not receive a transplant averaged across 3 runs (with 95% 
confidence interval)  
 Total discounted life 
years 
Total discounted 
QALYs 
Total discounted costs 
(million) 
Allocation scheme 1: 
random 
83,983 (82,866, 85,100) 66,563 (65,607, 67519) £   1,679 (1,669, 1,690) 
Allocation scheme 2: 
waiting time 
83,328 (81,938, 84,718) 66,068 (64,957, 67,179) £   1,684 (1,665, 1702) 
Allocation scheme 3: 
2006 NKAS 
88,776 (87,627, 89,925) 70,569 (69,591,71,547) £   1,722 (1,710, 1,735) 
Allocation scheme 4: 
Longevity matching 
82,258 (80,754, 83,761) 65,665 (64,367, 66,964) £   1,473 (1,469, 1,478) 
Allocation scheme 5: 
utility-maximising 
85,506 (84,675, 86,336) 68,549 (67,915, 69,184) £   1,499 (1,480, 1,518) 
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Table 9 Incremental cost-effectiveness analysis identifying dominated alternatives based on total costs and QALYs for transplant recipients and waiting-
list patients who did not receive a transplant combined 
 
  
Discounted costs  Discounted QALYs Comparison Incremental  cost Incremental  QALY ICER 
Allocation scheme 4: 
longevity matching 
£  0  0  -  - -  - 
Allocation scheme 5: 
utility-maximising 
£  25,236,780 2,884 5 vs. 4 £ 25,236,780 2884 £ 8,752 
Allocation scheme 1: 
Random 
£  206,020,093 898 1 vs. 5 £ 180,783,313 -1986 Dominated 
Allocation scheme 2: 
waiting time 
£  210,422,609 403 2 vs. 5 £ 185,185,829 -2481 Dominated 
Allocation scheme 3: 
2006 NKAS 
£  248,891,110 4,904 3 vs. 5 £ 223,654,330 2020 £110,720 
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Figure 3 Cost-effectiveness plane showing incremental costs and QALYs for transplant 
recipients and patients who did not receive a transplant combined 
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DISCUSSION 
There are a number of examples from across the clinical, decision modelling and operations 
research literature that have described the application of simulation to evaluate different 
approaches to kidney allocation [4, 5, 7, 19, 20]. While these examples differ in terms of 
data sources, model structure, outcomes and allocation schemes of interest, all of them 
acknowledge the tension that exists between the competing objectives of equity in access 
to transplantation and efficient use of a limited supply of donor kidneys.  
The motivation for the simulation exercise described in this paper was not only to explore a 
number of newer allocation concepts in the UK context, but also to improve our ability to 
estimate variability in outcomes resulting from different approaches to allocation at the 
individual patient level. If alternative approaches to kidney allocation result in different 
patients receiving transplants, then an accurate comparison of the consequences of 
alternative allocation schemes depends on our ability to predict variability in outcomes 
dependent on individual patient characteristics. This simulation exercise relied on the 
availability of a number of rich sources of patient-level data including the ATTOM study, the 
UK Transplant Registry, Hospital Episode Statistics and the UK Renal Registry in order to 
develop predictive regression models to estimate survival, health state utilities and costs. 
These predictive models were not only used to estimate QALYs and costs for transplant 
recipients in all five allocation schemes, but were also used as part of the criteria to inform 
the kidney allocation process for the longevity matching and utility-maximising schemes.  
In our simulation, we demonstrated the feasibility of designing an allocation scheme that 
maximised total QALYs among transplant recipients by allocating each kidney to the patient 
on the waiting list who would gain the most QALYs compared to remaining on dialysis. 
However, when we also took into account outcomes for patients who were not prioritised to 
receive a transplant under the utility-maximising scheme, it was clear that this allocation 
scheme was no longer utility-maximising across the total patient population. The 
assumption that patients on the waiting list at the end of the simulation would never receive 
a transplant is unlikely to be met in practice. Survival on the waiting list is on average poorer 
than survival following transplant, so the likely effect of this assumption is that we have 
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underestimated total QALYs for all allocation schemes. However, it is difficult to anticipate 
the net impact of this assumption on the relative positions of the five allocation schemes on 
the cost-effectiveness plane in Figure 3. Different allocation criteria will result in different 
types of patients receiving transplants and by corollary, the composition of patients who 
remain on the waiting list will also differ between schemes. Under the waiting time allocation 
scheme, patients who remain on the waiting list at the end of the simulation would in practice 
still have a reasonable prospect of receiving a future transplant as their likelihood of being 
prioritised for transplant increases with time. In contrast, under the utility-maximising 
scheme, patients who remain on the waiting list at the end of the simulation may be less 
likely to receive a future transplant if their expected QALY gains from transplant decrease 
over time relative to new patients joining the waiting list. Rather than attempt to apply 
different assumptions to each allocation scheme to project what proportion or which types 
of patients on the waiting list are likely to receive a future transplant at the end of the 
simulation, we chose to implement a standardised assumption so as not to confound our 
ability to observe and compare the effect of the different allocation schemes themselves. 
Given the importance of this assumption on estimates of QALYs and costs for the total 
patient population, further modelling efforts should focus on testing alternative assumptions 
and, for example, explore if a non-terminating model could achieve a steady-state outcome 
that can be compared across allocation schemes over a long enough period of time. 
As with all simulation exercises, it was necessary to make a number of other simplifying 
assumptions that limit the generalisability and direct applicability of the results to the real 
world context. The ATTOM study recruited prevalent waiting list patients aged 18-75 years 
and therefore our analysis did not include any paediatric recipients. We also restricted the 
simulation to first-time transplant recipients and did not consider the impact of combined 
kidney and pancreas offers, which fall under a separate national allocation policy in the UK. 
With these caveats in mind, simulation modelling is still an important tool that can help 
increase our understanding of the potential consequences of different approaches to kidney 
allocation in relation to one another.   
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Although we chose to report lifetime QALYs and costs as the main outcomes of interest, 
this simulation exercise was not specifically designed with standard methods for cost-
effectiveness modelling at the forefront of our approach [21]. There were both technical and 
philosophical reasons that contributed to this decision. During development of the 
simulation model, primary emphasis was placed on the design, feasibility and coding of the 
different allocation schemes. Each scheme requires the simulation model to loop through 
all patients on the waiting list in order to evaluate donor-recipient compatibility. In the case 
of the utility-maximising and longevity matching schemes, survival predictions take into 
account both recipient and donor characteristics and therefore need to be recalculated for 
all patients on the waiting list each time a donor kidney enters the simulation. The 
computational burden of the allocation process itself led to long model running times even 
in the absence of introducing parameter uncertainty and therefore we were unable to 
perform probabilistic sensitivity analysis. On a more philosophical note, kidney allocation 
represents a somewhat unique resource allocation problem constrained not only by a finite 
healthcare budget, but more fundamentally by a limited supply of organs. Conventional 
cost-effectiveness methods focus on maximising health gains [22], but in the case of kidney 
allocation it is clear that maximising health gains is not the only objective. For this reason, 
we presented all five allocation schemes on the cost-effectiveness planes and refrained 
from comparing ICERs with respect to a specific willingness-to-pay threshold.  
The results of this simulation exercise cannot answer the question about what the objectives 
of a national kidney allocation scheme should be, but nonetheless provide insight into the 
magnitude of QALY and cost differences to inform the discussion about trade-offs 
associated with alternative allocation concepts from across the equity-efficiency spectrum. 
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6. DISCUSSION 
6.1. Research objective 
This thesis sought to use simulation modelling to compare the costs and consequences of 
alternative approaches to kidney allocation in the UK context from across the equity-
efficiency spectrum. The primary emphasis of this research was on feasibility, sourcing of 
data inputs and design of the modelling approach rather than on any attempt to define in a 
normative sense what the objectives of an allocation scheme should be. There is no 
shortage of discussion in the literature about the tension that exists between the competing 
priorities of ensuring equity in access to transplantation and making the most efficient use 
of a scarce resource.19,23,26,35 So far in this thesis, any attempt to define equity and efficiency 
has been limited to the use of these terms as anchors on either end of the spectrum to 
describe the relative positions of the allocation concepts of interest. Deeper insight into how 
trade-offs between equity and efficiency should be valued would require further research 
that is beyond the scope of this thesis. However, this concluding section will highlight some 
potential considerations arising from the simulation exercise. 
6.2. Key findings of simulation modelling results 
Reassuringly, the results of the simulation exercise demonstrated that the QALY-
maximising approach to kidney allocation generated the most QALYs among transplant 
recipients. The QALY-maximising scheme also generated the highest total costs for 
transplant recipients. This result is not entirely unexpected because the longer transplant 
recipients survive, the longer they will continue to incur costs. Allocation based on waiting 
time generated the fewest QALYs and costs. Although formal threshold analysis was not 
used to determine the optimal allocation strategy, ICERs for the 2006 NKAS, longevity 
matching and QALY-maximising approaches relative to waiting-time allocation were all well 
below the commonly referenced threshold of £30,000 / QALY. In the UK, this is the threshold 
below which the National Institute for Health and Care Excellence (NICE) generally 
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considers a technology, service or treatment strategy to be a cost effective use of NHS 
resources.53,54 
While the simulation exercise has clearly demonstrated the benefits of a QALY-maximising 
approach for patients who receive a transplant, less thorough consideration has been given 
to the implications for patients who are not prioritised to receive a transplant. Each run of 
the model simulated the allocation of kidneys from 2200 donors. As the model was designed 
to estimate lifetime costs and QALYs, an assumption had to be made about the lifetime 
costs and QALYs for those patients who did not receive a transplant during the simulation 
and therefore remained on the waiting list at the end of each run. To be consistent across 
allocation schemes, a simplifying assumption was made that patients who did not receive a 
transplant during the simulation would face a mortality risk equivalent to remaining on the 
waiting list until death. When the costs and QALYs for patients who remained on the waiting 
list were combined with those for transplant recipients, the relative positions of the allocation 
schemes on the cost-effectiveness plane changed, with longevity matching producing the 
lowest total costs and QALYs and the 2006 NKAS producing the highest.   
6.3. Equity considerations 
Although it is often stated that kidney allocation schemes should be designed to balance 
both efficiency and equity considerations, in practice there is a lack of clarity about how to 
define equity and a lack of data to inform discussions about the potential trade-offs between 
efficiency and equity that would be acceptable to society. Conventional cost-effectiveness 
methods aim to maximise efficiency, but do not explicitly consider equity. In order to 
supplement the results of the simulation model presented in Chapter 5, Tables 6.1 and 6.2 
demonstrate how the simulation model can also be used to explore the distributional 
consequences of each of the kidney allocation schemes in terms of equity in access to 
transplantation and equity in outcomes for example by patient age, gender, ethnicity and 
diabetes status. 
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Table 6.1 summarises the characteristics of the patients who received a transplant under 
each scheme alongside the prevalent waiting list at the start of the simulation. Allocation 
schemes that generated more total QALYs resulted in a lower proportion of kidneys being 
allocated to patients aged 50 years and over, as well as a lower proportion of male patients, 
diabetic patients and patients of white ethnicity.  
Table 6.2 summarises post-transplant outcomes in terms of mean undiscounted life years 
and QALYs. Compared to allocation based on waiting time, which produced the fewest total 
QALYs, the QALY-maximising approach to kidney allocation resulted in an average 
increase in life expectancy of 6.5 years (17.1 versus 23.6 years) and an average increase 
of 5.4 QALYs (13.9 versus 19.3 QALYs) for each transplant recipient. When considering 
the distribution of health outcomes by patient characteristics within each allocation scheme, 
Table 6.2 suggests that in comparison to the 2006 NKAS, the QALY-maximising approach 
resulted in larger differences in average life years and QALYs by gender and diabetes 
status, but smaller differences in average life years and QALYs by age group and ethnicity. 
There are many other possible ways of defining equity and many other patient 
characteristics that could be considered beyond the examples given here. Once again, the 
intention is not to use these results on the distributional consequences of the different kidney 
allocation schemes to try and draw a conclusion or make a recommendation about which 
of the allocation approaches is optimal. Rather, the motivation behind presenting these 
results is to highlight the richness of outputs that can be generated from the patient-level 
simulation model and, alongside the results presented in Chapter 5, can be used to inform 
future discussions about trade-offs between equity and efficiency in the design of a kidney 
allocation policy. 
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Table 6.1 Characteristics of transplant recipients for each allocation scheme and the initial prevalent waiting list 
 
Waiting list 
(n = 5500) 
Random 
allocation  
(n = 4352) 
Waiting time 
(n = 4376)  
2006 NKAS  
(n = 4341) 
Longevity 
matching  
(n = 4346) 
QALY-
maximising  
(n = 4355) 
Age, mean years (SD) 51·1 (12·7) 51·4 (12·8) 52·6 (12·3) 46·7 (12·5) 46·4 (12·6) 41·8 (10·7) 
Age group, n (%)             
18-29  369 (7%) 299 (7%) 210 (5%) 442 (10%) 461 (11%) 645 (15%) 
30-39 708 (13%) 541 (12%) 486 (11%) 846 (19%) 886 (20%) 1204 (28%) 
40-49 1245 (22%) 957 (22%) 940 (21%) 1216 (28%) 1251 (29%) 1562 (36%) 
50-59 1576 (29%) 1229 (28%) 1316 (30%) 1075 (25%) 986 (23%) 779 (18%) 
>60 1602 (29%) 1326 (31%) 1424 (33%) 762 (18%) 762 (18%) 165 (4%) 
Gender, n (%)             
Male 3180 (58%) 2529 (58%) 2511 (57%) 2431 (56%) 2422 (56%) 2175 (50%) 
Female 2320 (42%) 1823 (42%) 1865 (43%) 1910 (44%) 1924 (44%) 2180 (50%) 
Ethnicity, n (%)             
White 4017 (73%) 3146 (72%) 3128 (72%) 3003 (69%) 3005 (69%) 2904 (67%) 
Asian 727 (13%) 634 (15%) 602 (14%) 659 (15%) 666 (15%) 738 (17%) 
Black  616 (11%) 465 (11%) 535 (12%) 555 (13%) 552 (13%) 571 (13%) 
Other 140 (3%) 107 (2%) 111 (2%) 124 (3%) 123 (3%) 142 (3%) 
Diabetes, n (%)             
No 4674 (85%) 3680 (85%) 3715 (85%) 3714 (86%) 3749 (86%) 3879 (89%) 
Yes 826 (15%) 672 (15%) 661 (15%) 627 (14%) 597 (14%) 476 (11%) 
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Table 6.2 Average undiscounted post-transplant life years and QALYs per patient for each allocation scheme and by patient characteristics 
 Random allocation Waiting time 2006 NKAS Longevity matching QALY-maximising 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
                
All patients                
  Life years 18·0  (16·6) 17·1  (15·6) 21·1  (19·5) 21·2  (19·1) 23·6  (20·8) 
  QALYs 14·6  (13·6) 13·9  (12·8) 17·1  (16·0) 17·2  (15·7) 19·3  (17·2) 
                
Life years Mean 95% CI p-value Mean 95% CI p-value Mean 95% CI p-value Mean 95% CI p-value Mean 95% CI p-value 
By age                
  18-29  27·2 (25·5, 29·0) <0·0001 27·2 (25·2, 29·1) <0·0001 32·8 (31·1, 34·5) <0·0001 31·5 (29·9, 33·1) <0·0001 29·2 (27·7, 30·8) <0·0001 
  30-39 26·5 (25·2, 27·8)  25·4 (24·1, 26·7)  29·2 (28·0, 30·5)  30·2 (29·0, 31·3)  27·5 (26·3, 28·6)  
  40-49 23·5 (22·5, 24·4)  22·2 (21·2, 23·1)  23·4 (22·4, 24·4)  22·6 (21·7, 23·6)  23·4 (22·4, 24·4)  
  50-59 15·2 (14·4, 16·1)  15·0 (14·2, 15·8)  14·5 (13·4, 15·6)  14·5 (13·4, 15·6)  15·6 (14·2, 17·1)  
  >60 11·2 (10·3, 12·0)  11·4 (10·7, 12·2)  10·7 (9·5, 12·0)  11·0 (9·8, 12·3)  13·2 (10·1, 16·3)  
By gender                
  Male 18·0 (17·3, 18·6) 0·7986 17·0 (16·4, 17·7) 0·7329 21·0 (20·3, 21·8) 0·9126 21·5 (20·7, 22·2) 0·3349 24·5 (23·8, 25·4) 0·0069 
  Female 18·1 (17·3, 18·9)  17·2 (16·5, 17·9)  21·1 (20·2, 22·0)  20·9 (20·1, 21·8)  22·8 (21·9, 23·6)  
By ethnicity                
  White 17·6 (17·1, 18·2) 0·0097 16·8 (16·3, 17·3) 0·1442 20·8 (20·1, 21·5) 0·0143 20·7 (20·1, 21·4) 0·0112 23·6 (22·9, 24·4) 0·1385 
  Asian 18·8 (17·5, 20·0)  18·3 (17·0, 19·5)  21·7 (20·2, 23·2)  23·0 (21·5, 24·4)  24·7 (23·2, 26·2)  
  Black  18·7 (17·2, 20·2)  17·7 (16·4, 19·0)  20·5 (18·9, 22·1)  21·0 (19·4, 22·6)  22·9 (21·1, 24·6)  
  Other 22·5 (19·3, 25·6)  16·8 (13·9, 19·7)  26·3 (22·9, 29·7)  24·4 (21·1, 27·8)  20·7 (17·3, 24·2)  
By diabetes                
  No 18·7 (18·2, 19·3) <0·0001 17·9 (17·4, 18·4) <0·0001 22·0 (21·4, 22·7) <0·0001 22·2 (21·5, 22·8) <0·0001 24·6 (24·0, 25·3) <0·0001 
  Yes 14·3 (13·3, 15·3)  12·9 (12·0, 13·8)  15·4 (14·3, 16·5)  15·3 (14·2, 16·5)  15·4 (14·1, 16·6)  
                
QALYs Mean 95% CI p-value Mean 95% CI p-value Mean 95% CI p-value Mean 95% CI p-value Mean 95% CI p-value 
By age                
  18-29  22·4 (21·0, 23·9) <0·0001 22·4 (20·7, 24·0) <0·0001 27·1 (25·7, 28·5) <0·0001 26·0 (24·6, 27·3) <0·0001 24·1 (22·8, 25·4) <0·0001 
  30-39 21·4 (20·3, 22·5)  20·6 (19·6, 21·7)  23·8 (22·8, 24·8)  24·5 (23·6, 25·5)  22·4 (21·5, 23·4)  
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  40-49 18·9 (18·1, 19·7)  17·9 (17·1, 18·7)  18·9 (18·1, 19·8)  18·3 (17·5, 19·1)  19·1 (18·2, 19·9)  
  50-59 12·3 (11·6, 13·0)  12·1 (11·2, 12·8)  11·7 (10·8, 12·6)  11·7 (10·8, 12·6)  12·7 (11·5, 13·9)  
  >60 9·0 (8·4, 9·7)  9·2 (8·6, 9·8)  8·7 (7·6, 9·7)  8·9 (7·9, 10·0)  10·7 (8·1, 13·2)  
By gender                
  Male 14·7 (14·1, 15·2) 0·6211 13·9 (13·4, 14·4) 0·6494 17·3 (16·6, 17·9) 0·5030 17·6 (17·0, 18·2) 0·0864 20·2 (19·5, 21·0) 0·0004 
  Female 14·5 (13·8, 15·1)  13·8 (13·2, 14·3)  16·9 (16·2, 17·7)  16·8 (16·1, 17·5)  18·4 (17·7, 19·0)  
By ethnicity                
  White 14·3 (13·8, 14·8) 0·0068 13·7 (13·2, 14·1) 0·3586 17·0 (16·4, 17·5) 0·0170 16·9 (16·3, 17·5) 0·0575 19·4 (18·7, 20·0) 0·4163 
  Asian 14·7 (13·7, 15·8)  14·3 (13·3, 15·4)  17·1 (15·9, 18·4)  18·2 (17·0, 19·4)  19·6 (18·4, 20·9)  
  Black  15·4 (14·2, 16·6)  14·5 (13·5, 15·6)  16·9 (15·6, 18·3)  17·4 (16·1, 18·7)  18·9 (17·5, 20·4)  
  Other 18·6 (16·0, 21·1)  13·6 (11·3, 16·0)  21·6 (18·8, 24·4)  20·0 (17·3, 22·8)  17·1 (14·3, 19·9)  
By diabetes                
  No 15·3 (14·9, 15·8) <0·0001 14·6 (14·2, 15·1) <0·0001 18·1 (17·5, 18·6) <0·0001 18·2 (17·7, 18·7) <0·0001 20·3 (19·7, 20·8) <0·0001 
  Yes 10·4 (9·7, 11·2)  9·5 (8·8, 10·1)  11·4 (10·6, 12·1)  11·3 (10·5, 12·1)  11·4 (10·5, 12·3)  
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6.4. Policy implications 
If the explicit objective of a kidney allocation scheme is to maximise health gains from a 
limited supply of kidneys, then this simulation exercise demonstrates how this can be 
achieved through the QALY-maximising scheme. However, the simulation also provides 
insight into some of the potential unintended consequences of a QALY-maximising 
approach:  
1. Although it produces the most QALYs, it also generates the highest costs 
2. Inequity in access: similar to the LYFT concept, a QALY-maximisation approach can 
negatively impact access to transplantation for patients with lower expected QALY 
gains, such as diabetic patients and older patients  
3. Inequity in outcomes: while health gains for transplant recipients are maximised, 
patients who are not prioritised for a transplant may have worse outcomes. 
Before making changes to a kidney allocation scheme, the underlying policy objectives 
need to be understood and made explicit. This simulation exercise on its own cannot be 
used as the basis for recommending a change in policy, but it quantifies the magnitude of 
potential gains and losses associated with moving from one allocation strategy to another. 
It also reveals some of the complexities of the decision problem. This information can help 
inform the debate about trade-offs between allocation approaches. The simulation exercise 
presented in this thesis only compared five different allocation concepts from across the 
equity-efficiency spectrum, but there are many more potential approaches or combinations 
of approaches that could be explored using the same data inputs and model structure.  
6.5. Contributions of this research to the field 
There are a number of ways in which this research contributes to the field of kidney 
transplantation and allocation: 
1. New insight into variations in hospital costs for RRT patients 
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Linkage of the UK Renal Registry and HES datasets provided a rare opportunity to analyse 
variations in hospital costs over time for RRT patients in relation to age, treatment modality 
and comorbidities. The regression models that were developed in Chapter 2 can also be 
used as cost inputs in other cost-effectiveness analyses involving RRT patients. 
2. Application of flexible parametric modelling techniques to analyse post-transplant 
survival 
While the use of standard parametric models to extrapolate survival data in economic 
evaluation is well established, there are still relatively few applied examples of flexible 
parametric modelling techniques in the literature. The survival models described in Chapter 
3 have two important features that were crucial for the simulation of alternative kidney 
allocation schemes. Firstly, the flexible parametric modelling approach facilitates 
extrapolation of the data in order to predict mean survival. This allowed survival estimates 
to be used both deterministically (for the calculation of expected post-transplant survival in 
the longevity matching allocation scheme and for the calculation of QALY differences in the 
utility-maximising scheme) and stochastically to model competing risks after each kidney 
had been allocated to a specific patient. Secondly, the survival model was based on a 
historical cohort of patients from the UK Transplant Registry and allowed for inclusion of 
both donor and recipient characteristics as covariates in the analysis, thus facilitating the 
prediction of expected post-transplant survival for each patient taking into consideration the 
characteristics of a given donor, namely age and hypertension status. 
3. Updated health-state utility estimates for transplant recipients and waiting list patients 
The ATTOM study presented an opportunity to collect utility values in a large, representative 
population of ERF patients in the UK using the EQ-5D-5L questionnaire. Using data 
collected on patient and treatment factors, regression models were fitted to provide insight 
into variations in health-state utility values, including characterisation of the decline in health 
status in relation to time on dialysis. Similar to the models for estimating hospital costs, the 
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regression models in Chapter 4 and Appendix 4 can be used as inputs to inform other cost-
effectiveness analyses involving RRT patients. 
4. Exploration of newer allocation concepts that have not previously been studied in the 
UK context  
The concepts of longevity matching and utility-maximisation emerged in the last 10 years 
as part of the proposals to revise the kidney allocation scheme in the US, but these concepts 
have not previously been studied in the UK context. The simulation exercise undertaken for 
this thesis tested these newer concepts using UK data and allowed for a comparison of 
outcomes with the current national allocation scheme. In addition, this thesis demonstrated 
the feasibility of designing an allocation system that can estimate post-transplant survival 
for each potential recipient for a given donor kidney. In theory, this should further optimise 
the matching process in comparison to predictive models that are based on an average 
donor or an average patient. Interestingly in the US, when the OPTN was considering LYFT 
as a potential allocation concept, matching each kidney and patient was deemed too 
complicated and unpredictable to be feasible.30 This is likely because the LYFT calculation 
attempted to simultaneously model graft failure and patient survival and included a much 
larger number of covariates than the final predictive models presented in this thesis, 
highlighting the trade-off between complexity and feasibility that is inherent in the modelling 
process.24 
5. Quantification of the consequences of different allocation schemes in terms of both 
costs and QALYs 
None of the previously identified simulation studies (Chapter 1) that have compared 
different approaches to deceased donor kidney allocation have quantified outcomes in 
terms of both lifetime costs and QALYs. Although the supply of donor kidneys is often seen 
as the primary resource constraint that limits the rate of transplantation, all decision-making 
in healthcare is subject to a budget constraint and therefore cost should be a relevant 
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consideration. Going beyond survival to report quality-adjusted survival or QALYs 
recognises the fact that there are disparities in health status associated with different RRT 
modalities. Although a decision was made not to evaluate the ICERs from the simulation 
exercise by applying a specific willingness-to-pay threshold, policy makers may wish to do 
so alongside equity and distributional considerations.   
6.6. Limitations  
As a simulation exercise, there are several ways in which the model and results presented 
here may not accurately reflect the kidney allocation process in the real world. The waiting 
list population in the simulation model was based on patients recruited into the ATTOM 
study and therefore did not include any paediatric candidates. Elements on the 2006 NKAS 
give priority to paediatric patients, and this has not been directly modelled here. Structurally, 
the model also made a number of important simplifying assumptions. For example, the 
model did not allow for re-transplantation and the waiting list was maintained at a constant 
size throughout. In terms of data inputs and assumptions, health-state utility estimates for 
transplant patients only reflected data that were captured at a single point in time in the 
ATTOM study (6 months after transplant) as the study design and resources did not allow 
for longitudinal measurement. However, given that all of the allocation schemes were run 
using the same data inputs and subject to the same set of assumptions, these limitations 
reinforce the fact that, as with any simulation modelling exercise, the outputs should be 
interpreted in terms of the costs and consequences of the five allocation schemes in relation 
to one another, rather than the absolute value of any one output in isolation.  
The most important limitation of this simulation exercise is the assumption that was made 
regarding the outcomes for those patients who did not receive a transplant. Factoring in the 
costs and QALYs for these patients had a dramatic effect on the relative positions of the 
allocation schemes on the cost-effectiveness plane. This also raises questions about the 
objectives and principles underpinning allocation concepts. For example, is an allocation 
strategy still QALY-maximising if it only maximises outcomes among patients who receive 
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a transplant? Whose outcomes matter? This simulation exercise cannot provide the 
answers, but brings to light some of the questions that require further consideration. 
Finally, although the patient-level analyses of costs, survival and health-state utility values 
all provided estimates of uncertainty, it was not possible to consider parameter uncertainty 
in the simulation process as this would have had profound implications for model running 
time. It is possible that if the coding of the allocation process itself could be made more 
efficient, parameter uncertainty could be incorporated to allow for a fully probabilistic 
analysis.  
6.7. Areas for future research  
There are two main areas of future research that have emerged as priorities resulting from 
this thesis: 
1. Explore alternate assumptions and modelling approaches to determine outcomes for 
patients who are not prioritised to receive a transplant 
Using information about which types of patients received a transplant under each of the 
allocation schemes, predictive models could be developed to estimate time to 
transplantation for each of the patients who remains on the waiting list at the end of the 
simulation run, from which more accurate estimates of lifetime costs and QALYs could be 
generated. Alternatively, if the model could be run continuously by repeating the sequence 
of arriving donor kidneys many times, it may be possible to achieve a steady-state that can 
be compared across allocation schemes.  
2. Determine priorities and societal preferences in trading off equity and efficiency in the 
design of a national kidney allocation scheme 
Conventional methods for economic evaluation place emphasis on informing decisions that 
maximise efficiency but do not give consideration to distributional effects. Implicitly each 
QALY is assigned equal value irrespective of the characteristics of the recipients or how the 
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health gains are achieved, thereby overlooking the equity dimension of resource allocation 
decisions.55-57  
Alternative methods exist to help make resource allocation decisions when faced with 
multiple and sometimes conflicting objectives. Multi-criteria decision analysis (MCDA) 
methods are increasingly being applied to healthcare decision making and can provide a 
structured, explicit approach that can also improve transparency in decision making 
processes.58 This thesis has demonstrated the range of outputs that can be generated from 
the simulation model, including total costs and QALYs associated with each approach to 
allocation and the impact of different allocation schemes in terms of equity in access to 
transplantation and the distribution of outcomes among patients. An MCDA approach could 
be used in a deliberative process that brings together relevant stakeholders in order to 
identify which attributes of a kidney allocation scheme are important by considering some 
of the questions that have emerged in this thesis, including: 
 In which patient population should we be seeking to maximise outcomes, transplant 
recipients or all ERF patients (including those who do not receive transplants)? 
 How should equity be defined? In terms of access to transplantation? In terms of 
outcomes of transplantation? What patient characteristics are relevant to consider? 
What distribution of outcomes would be considered equitable? 
 Are there other attributes beyond efficiency and equity that are important in the design 
of a national kidney allocation policy?  
If it is possible to reach agreement on the relative importance of these attributes through a 
deliberative process, then each of the allocation schemes could be scored in relation to 
these attributes to produce an overall ranking and identify the preferred approach to 
allocating deceased donor kidneys in the UK. 
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APPENDIX 1: Summary of economic evaluation literature comparing transplantation and dialysis 
Table 1 Economic evaluations comparing dialysis and transplantation – basic study characteristics 
 
  
Author Year Title Journal Country Population Intervention Comparator 
Modelling 
approach 
Patient 
characteristics 
and co-
morbidities 
Perspective 
Time 
horizon 
Outcomes and 
key health events 
1 Klarman  1968 Cost 
effectiveness 
analysis applied 
to the treatment 
of chronic renal 
disease 
Medical Care  USA Chronic 
renal 
disease  
Haemodialysis  Transplantation Cumulative 
costs and 
life 
expectancy 
analysis  
(decision 
tree) 
Age Health service Lifetime Life years 
2 Stange  1978 Predicting 
treatment costs 
and life 
expectancy for 
end-stage renal 
disease 
New England 
Journal of 
Medicine 
USA ESRD 
patients 
Transition from 
facility dialysis to 
home dialysis 
Transition from 
facility dialysis to 
cadaveric 
transplantation; 
transition from 
home dialysis to 
cadaveric 
transplantation 
Cumulative 
costs and 
life 
expectancy 
analysis  
(decision 
tree) 
Not specified Health service 
(Medicare) 
10 years Dialysis survival, 
graft and 
transplant survival  
3 Roberts 1980 Cost-effective 
care of end-
stage renal 
disease: a billion 
dollar question 
Annals of 
Internal 
Medicine 
USA ESRD 
patients 
Home 
haemodialysis, 
centre 
haemodialysis 
Cadaver donor 
transplantation, 
live related donor 
transplantation 
Simulation 
(INS 
language) 
Age Medicare Lifetime Transplantation, 
dialysis, death 
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4 Ludbrook  1981 A cost-
effectiveness 
analysis of the 
treatment of 
chronic renal 
failure 
Applied 
Economics 
UK Patients 
with chronic 
renal failure 
Hospital dialysis, 
home dialysis 
Dialysis and 
transplantation 
Markov (1 
month 
cycle) 
Age  Department of 
Health 
Lifetime Dialysis training, 
hospital dialysis, 
home dialysis, first 
transplant, 
rejection, death 
5 Ohi 1986 Why are 
cadaveric renal 
transplants so 
hard to find in 
Japan? 
Health Policy Japan ESRD 
patients 
Haemodialysis  Transplantation Cumulative 
costs and 
life 
expectancy 
analysis  
Not specified Payer (health 
insurance) 
Lifetime Survival, graft loss 
rate for 
transplantation, % 
on dialysis after 
graft failure 
6 Garner 1987 Cost-
effectiveness 
analysis of end-
stage renal 
disease 
treatments 
Medical Care USA ESRD 
patients 
Home dialysis, 
in-centre dialysis 
Living-related 
donor transplant, 
cadaveric 
transplant 
Cumulative 
costs and 
life 
expectancy 
analysis  
(decision 
tree) 
Age, sex Health service 
(gross social 
costs model) 
and societal 
(net social 
costs model) 
20 years Life years x (value 
of a life year); 
assumed dialysis 
patients continue 
on same modality 
for entire period, 
transplant patients 
could experience 
graft failure, 
second transplant 
and dialysis 
7 Laupacis 1996 A study of the 
quality of life 
and cost-utility 
of renal 
transplantation 
Kidney 
International 
Canada Clinically 
stable 
patients on 
transplant 
list for at 
least 3 
months 
Transplantation Dialysis Prospective 
within-trial 
analysis  
(decision 
tree) 
Age, gender, 
time on dialysis, 
employment 
status, type of 
renal disease 
Societal 2 years 
after 
transplant
ation 
Survival at 2 years 
(patient and graft), 
quality of life, 
employment 
outcome 
8 Hornberger 1997 Cost-
effectiveness of 
repeat medical 
procedures: 
kidney 
transplantation 
as an example 
Medical 
Decision 
Making 
USA ESRD 
patients 
who are 
candidates 
for 
transplantati
on 
Re-
transplantation 
policy in event of 
graft failure 
No re-
transplantation 
policy 
Markov 
(monthly 
cycle) 
None Societal Lifetime On dialysis (pre-
transplant), first 
transplant, failed 
first transplant, 
repeat transplant, 
failed repeat 
transplant, death 
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9 de Wit 1998 Economic 
evaluation of 
end stage renal 
disease 
treatment 
Health Policy Netherlands Patients 
receiving 
ESRD 
treatment  
5 forms of 
dialysis (home 
HD, limited care 
HD, in-centre 
HD, CAPD, 
CCPD) 
Renal transplant Markov (1 
year cycle)  
Age, gender, 
number of 
comorbid 
diseases, 
months on 
dialysis 
Societal 5 years Death, technical 
failure,  
10 Douzdjian 1998 Treatment 
strategies for 
insulin0depende
nt diabetics with 
ESRD: a cost-
effectiveness 
decision 
analysis model 
American 
Journal of 
Kidney 
Diseases 
USA Patients 
with type 1 
diabetes 
and ESRD 
Dialysis Transplant from 
cadaver donor, 
transplant from 
living donor, 
simultaneous 
pancreas-kidney 
transplant 
Decision 
tree  
None Medicare 5 years Dialysis, graft 
failure, death and 4 
health states for 
pancreas-kidney 
transplant 
recipients: dialysis-
free/insulin-free, 
dialysis-
free/insulin-
dependent, dialysis 
dependent/insulin-
free, dialysis-
dependent/insulin-
dependent 
11 Kalo 2001 Economic 
evaluation of 
kidney 
transplantation 
versus 
haemodialysis in 
patients with 
end-stage renal 
disease in 
Hungary 
Progress in 
Transplantati
on 
Hungary ESRD 
patients 
Cadaveric 
kidney 
transplantation 
Haemodialysis Retrospecti
ve analysis 
of patient 
files  
(decision 
tree) 
Age, gender, 
time on dialysis 
National 
health insurer 
3 years   
12 Kaminota 2001 Cost-
effectiveness 
analysis of 
dialysis and 
kidney 
transplants in 
Japan 
Keio J Med Japan ESRD 
patients 
who are 
candidates 
for dialysis 
or 
transplantati
on 
Transplantation Dialysis Decision 
tree 
(implied) 
Age Health insurer Lifetime Duration on 
dialysis, survival 
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13 Greiner 2001 Socio-economic 
evaluation of 
kidney 
transplantation 
in Germany 
Archives of 
Hellenic 
Medicine  
Germany ESRD 
patients on 
wait list for 
kidney 
transplant 
Transplantation Dialysis Prospective 
single 
centre 
study  
(decision 
tree) 
None Societal  Not 
specified 
Survival status and 
transplant function 
in first year, quality 
of life (EQ-5D and 
NHP), survival 
between dialysis 
and transplant 
assumed to be 
equal 
14 Jassal 2003 Kidney 
transplantation 
in the elderly: a 
decision 
analysis 
J Am Soc 
Nephrol 
Canada Patients 
stable on 
dialysis 
aged 65 yrs 
or more 
Transplantation Dialysis Markov (3 
month 
cycle) 
Separate 
analyses for 
patients with 
diabetes or 
cardiovascular 
disease  
Third-party 
payer 
Lifetime Dialysis, 
transplant, acute 
rejection, 
transplant-related 
complication, acute 
rejection and 
transplant-related 
complication, 
death 
15 Mutinga 2005 Consequences 
of eliminating 
HLA-B in 
deceased 
kidney allocation 
to increase 
minority 
transplantation 
American 
Journal of 
Transplantati
on 
USA ESRD 
patients on 
dialysis 
awaiting 
transplantati
on 
Allocation policy 
with HLA antigen 
matching 
Allocation policy 
without HLA 
antigen matching, 
allocation policy 
with HLA matching 
by partial priority 
to minorities 
Markov (1 
year cycle) 
Costs adjusted 
for (patient age, 
race, gender, 
degree of 
immunologic 
sensitization, 
cause of renal 
disease, insulin 
dependence, 
length of time on 
dialysis, number 
of HLA 
mismatches); 
survival adjusted 
for (age, race, 
gender, cause of 
renal disease, 
blood type) 
Medicare  20 years Functioning 
transplant (alive), 
functioning 
transplant (death), 
return to dialysis 
(retransplantation 
not explicitly 
modelled, but 
included as part of 
patients who return 
to dialysis), death 
after return to 
dialysis 
16 Lee 2006 A simulation 
model to 
estimate the 
cost and 
effectiveness of 
alternative 
dialysis initiation 
strategies 
Medical 
Decision 
Making 
USA ESRD 
patients 
Current practice Early initiation, late 
initiation, no 
dialysis (wait for 
transplant only) 
Simulation 
(ANSI C 
programmin
g) 
Demographics: 
age, gender, 
race, blood type 
(correlates with 
waiting time for 
transplant); 
cormorbid 
conditions: 
diabetes, CV 
disease, CHF, 
cancer; disease 
markers: eGFR, 
Payer 
(Medicare) 
Lifetime eGFR 
deterioriation, 
transplant, graft 
failure, 
hospitalization, 
death (all hazard 
rates) 
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serum albumin; 
clinical flags: 
previously 
hospitalised, 
currently on 
transplant 
17 Kontodimop
oulos 
2008 An estimate of 
lifelong costs 
and QALYs in 
renal 
replacement 
therapy based 
on patients' life 
expectancy 
Health Policy Greece  ESRD 
patients 
In-center 
haemodialysis, 
peritoneal 
dialysis 
Transplantation Cumulative 
costs and 
life 
expectancy 
analysis  
(decision 
tree) 
Age, gender Health service 
(implied) 
Lifetime Life expectancy 
(90-day, 1, 2 and 
5-year survival 
curves) 
18 Howard 2009 The cost-
effectiveness of 
increasing 
kidney 
transplantation 
and home-
based dialysis 
Nephrology Australia New ESKD 
patients 
Service 
provision model 
(1) increase rate 
of kidney 
transplantation 
by 10% and 50% 
(2) increase 
number of new 
dialysis patients 
receiving home-
based care (by 
50% on PD, by 
2-35% 
depending on 
age for HHD) 
Current practice Markov 
(multiple 
cohort, 1 
year cycle) 
Stratified by age 
group, time-
dependent 
probabilities 
used for first 5 
cycles 
Central 
healthcare 
funder  
Lifetime Pre-emptive 
transplant (does 
not differentiate 
between live or 
deceased), dialysis 
(hospital HD, home 
HD, satellite HD, 
PD), transplant 
(does not 
differentiate 
between live or 
deceased), graft 
failure, re-graft, 
death ESKD, death 
other causes 
19 Perovic 2009 Renal 
transplantation 
vs 
haemodialysis: 
cost-effective 
analysis 
Vojnosanitets
ki Pregled 
Serbia ESRD 
patients 
Haemodialysis  Transplantation Cumulative 
costs and 
life 
expectancy 
analysis 
None Health insurer 10 years Not clearly 
described 
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20 Haller 2011 Cost-
effectiveness 
analysis of renal 
replacement 
therapy in 
Austria 
Nephrol Dial 
Transplant  
Austria Incident 
ESRD 
disease 
patients 
Strategy 1: 
current 
assignment to 
haemodialysis 
(90.6%) 
peritoneal 
dialysis (7.2%), 
transplantation 
(living donor 
0.1%), 
transplantation 
(deceased donor 
2.1%)  
Strategy 2: 
increase PD by 
20%; Strategy 3: 
increase PD by 
20% and increase 
living donor 
transplantation by 
10% 
Markov 
(monthly 
cycle) 
Reported age, 
gender, co-
morbidities at 
baseline but not 
used in model 
Health service 10 years Haemodialysis 
(first 12 mths, 13-
24 mths, beyond 
25 mths), 
peritoneal dialysis 
(first 12 mths, 13-
24 mths, beyond 
25 mths), living 
donor 
transplanation (first 
12 mths), 
deceased donor 
transplantation 
(first 12 mths), 
transplantation 
(13-24 mths), 
transplantation 
(beyond 25 mths), 
death 
21 Wong  2012 Comparative 
survival and 
economic 
benefits of 
deceased donor 
kidney 
transplantation 
and dialysis in 
people with 
varying ages 
and co-
morbidities 
PLoS One Australia, 
New Zealand 
Potential 
transplant 
candidates 
Listing on 
deceased kidney 
donor waiting list 
and 
transplanting 
(approx 10 
health states) 
Non waitlisting on 
dialysis (approx 5 
health states) 
Markov (1 
year cycle) 
in 
Treeage/Ex
cel 
Cardiovascular 
disease, 
diabetes, 
cerebrovascular 
disease, obesity, 
smoking status, 
age at listing and 
transplantation 
Third-party 
payer 
Lifetime Allograft failure, 
dialysis, death, 
post-transplant 
complications, 
delayed graft 
function, wound 
infection 
22 Villa  2012 Cost-
effectiveness 
analysis of the 
Spanish renal 
replacement 
therapy program 
Peritoneal 
Dialysis 
International 
Spain ESRD 
patients  
Strategy 1: 
current situation 
(with respect to 
scheduled 
dialysis patients 
i.e. to avoid non-
planned or 
urgent start 
patients) 
Strategy 2: 
increase in 
scheduled incident 
patients; Strategy 
3: constant 
scheduled 
incidence, 
increase PD, lower 
HD; Strategy 4: 
increase in 
scheduled incident 
patients and 
increase PD 
Markov (1 
year cycle) 
Not specified Societal 5, 10 and 
15 years 
Haemodialysis, 
peritoneal dialysis, 
transplantation, 
death 
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Table 2 Economic evaluations comparing dialysis and transplantation – data sources and results 
 
 Author Year 
Source of clinical 
data 
Modelling 
outcomes 
Cost categories Source of cost data 
Outputs 
reported 
Sensitivity 
analysis 
Key conclusion 
1 Klarman  1968 Death rate on 
dialysis, 
transplantation and 
failures (Committee 
on Chronic Kidney 
Disease, Bureau of 
the Budget), quality 
adjustment for life 
after 
transplantation vs. 
dialysis (source or 
assumptions not 
specified) 
Assume 
constant death 
rate for 
subsequent 
years 
Transplantation, re-
transplantation, maintenance 
drugs, dialysis 
Not specified Life years 
gained, cost per 
life year for 
dialysis vs. 
transplantation 
None Maximising 
transplantation is 
the more effective 
way to increase life 
expectancy at a 
given cost 
2 Stange  1978 Dialysis survival 
(National Dialysis 
Registry), graft and 
transplant survival 
(Human Renal 
Transplant Registry 
NIH) 
Linear 
extrapolation 
Annual cost of facility dialysis, 
annual cost of home dialysis, 
cost of cadaveric 
transplantation (1st year, 
subsequent years for stable vs. 
unstable patients), rejection 
costs 
Medicare (Health Care 
Financing Administration) 
Discounted life 
years and costs 
for 1000 patient 
cohort for each 
treatment and 
then for shifting 
patients from 
one treatment to 
another 
('incremental') 
Low and high 
assumptions for 
cadaveric 
transplantation cost 
and survival 
Shifting patients 
from facility to 
home dialysis leads 
to similar life 
expectancy and 
lower costs. 
Shifting patients 
from dialysis to 
transplant may 
reduce life 
expectancy 
(associated with 
higher first-year 
mortality) and also 
reduce costs 
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3 Roberts 1980 Survival on dialysis 
(National Dialysis 
Registry), patient 
and graft survival 
on transplant 
(Human Renal 
Transplant 
Registry) 
Assumed 
constant 
survival after 
Year 1 post-
transplant 
Home haemodialysis (first year  
training, physician fees, 
modifications to home, 
equipment purchase, supplies; 
subsequent years including 
declotting and access revisions, 
hospitalizations, routine lab 
work); in-centre haemodialysis 
(Medicare charge and medical 
costs similar to home); 
transplantation (first year 
including kidney retrieval, 
hospitalisation, physician fees, 
complications, 
immunosuppressive therapy); 
follow-up for subsequent years 
after transplantation (including 
hospitalisations), graft rejection 
Dialysis (Medicare charge 
data), General Accounting 
Office, literature 
Life expectancy 
(survival), 
average cost 
per patient, 
average cost 
per life year for 
each treatment 
Survival probability 
on dialysis, 
proportion of 
patients treated, 
survival probability 
after cadaver 
transplantation, 
discounting 
In-centre dialysis is 
not cost effective 
4 Ludbrook  1981 Transition 
probabilities 
(unpublished data 
from regional 
health authority), 
patient and graft 
survival (European 
Dialysis and 
Transplant Society, 
including by age 
group) 
Not applicable Not described Unpublished Department 
of Health and Social 
Security study, age effect 
(assumptions) 
Cost per life 
year gained 
Discount rate Transplantation is 
most cost-effective, 
however selection 
criteria such as age 
may affect outcome 
of the cost-
effectiveness 
analysis 
5 Ohi 1986 Survival rates 
(published 
literature), quality 
of life adjustment 
(assumed 25% 
better in 
transplanted 
patients based on 
Klarman 1968) 
Not applicable Annual cost of dialysis (cost per 
session x number of sessions, 
training fees, miscellaneous 
costs), cost of transplantation 
(and miscellaneous costs) 
Annual medical insurance 
coverage 
Total life 
expectancy, 
total cost, 
average cost/life 
year 
Evaluated 
increased cost if 
increased patients 
on haemodialysis or 
increased patients 
receiving cadaveric 
transplant  
Renal 
transplantation is 
more cost effective 
than haemodialysis 
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6 Garner 1987 Survival (NIH) Not applicable Labour costs, materials, capital, 
imputed earnings (for net social 
costs model as offset to gross 
social costs) 
ESRD treatment costs 
(US HHS Medicare 
charge data), probability 
of working (National 
Kidney Dialysis and 
Kidney Transplant Study), 
earnings (US Bureau of 
the Census) 
Cost per life 
year gained, no 
ICERs 
presented 
Survival probability, 
costs past 20 years 
The most cost-
effective treatment 
is living-related 
donor transplant, 
followed by home 
dialysis. 
7 Laupacis 1996 Trial data (survival, 
QALY by TTO in 
patients); n=168 
Not applicable In-patient hospitalizations, 
outpatient visits (dialysis, 
transplant clinic visits, 
medications, lab tests, 
physician fees), nephrectomy of 
living related donor, transplant 
program (organ retrieval and 
cross-matching), patient costs 
(transportation, 
accommodation, child care and 
time) 
Patient charts 
(hospitalizations and 
outpatient visits), 
provincial billing system 
(physician fees, 
diagnostics), patient 
interview (cost to patient 
and family), time spent 
receiving care (provincial 
industrial sector rate) 
Total and 
incremental 
costs, QALYs, 
ICER 
None Renal 
transplantation is 
more effective and 
less costly than 
dialysis 
8 Hornberger 1997 Patient and graft 
survival (USRDS, 
HCFA), QOL 
adjustment from 
literature 
Not applicable Dialysis and never 
transplanted, first or second 
transplant procedure, 
functioning first or second graft, 
dialysis after graft failure, 
patient costs (copayments for 
immunosuppressive drugs, 
transplant therapies) 
HCFA, published 
literature 
Total life 
expectancy, 
QALYs, costs, 
ICER 
Median waiting 
time, age group, 
discount rate, 
probability of 
survival on dialysis, 
effect of disallowing 
retransplantation on 
average median 
time until first 
transplant, effect of 
longer median time 
until first transplant 
when 
retransplantation 
allowed 
ICER = $9,656 
/QALY: 
retransplantation 
policy is cost 
effective 
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9 de Wit 1998 Dialysis outcomes 
and utility 
assessment from 
patients in 
prospective clinical 
study (NECOSAD), 
transplant 
outcomes from 
renal replacement 
registry (RENINE) 
Not applicable Resource use (days 
hospitalisations, medication 
use), costs of work force at 
dialysis centres by 
questionnaire (nephrologist 
services, overheads), cost of 
materials, cost of lab services 
from recent published study, 
patient travel cost and primary 
care costs outside of hospital, 
transplant costs 
NECOSAD study 
(resource use, costs), 
patient interviews (travel 
and primary care costs), 
published clinical trial 
(transplant costs) 
Total costs, life 
years gained, 
QALYs, appears 
to present 
average 
cost/LYG and 
average 
cost/QALY 
One-way scenarios 
for cost reduction, 
substitution of 
patients to less 
expensive 
modalities 
Transplantation is 
less costly than 
dialysis. Among 
dialysis modalities, 
CAPD is cost-
effective. 
10 Douzdjian 1998 Probability of graft 
and patient survival 
(USRDS, UNOS, 
literature), 
preference 
measures using 
Standard Gamble 
for simultaneous 
pancreas-kidney 
transplant from 17 
patients 
Not applicable Hospital charge fees, 
professional fees, organ 
acquisition fees 
Dialysis and kidney 
transplantation 
(Medicare), pancreas-
kidney transplant 
(literature and 
assumptions) 
Total costs, 
QALYS, 
average and 
incremental 
cost/QALY  
One-way sensitivity 
analyses varying  
patient and graft 
survival 
probabilities, health 
state utility values, 
costs 
For patients with 
insulin-dependent 
diabetes and 
ESRD, 
simultaneous 
pancreas-kidney 
transplantation is 
cost effective 
compared to kidney 
alone 
transplantation and 
dialysis 
11 Kalo 2001 Mortality data from 
Hungarian subset 
of European 
database 
Cox 
regression 
analysis to 
control for 
effect of age, 
gender, time 
on dialysis 
Cost of dialysis, transplantation, 
transportation 
National Health Insurance 
Fund database 
Total costs, cost 
per life year 
saved 
Discount rate Kidney 
transplantation 
provides survival 
benefits at a 
reduced cost 
compared to 
haemodialysis 
12 Kaminota 2001 Disability weights 
(questionnaire of 
Japanese Govt 
officials), duration 
dialysis (Japanese 
Society for Dialysis 
Therapy), graft 
survival (Japanese 
Society for 
Transplantation), 
abridged life table 
for Japan 
Disease 
duration / 
survival 
(Weibull) 
Cost of dialysis (excluding 
transportation, opportunity cost 
of time), cost of kidney 
transplants 
Health insurance 
payments (National 
Sakura Hospital) 
Costs, DALYs, 
ICER  
Discount rate, age, 
disability weight 
Transplantation is 
cost effective 
compared to 
dialysis 
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13 Greiner 2001 QOL 
(questionnaire), 
graft loss past first 
year 
(Eurotransplant) 
Not described 
in detail 
Transplant operation, 
immunosuppressive drugs, 
hospital stay, organ acquisition, 
evaluation costs, indirect work 
productivity loss, dialysis 
equipment, lab tests, drugs 
Personnel 
(questionnaire), drugs, 
catheters, administrative 
expenses (from hospital 
accounting system), 
capital costs (estimated), 
productivity loss 
(estimated based on 
GDP) 
Total QALYs, 
costs and 
average cost 
per QALY 
Discount rate Dialysis is more 
expensive and of 
lower value 
concerning patient 
quality of life 
14 Jassal 2003 Mortality, acute 
rejection, graft 
survival (USRDS); 
utility data 
(literature) 
Not applicable Annual cost of dialysis, cost of 
transplantation, cost of 
immunosuppressive 
medication, cost associated 
with acute rejection and 
complications 
Dialysis and 
transplantation costs 
(Medicare), 
immunosuppressive 
therapy(literature), 
rejection and 
complications (literature) 
Total and 
incremental life 
expectancy,  
QALYs, and 
costs 
One-way sensitivity 
analyses for all 
probabilities, utility  
and mortality 
estimates  
In older patients, 
transplantation 
offers gains in both 
life years and 
QALYs, but also 
increases costs 
15 Mutinga 2005 Clinical outcomes, 
patient and graft 
survival (USRDS), 
utility weights 
(Laupacis 1996); 
for new policy with 
no HLA allocation, 
2% increase in 
graft loss was 
based on Roberts 
2004 
Multivariate 
Cox 
regression to 
estimate graft 
survival at 1, 
2, 3, and 4 
years post-
transplant and 
graft survival 
at year 4 post-
transplant, 
given survival 
at year 2 
Initial hospitalization cost, 
organ procurement cost, first 
year cost transplantation, 
maintenance cost 
transplantation (month 12-24), 
cost first year post-graft loss, 
maintenance cost on dialysis 
Medicare, kidney 
acquisition cost (CMS 
estimate) 
QALYs, costs, 
average 
cost/QALY 
PSA on parameters 
with distributions, 
utility values (± 
30%), discount rate, 
number of organs 
that would be 
redistributed (± 
50%) 
Eliminating HLA-B 
matching is likely to 
increase allocation 
of deceased donor 
kidneys to 
minorities and save 
costs, but at a loss 
of QALYs (to 
Caucasions)  
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16 Lee 2006 Hospitalisation 
rates (USRDS, 
Kaiser Permanente 
Northern California 
), transplant and 
graft failure rate 
(United Network for 
Organ Sharing),  
eGFR (San Fran 
Department of 
Public Health) 
Simulation 
based on 
hazard rates 
calculated 
from historical 
data 
Dialysis, hospitalization, graft 
failure, transplantation (cost for 
procedure and annual cost for 
each subsequent year) 
Medicare claims data  Costs, life years, 
QALYs, hospital 
admissions 
Used Approximate 
Dynamic 
Programming to 
assess whether 
perturbations in the 
dialysis strategy 
(number of 
sessions per week, 
duration of each 
session) led to an 
improvement 
Earlier initiation 
strategy is 
incrementally less 
cost-effective 
compared to other 
strategies 
17 Kontodimopoulos 2008 Life expectancy 
(Annual Report of 
European 
Registries), utilities 
(SF-6D collected 
from patients 
selected from 
Hellenic Renal 
Registry) 
Estimated 
from survival 
curves (not 
described in 
detail) 
Annual cost HD 
(equipment/infrastructure, 
diagnostic services, drugs and 
consumables, staff salaries, 
operational costs/overheads); 
PD (also included staff hours 
per month for training and 
visits); transplantation 
(preoperative diagnostic and 
histological), postoperative 
hospitalization (diagnostics, 
drugs, materials, consumables, 
staff), subsequent years costs 
(immunosuppressive drugs) 
PD and HD (micro-
costing), transplantation 
(published report) 
QALYs, annual 
and total costs, 
average 
cost/QALY 
Discount rates Transplantation 
results in greater 
QALYs and lower 
costs; PD is less 
costly than HD 
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18 Howard 2009 Incidence and 
transition 
probabilities for 
RRT modalities 
(ANZDATA), utility 
data (from 
Laupacis 1996 pre 
and post-transplant 
weights) 
Not applicable Annual cost of dialysis 
(equipment, buildings, 
maintenance, salaries, 
consumables, access, drugs 
including epo, calcitriol, iron, 
hospitalizations, due to 
infection and complications, 
cost of switching modalities, 
specialist consultations and 
reviews, work-up associated 
with transplant waiting list), 
transplantation (surgery, 
hospitalization, 
immunosuppressive drugs, 
specialist review and 
consultations), organ 
procurement cost 
Previous published 
costing study, 
transplantation and 
dialysis (AR DRG), drugs 
(PBS), medical services 
(MBS), organ 
procurement cost (expert 
opinion) 
QALYs, LYS, 
ICERs 
Discount rate, 
increases to cost of 
dialysis and 
transplantation 
Increasing rate of 
transplantation is 
dominant (less 
costly and more 
effective). 
Increasing PD and 
home HD rates is 
as effective and 
less costly.  
19 Perovic 2009 Not clear, quality of 
life measured using 
McGill 
Questionnaire but 
not clear how utility 
weights were 
derived 
Not clearly 
described 
Haemodialysis (consumables, 
drugs, other, operation); 
transplantation (drugs, 
operation cost) 
Not clear Total and 
incremental 
costs and 
QALYs 
None Haemodialysis is 
more costly than 
transplantation 
20 Haller 2011 Austrian Dialysis 
and Transplant 
Registry, utilities for 
dialysis (from de 
Wit 1998, EQ-5D, 
SG, TTO) and 
literature-based 
estimates for 
transplantation 
(Laupacis 1996) 
Incidence 
(Poisson 
regression); 
transition prob 
and survival 
(multinomial 
model) 
Cost of transplantation to renal 
unit, costs of medication, costs 
of non-ESRD-related hospital 
admissions (inpatient, 
outpatient, investigations, blood 
tests, medications received in 
hospital including epo and 
immunosuppressants, 
radiological imaging, 
consultations, nursing, supplies 
and overhead costs for 
maintenance, hospital admin, 
laundry, equipment and 
building acquisition). Excluded 
'reimbursements and charges 
for cost data collection' as well 
as societal costs such as ability 
to work 
Patient-level cost data 
from electronic records. 
Cost of outpatient 
prescription medication 
and transportation for 
dialysis (Upper Austrian 
Health Insurance); all 
other medical treatment 
including haemodialysis 
cost, cost or organ 
harvesting from live donor 
including health checks 
and follow up 
(Elisabethinen Hospital 
Linz); cost of organ 
harvesting from deceased 
donor based on expert 
assumptions about length 
Total costs, total 
life years saved, 
total years free 
of dialysis, total 
QALYs (no 
ICERs both 
Strategy 2 and 3 
dominated) 
Policy parameters 
(different values for 
PD proportion and 
living-donor 
proportion), one-
way sensitivity 
analysis individual 
parameters 
including cost, 
QALY, transition 
prob and 
prevalence 
Increasing PD and 
kidney 
transplantation 
compared to 
current practice 
increases QALYs 
and reduces costs 
 155 
 
of ICU stay for brain-dead 
donor 
21 Wong  2012 Transplant registry, 
organ matching 
service, published 
literature 
Multivariate 
Cox 
proportional 
hazard models 
for association 
of co-
morbidities  
Unit costs for initial and 
maintenance dialysis, annual 
resource use for patients with 
comorbidities (diabetes, 
cardiovascular disease), 
maintenance costs for kidney 
transplantation 
DRGs, Medicare benefits 
schedule, published 
literature 
Total and 
incremental 
costs, life years 
gained, ICER, 
varied age and 
co-morbidities 
(one at a time) 
in sensitivity 
analyses 
Scenario analysis 
for age at time of 
listing and waiting 
time and 
comorbidities; PSA  
Wait-listing and 
transplantation 
increases life years 
and saves cost 
22 Villa  2012 Transition prob 
(Spanish Society of 
Nephrology 
registry), utilities 
from proprietary 
database (SF-36 
converted to SF-
6D) and from 
literature 
Not applicable Direct (scheduled HD, PD, 
transplantation, non-scheduled 
HD, PD, transplantation), 
indirect costs 
From previous published 
costing study by same 
first author 
Average annual 
cost, QALYs, 
ICER, net health 
benefit at WTP 
threshold or 
EURO 35,000 
per QALY 
Univariate by 
changing  by 
changing costs and 
utilities for PD, 
bivariate by both 
lowering PD utilities 
by 10% and 
increasing PD costs 
by 10% 
Increasing the 
number of 
scheduled incident 
patients receiving 
PD would result in 
greater QALYs at 
lower costs 
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APPENDIX 2: Summary of literature on the use of simulation as a tool to study 
kidney allocation 
 
 
 
A literature review was undertaken to identify examples of simulation studies that 
compared different approaches to kidney allocation in the clinical literature. This appendix 
contains a summary of the search strategy and studies that were identified. After applying 
inclusion/exclusion criteria, a total of 15 papers were deemed eligible, however for the 
majority of these (8 papers), the simulation evidence was of secondary consideration and 
the primary emphasis of the paper was on exploring the impact of a single clinical factor 
(for example HLA matching) on the allocation process. A further 3 papers reported on the 
introduction of a new national kidney allocation policy in which the emphasis of the paper 
was on explaining how the new and old kidney allocation schemes differed, with some 
supporting evidence from simulations presented. Only 4 studies were identified in which 
the simulation model of a deceased donor allocation process was the primary focus of the 
paper and in which simulation methods were described in some level of detail that made 
it possible to understand the general approach taken. These 4 simulation modelling studies 
are discussed in Chapter 1 of the thesis (see Table 1.2). A brief summary of the main 
characteristics of the other 11 studies that were identified is provided below. 
 
 
 
Search strategy 
 
Database: Ovid MEDLINE 
 
1 kidney.mp. 709977 
2 allocat$.mp. 169921 
3 simulat$.mp. 384410 
4 transplant$.mp. 581411 
5 1 and 2 and 3 and 4 48 
6 limit 5 to (english language and humans and yr=”1960 – 2015”) 44 
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Flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kidney allocation simulation literature 
search (n = 44) 
Database: Ovid MEDLINE 
Search results combined (n = 45) 
Identified in separate literature 
search on equity (n = 1) 
Articles screened on basis of title and abstract 
Excluded: 
Not kidneys (n = 3) 
Not deceased donor kidneys (n = 6) 
Not a simulation of allocation process (n = 16) 
Included (n = 20) 
Excluded: 
Not a simulation of allocation process (n = 5) 
Included (n = 15) 
3. Comparison of 
new national 
scheme to old, 
simulation not 
main focus 
(n = 3) 
1. Compares 
different 
approaches to 
HLA matching, 
simulation not 
main focus 
(n = 6) 
2. Explores a 
single aspect of 
allocation other 
than HLA 
matching, 
simulation not 
main focus 
(n = 2) 
4. Simulation 
model of 
alternative 
allocation 
approaches 
(n = 4)  
See Table 1.2 
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Use of simulation in the kidney allocation literature - study characteristics 
 
1. Comparing different approaches to HLA matching, simulation not main focus 
Author, year and 
country / region 
Allocation schemes 
Main results or outcomes 
considered 
Wujciak et al.  
1993a, Europe 
and North 
America 
1. HLA-A, -B, -DR matching only 
2. FIFO (“first in, first out” based on 
waiting time) 
3. HLA-FIFO (longest waiting patient 
among equivalent matches) and 
HLA-MMP (patient is selected with 
lowest mismatch probability) 
4. COMB: different weighted 
combinations of mismatch grade, 
waiting time and mismatch 
probability 
 % HLA-A, -B, -DR mismatches 
 One-year graft survival (%) 
 Waiting time 
Wujciak et al. 
1993b, Europe 
1. HLA1 (longest waiting patient is 
selected among patients with same 
mismatch grade 
2. LOCAL1: HLA1 plus local allocation 
3. LOCAL2: 25% HLA mismatch, 25% 
waiting time, 50% at random 
4. XCOMB: combination of HLA 
mismatch grade, mismatch 
probability, waiting time, local 
transplant rate, center import/export 
balance 
 HLA mismatch 
 Waiting time 
 DR homozygous (%) 
 Mismatch probability 
 Exchange balance 
 Local transplants (%) 
Ichikawa et al. 
1994, Japan 
Comparison of different degrees of 
histocompatibility based on zero 
mismatches (repeated taking blood type 
into consideration): 
1. 6-antigen (HLA-A, -B, -DR) 
2. 4-antigen (HLA-B, -DR) 
3. DRB1 
 Number of donors who had a 
certain number of possible 
recipients under each matching 
criterion 
 Possibility of finding 1 or more 
recipients for each matching 
grade and blood type  
Held et al. 
1994, United 
States 
1. Actual kidney-graft allocation system 
in 1989 
2. Allocation under maximal HLA 
matching 
 Patient characteristics (age, 
gender, ethnicity) 
 5-year graft survival 
Wujciak et al. 
1999, Western 
Europe 
1. Allocation based on conventional 
HLA-A, -B, -DR matching 
2. Allocation based on cross-reactive 
antigen groups (CREG) matching 
 Distribution of HLA-A and HLA-
B mismatches and impact on 
graft survival rate 
 
Schnitzler et al. 
1999, United 
States 
1. Current allocation system (in 1999) 
2. Local allocation based on minimal 
HLA mismatching  
3. National allocation based on minimal 
HLA mismatching 
 3-year graft survival rate 
 Average cumulative costs 3 
years after transplantation 
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2. Explores single aspect of allocation, simulation not main focus 
 
Author, year and 
country 
Allocation schemes 
Main results or outcomes 
considered 
Moers et al. 
2009, United 
States 
1. To explore influence of donor age on 
transplant (graft) outcome: 
2. Old-to-young (allow allocation of 
kidneys from donors over 65 to 
recipients under 65) 
3. Old-to-old (allow allocation of kidneys 
from donors over 65 to selected 
recipients over 65) 
4. Young-to-old (allow allocation of 
kidneys from donors under 65 to 
selected recipients over 65) 
5. Young-to-young (allow allocation of 
kidneys from donors under 65 to 
recipients under 65 who original 
received a 65+ graft) 
 Delayed graft function 
 Graft loss within 3 months 
posttransplant 
 Graft survival up to 10 years 
posttransplant 
Barnett et al. 
2012, United 
Kingdom 
1. To explore change in allocation to 
allow blood group incompatible 
transplants in paediatric patients: 
2. Current 2006 National Kidney 
Allocation Scheme (no antibody-
incompatible deceased-donor 
transplants) 
3. Allocation to any suitable antibody-
incompatible patient 
4. Allocation to antibody-incompatible 
patient with preferential allocation for 
blood group B donor kidneys to blood 
group A recipients 
 Number of paediatric transplant 
recipients 
 HLA mismatch level 
 Waiting time 
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3. Comparison of new national scheme to old, simulation not main focus 
 
Author, year and 
country 
Allocation schemes 
Main results or outcomes 
considered 
Johnson et al.  
2010, United 
Kingdom 
1. 1998 national kidney allocation 
scheme 
2. 2006 national kidney allocation 
scheme 
 Characteristics of transplanted 
patients (waiting time, HLA 
mismatch, age, location, 
homozygosity, blood group, 
ethnicity) 
 Estimated 5-year survival (%) 
Dominguez et al. 
2013, Chile 
1. Older allocation policy (blood group 
matching, medical priority, then 
points based on HLA match, waiting 
time, panel-reactive antibodies and 
paediatric recipients) 
2. Newer allocation policy (blood group 
matching, medical priority, previous 
living donor, 0 mismatch, paediatric 
recipients then points based on 
recipient age, HLA match, panel-
reactive antibodies and waiting time) 
 Characteristics of patients (age, 
waiting time, panel-reactive 
antibody, HLA mismatch) for 
both transplant recipients and 
patients who remained on the 
waiting list 
 
Israni et al. 
2014, United 
States 
1. Existing national deceased donor 
kidney allocation policy  
2. New national deceased donor kidney 
allocation policy approved introduced 
in 2014 (incorporates the concept of 
longevity matching based on the 
KDPI and EPTS) 
 Number of transplant recipients  
 Median lifespan posttransplant 
 Median extra life-years for 
transplant versus waiting-list 
candidates 
 Number of death on the waiting 
list by age  
 Characteristics of transplant 
recipients (e.g. age, blood type, 
ethnicity, pre-emptive 
transplant, HLA mismatch, local 
or shared kidney, primary 
cause of disease, time on 
dialysis) 
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ABSTRACT 
Background. In a number of countries, reimbursement to hospitals providing renal dialysis 
services is set according to a fixed tariff. While the cost of maintenance dialysis and 
transplant surgery are amenable to a system of fixed tariffs, patients with established renal 
failure commonly present with comorbid conditions that can lead to variations in the need 
for hospitalisation beyond the provision of renal replacement therapy.  
Methods. Patient-level cost data for incident renal replacement therapy patients in England 
was obtained as a result of linkage of the Hospital Episode Statistics dataset to UK Renal 
Registry data. Regression models were developed to explore variations in hospital costs in 
relation to treatment modality, number of years on treatment and factors such as age and 
comorbidities. The final models were then used to predict annual costs for patients with 
different sets of characteristics. 
Results. Excluding the cost of renal replacement therapy itself, inpatient costs generally 
decreased with number of years on treatment for haemodialysis and transplant patients, 
whereas costs for patients receiving peritoneal dialysis remained constant. Diabetes was 
associated with higher mean annual costs for all patients irrespective of treatment modality 
and hospital setting. Age did not have a consistent effect on costs.   
Conclusions. Combining predicted hospital costs with the fixed costs of renal replacement 
therapy showed that the total cost differential for a patient continuing on dialysis rather than 
receiving a transplant is considerable following the first year of renal replacement therapy, 
thus reinforcing the longer-term economic advantage of transplantation over dialysis for the 
health service.  
Key words: comorbidities, dialysis, established renal failure, hospital costs, regression, 
transplantation 
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 INTRODUCTION 
In an attempt to control rising costs, several countries have introduced a system of fixed 
reimbursement rates for the provision of chronic dialysis for patients with established renal 
failure (ERF) [1]. Since 2010, reimbursement to hospitals providing renal dialysis services 
in England has been set according to a national tariff under the Payment by Results (PbR) 
system [2]. There are plans to introduce a similar national tariff for kidney transplantation in 
the near future, with separate currencies being developed to capture three stages of the 
transplant pathway: preparation for transplant, the inpatient episode including the transplant 
procedure, and post-transplant outpatient activity [3]. 
While the annual cost of chronic maintenance dialysis and the cost of transplant surgery 
are amenable to fixed tariffs, patients with ERF commonly present with comorbidities such 
as diabetes, ischaemic heart disease and vascular disease, which can lead to variations in 
the use of healthcare resources beyond renal replacement therapy (RRT) itself [4]. A 
number of previous studies have explored hospitalisation rates or costs among dialysis 
patients, however, given the challenges of collecting patient-level resource use data, these 
studies have typically been restricted to a time horizon of one year or less [5-7].  
Linkage of the Hospital Episode Statistics (HES) dataset to UK Renal Registry (UKRR) data 
for patients who started RRT for ERF in England between 2003 and 2006 provides an 
opportunity to explore hospital inpatient and outpatient costs over a number of years among 
both dialysis and transplant patients. HES captures demographic information, comorbid 
conditions and data on all inpatient and outpatient care delivered in NHS hospitals in 
England, including treatment specialty and length of stay. The UKRR reports on the 
demography of incident RRT patients using data provided by renal centres. Linkage of these 
two datasets enhances the variables available for analysis and provides an opportunity to 
analyse a rich data source on hospitalisations for a cohort that represents >95% of all 
patients who started RRT during a defined period in England [8].  The aim of the current 
study is to analyse the linked dataset to explore variations in inpatient and outpatient 
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hospital costs, separately from the fixed cost of RRT, and in relation to treatment modality, 
number of years on treatment and factors such as age and comorbidities.  
 
METHODS 
The linked dataset comprised patients who started dialysis or received a kidney transplant 
in England between 1 April 2003 and 31 December 2006. The date of starting RRT was 
taken as the index date. If a patient on dialysis subsequently received a transplant, this 
patient then became part of the incident transplant cohort and the date of transplant was 
taken as the new index date for measuring subsequent hospitalisations. Comorbidity 
information in HES was determined from discharge codes from hospitalisations prior to 
starting RRT. Comorbidities were defined using International Classification of Disease 
version 10 (ICD10) codes applying algorithms previously described in the literature [9]. 
Inpatient costs were generated by grouping hospital episodes by Healthcare Resource 
Group (HRG) and applying the relevant 2011/12 PbR tariff associated with each HRG. 
Costs for outpatient appointments were assigned according to treatment function code [10]. 
Hospital episodes for the purpose of receiving maintenance dialysis or for undergoing 
transplant surgery were specifically excluded, but hospital episodes for any other reason, 
including procedures such as vascular access surgery, were included. This is because the 
aim of the present analysis is to explore variations in hospital costs separately from the 
costs associated with the fixed tariffs for dialysis and transplant surgery.  
Linkage of the HES and UKRR datasets ended in December 2009 and therefore no further 
hospitalisation data were available beyond this point. Over the observation period, an 
increasing proportion of patients were therefore administratively censored part-way through 
a given year due to the end of data availability. The proportion of patients who were 
administratively censored ranged from 0% in year one to 47% in year six for haemodialysis 
patients, from 0% in year one to 38% in year six for peritoneal dialysis patients and from 
11% in year one to 63% in year six for transplant patients. A comparison of patient 
characteristics and annual costs in the years prior to administrative censoring did not identify 
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any systematic differences between those patients who had been censored and those who 
had not. Therefore for the purposes of the current analysis, data from any year in which a 
patient was administratively censored were excluded under the assumption that these data 
were missing at random. 
Patient characteristics and hospital costs in the first year after starting RRT are summarised 
by treatment modality using percentages and mean values as appropriate. Results of 
significance tests are presented to compare mean hospital costs between groups of patients 
with different characteristics of interest. Although cost data are typically not normally 
distributed, sample sizes in this dataset were sufficiently large for the use of t-tests or 
ANOVA to be robust to violations of the assumption of normality [11, 12]. In cases of 
unequal variances, Satterthwaite’s approximation for standard errors was computed. To 
explore changes in hospital costs over time, mean annual costs and standard errors are 
presented by number of years on RRT.   
Multiple regression was carried out to further determine which patient and treatment 
characteristics are important predictors of hospital costs. As cost data were positively 
skewed with a high proportion of patients with zero costs in the inpatient setting in any 
particular year, a two-part approach to the regression model was taken. Logistic regression 
was used to predict the probability of incurring any costs, followed by fitting generalised 
linear models to predict costs in patients who had at least one hospital episode in a given 
year. The effects of comorbidities on costs were explored using two approaches. In the first 
approach, individual comorbidities were included as covariates in the regression model and 
in the second approach, only the number of comorbidities was included as a covariate. 
Initially, all variables that were available in the dataset were included in the regression 
models and a process of backward elimination was used to inform variable selection using 
a P-value threshold of 0.2 [13].  Events such as transplant, renal recovery, death, or graft 
failure were included as covariates. In addition, a new variable was created to indicate if a 
patient died in the first half of the following year in order to adequately capture increased 
costs in the period prior to death.  
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All analyses were conducted in Stata (Version 13, Stata Corp, College Station, Texas, 
USA). 
 
RESULTS  
Descriptive analysis 
Data on hospitalisations for 12 068 incident haemodialysis patients (Table 1a), 4 018 
incident peritoneal dialysis patients (Table 1b) and 4 149 incident transplant patients (Table 
1c) were available for analysis. The mean age for haemodialysis patients was 68.3 years 
compared with 56.0 years for peritoneal dialysis patients and 45.4 years for transplant 
patients. The two most common comorbidities were diabetes and hypertension and, of the 
nine comorbidities included in the scope of the analysis, the average number of 
comorbidities per patient at baseline was approximately 1.60 for haemodialysis patients, 
1.26 for peritoneal dialysis patients and 1.56 for transplant patients.  
Mean costs for patients during their first year of dialysis showed differences by modality, 
with haemodialysis patients incurring higher inpatient costs and peritoneal dialysis patients 
incurring higher outpatient costs. According to bivariate analysis, the presence of most 
comorbidities was associated with higher costs in the inpatient setting, but only diabetes 
was associated with significantly higher costs in both inpatient and outpatient settings and 
among both haemodialysis and peritoneal dialysis patients. Among transplant patients, 
congestive heart failure, peripheral vascular disease, diabetes and hypertension were all 
associated with higher costs in both inpatient and outpatient settings, whereas myocardial 
infarction, liver disease, cerebrovascular disease and deceased donor transplants were 
associated with higher costs only in the inpatient setting.  
Table 2 summarises mean annual costs for patients receiving each type of RRT over the 
six years of available data.  Combined inpatient and outpatient costs in the first year of RRT 
were similar for haemodialysis and transplant patients, however costs for transplant patients 
decreased more rapidly in subsequent years. Peritoneal dialysis patients had lower total 
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hospital costs compared to haemodialysis patients in the first year, but higher average costs 
in year six.  
 
Multiple regression 
Bivariate analysis of year 1 costs (Tables 1a, 1b and 1c) showed that events such as death 
can have opposite effects on inpatient and outpatient costs. Therefore it was important to 
control for these in multiple regression analyses and to keep the development of models for 
inpatient and outpatient costs separate. Two-part regression models were developed to 
determine which patient and treatment characteristics are important predictors of hospital 
costs. The final two-part models for each treatment modality are provided as supplementary 
material (available online at http://ndt.oxfordjournals.org). Key findings can be summarised 
as follows:  
In the inpatient setting, logistic regression results (Supplementary Table 1a) showed that 
the probability of incurring any inpatient costs generally decreased as the number of years 
on haemodialysis increased. Female gender and presence of comorbidities, with the 
exception of liver disease, increased the probability of incurring inpatient costs. The effect 
of comorbidities on the probability of incurring outpatient costs for haemodialysis patients 
was less consistent.  
Compared to the first year on RRT, patients on peritoneal dialysis had a lower probability 
of incurring inpatient and outpatient costs in subsequent years (Supplementary Table 1b), 
however there was not a consistent trend in the probability of incurring costs over time as 
seen among haemodialysis patients.  
For transplant patients, logistic regression results indicated that the probability of incurring 
inpatient costs, but not outpatient costs, generally decreased over time (Supplementary 
Table 1c). Female gender and comorbidities were again associated with a higher probability 
of incurring inpatient costs, whereas living donor transplants were associated with a lower 
probability of incurring inpatient costs compared to deceased donor transplants.  
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Following logistic regression, generalised linear models were fitted to model costs in the 
subset of patients who had at least one inpatient or outpatient episode in a given year 
(Supplementary Tables 2a, 2b and 2c). For haemodialysis and transplant patients, inpatient 
costs tended to decrease as number of years on RRT increased, however this pattern was 
not seen among peritoneal dialysis patients. Age did not have a consistent effect on costs 
across hospital settings and treatment modalities, however where significant differences 
were noted, higher age was associated with lower costs. Of the comorbidities, only diabetes 
was consistently associated with higher mean annual costs for all patients irrespective of 
treatment modality and hospital setting. 
Inpatient costs in the year of death were higher across all three RRT modalities, whereas 
outpatient costs in the year of death were lower. With the exception of the first year of the 
dataset, death events were fairly evenly distributed throughout the year, meaning that 
patients who died incurred significantly higher costs despite only being alive, on average, 
for approximately half of the year.  
Alternative regression models based on the total number of comorbidities as a covariate, 
rather than on the presence or absence of individual comorbidities, yielded similar results, 
but were associated with slightly higher root-mean-square errors (RMSE). The number of 
comorbidities had a larger effect on hospital costs among transplant patients than among 
dialysis patients.  
 
Application of regression models for predicting costs 
A useful application of the regression models developed here is to predict hospital costs for 
patients with a given set of characteristics over time. Applying the models that have been 
developed, we can predict and compare costs for patients with different characteristics and 
by treatment modality. For illustrative purposes, Table 3 shows predicted inpatient and 
outpatient costs over a period of four years on each of the forms of RRT for three 
hypothetical patients: a 25-year-old female with no comorbidities, a 50-year-old male with 
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diabetes and a 65-year-old male with peripheral vascular disease. Table 3 also shows the 
fixed costs associated with national tariffs for RRT (maintenance haemodialysis, peritoneal 
dialysis or deceased heart-beating donor transplant) [10, 14]. When comparing combined 
RRT and hospital costs over the four years among the three patients on the same modality, 
costs are similar on haemodialysis and transplant, however larger variations in costs are 
seen with peritoneal dialysis (range £101 938 to £109 213), mostly attributable to 
differences in inpatient costs. In all three patient examples, total costs are highest on 
haemodialysis and in each case, are approximately four times the total costs compared with 
a scenario in which each of these patients had received a transplant from a deceased donor. 
 
DISCUSSION 
Many health systems around the world are grappling with the need to contain the increasing 
costs of providing care for patients with ERF and in recent years this has led to the 
emergence of bundled payments or fixed tariffs for reimbursement to providers of dialysis 
services. Considerable attention has been focused on determining what costs should be 
included or excluded within a fixed rate of payment and there is variation between countries 
especially with respect to drug costs, laboratory tests and physician fees [1]. Less attention 
has been directed at characterising the magnitude of other hospital costs beyond the fixed 
tariffs for RRT that are incurred by patients with ERF. These costs can be considerable 
given the high rate of comorbidities among this patient population.  Insight into variable 
hospital costs in addition to the fixed costs of RRT is important for having an overall 
understanding of the costs of managing ERF. Linkage of the United States Renal Data 
System (USRDS) and Medicare data allows for extensive analysis of costs in relation to 
patient characteristics and treatment factors, however such data sources outside the US 
are limited [15].    
One-time linkage of the HES and UKRR datasets has provided a rare opportunity to analyse 
variations in hospital costs beyond RRT in a large cohort of patients with ERF in England 
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and to explore changes in costs over several years, as well as in relation to treatment 
modality and comorbidities. As no attempt was made to distinguish renal-related resource 
use from non-renal-related resource use, the findings presented here are most relevant for 
looking at incremental costs between inpatient and outpatient settings, or between patients 
receiving different forms of RRT.  
Excluding the fixed costs of RRT, our analysis showed that hospital costs were highest for 
all treatment modalities in the first year but hospital inpatient costs for both haemodialysis 
and transplant patients generally decreased with number of years on RRT, with transplant 
patients incurring lower annual costs than dialysis patients. A possible explanation for 
higher inpatient costs among incident haemodialysis patients could be access-related 
complications such as catheter-related infections, the need for catheter replacement or 
fistuloplasty and other forms of attention to dialysis access. In the UK, during the time period 
reflected in our analysis, a national audit showed that 69% of incident haemodialysis 
patients commenced treatment using venous catheters [16]. For transplant patients, higher 
costs in the first year reflect the need for frequent monitoring in the post-operative phase to 
manage immunosuppression, including detection and management of complications such 
as new onset diabetes after transplant (NODAT) [17-19]. 
In the current analysis there was little evidence to suggest that hospital costs increased with 
age or number of years on RRT. In some cases, older age was in fact associated with lower 
costs. However, a pattern of increasing costs was seen with many comorbidities and it is 
plausible that the patients who remained alive for longer on RRT were on average healthier 
and required fewer hospitalisations. The possibility of unobserved confounding could not be 
ruled out, but we believe this highlights the importance of controlling for comorbidities when 
exploring the effect of age on costs in the ERF population. Outpatient costs for transplant 
patients were highest in the first year of RRT, but dropped considerably in subsequent years 
and fell below average outpatient costs for haemodialysis patients by year six. In 
comparison, hospital costs for patients on peritoneal dialysis remained relatively constant 
over time, except for a slight decrease in years 2 and 3. These findings challenge the 
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commonly held assumption that costs increase with both age and time on RRT although 
caution should be exercised in extrapolating the findings beyond the 6-year period of our 
analysis. As with most retrospective datasets, there are several limitations to our analysis. 
In the HES dataset, coding practices meant that patients with missing comorbidity 
information could only be recorded as having no comorbidities, so the true extent of missing 
data was not known. However, the UKRR dataset also contained information on 
comorbidities at the start of RRT for approximately half of the patients in the sample. Where 
comorbidity data were available from both HES and UKRR data sources, concordance was 
93% [8]. This high level of concordance between two independently collected data sources 
increases our confidence that missing data on comorbidities is unlikely to be a source of 
systematic bias in our analysis. Due to the structure of our dataset, another limitation is that 
we were unable to explore in more detail the specific reasons for variations in hospital costs 
as this would have required a more granular breakdown of admission codes and 
procedures. In addition, the current analysis did not take into account drug costs, which fall 
outside both the fixed tariff for RRT and the hospital reimbursement codes in England.  
Although differences in currency, reimbursement rates for RRT and the organisation of 
healthcare systems varies from country to country, a deeper understanding of the 
relationship between factors such as age, comorbidities, treatment modality and hospital 
costs is likely to cut across different countries with varied healthcare delivery paradigms. 
Looking beyond fixed tariffs for RRT, hospital costs make up approximately 20-25% of the 
overall cost of managing patients on chronic dialysis. Taking into account both the fixed 
costs of RRT and variations in hospital costs characterised in the current analysis, it is 
readily apparent that although the total costs of treating dialysis and transplant patients may 
be similar in the first year of RRT, the cost differential in subsequent years is considerable. 
This reinforces the longer-term economic advantage of transplantation over dialysis for the 
health service.  
 177 
 
SUPPLEMENTARY DATA 
Supplementary data have been submitted with this manuscript. 
 
ACKNOWLEDGEMENTS 
This article presents independent research commissioned by the National Institute for 
Health Research (NIHR) under the Programme Grant for Applied Research (RP-PG-0109-
10116) entitled Access to Transplantation and Transplant Outcome Measures (ATTOM). 
The views expressed in this publication are those of the authors and not necessarily those 
of the NHS, the NIHR or the Department of Health.  
 
Hospital Episode Statistics: Copyright 2014, re-used with the permission of the Health and 
Social Information Centre. All rights reserved. 
 
FUNDING 
Funded by a National Institute for Health Research (NIHR) Programme Grant for Applied 
Research.  
 
CONFLICT OF INTEREST STATEMENT 
None to declare. 
 
The results presented in this paper have not been published previously in whole or part, 
except in abstract form. 
 
 
 
 178 
 
REFERENCES 
 
1. Vanholder R, Davenport A, Hannedouche T, et al. Reimbursement of dialysis: a 
comparison of seven countries. J Am Soc Nephrol 2012; 23: 1291-1298. 
2. Sharif A, Baboolal K. Update on dialysis economics in the UK. Perit Dial Int 2011; 
31 (Suppl 2): S58-62. 
3. Department of Health. Payment by results guidance for 2013-14. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/2149
02/PbR-Guidance-2013-14.pdf (Accessed 16 July 2014). 
4. Rao A, Steenkamp R, Caskey F. UK Renal Registry 16th Annual Report: Chapter 5 
Comorbidities and current smoking status amongst patients starting renal 
replacement therapy in England, Wales and Northern Ireland from 2011 to 2012. 
Nephron Clin Pract 2013; 125: 99-110. 
5. Grun RP, Constantinovici N, Normand C, et al. Costs of dialysis for elderly people in 
the UK. Nephrol Dial Transplant 2003; 18: 2122-2127. 
6. Metcalfe W, Khan IH, Prescott GJ, et al. Hospitalization in the first year of renal 
replacement therapy for end-stage renal disease. QJM 2003; 96: 899-909. 
7. Roderick P, Nicholson T, Armitage A, et al. An evaluation of the costs, effectiveness 
and quality of renal replacement therapy provision in renal satellite units in England 
and Wales. Health Technol Assess 2005; 9: 1-178. 
8. Fotheringham J, Fogarty D, Jacques R, et al. Chapter 13 The linkage of incident 
renal replacement therapy patients in England (2002-2006) to hospital episodes and 
national mortality data: improved demography and hospitalisation data in patients 
undergoing renal replacement therapy. Nephron Clin Pract 2012; 120 (Suppl 1): 
c247-260. 
9. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining 
comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 
2005;43:1130-1139. 
10. Department of Health. Confirmation of payment by results (PbR) arrangements for 
2011-12. 
 179 
 
http://webarchive.nationalarchives.gov.uk/20130507170152/https:/www.gov.uk/gove
rnment/publications/confirmation-of-payment-by-results-pbr-arrangements-for-2011-
12 (Accessed 21 July 2014). 
11. Fagerland MW. t-tests, non-parametric tests, and large studies - a paradox of 
statistical practice? BMC Med Res Methodol 2012; 12: 78-84. 
12. Skovlund E, Fenstad GU. Should we always choose a nonparametric test when 
comparing two apparently nonnormal distributions? J Clin Epidemiol 2001; 54: 86-
92. 
13. Kirkwood BR, Sterne JAC. Essential Medical Statistics. 2nd ed. Oxford, UK: 
Blackwell Publishing, 2003. 
14. Department of Health. NHS Reference Costs: Financial Year 2011 to 2012. 
https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-
2011-to-2012 (Accessed 21 July 2014). 
15. Foley RN, Collins AJ. The USRDS: what you need to know about what it can and 
can't tell us about ESRD. Clin J Am Soc Nephrol 2013; 8: 845-851. 
16. The UK Renal Registry 8th Annual Report. Bristol, UK, 2005.  
17. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing 
incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 
59: 732-737. 
18. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic 
review of the literature. Diabetes Care 2002; 25: 583-592. 
19. Joss N, Staatz CE, Thomson AH, et al. Predictors of new onset diabetes after renal 
transplantation. Clin Transplant 2007; 21: 136-143. 
 
 
 180 
 
Table 1a Haemodialysis patient characteristics and mean inpatient and outpatient costs 
(excluding the costs of maintenance dialysis) during the first year of renal replacement 
therapy  
 n (%) 
Mean inpatient cost (£) 
(95% CI) 
p 
Mean outpatient cost (£) 
 (95% CI) 
p 
Age group      
<50 years  2 384 (19.8%) 7 452 (6 951 , 7 954) 0.319 1 342 (1 288 , 1 396) <0.0005 
50-64 
years 2 900 (24.0%) 7 122 (6 667 , 7 577)  1 340 (1 291 , 1 389)  
65-75 
years 3 911 (32.4%) 7 423 (7 032 , 7 815)  1 121 (1 079 , 1 163)  
>75 years 2 873 (23.8%) 6 934 (6 477 , 7 391)  893 (844 , 942)  
Gender      
Male 7 478 (62.0%) 7 084 (6 797 , 7370) 0.079 1 185 (1 153 , 1 216) 0.026 
Female 4 590 (38.0%) 7 495 (7 140 , 7 850)  1 128 (1 090 , 1 165)  
Death      
No  9 530 (79.0%) 7 087 (6 821 , 7 354) 0.009 1 309 (1 280 , 1 337) <0.0005* 
Yes 2 538 (21.0%) 7 814 (7 467 , 8 160)  616 (578 , 655)  
Transplant      
No  11 644 (96.5%) 7 336 (7 106 , 7 566) <0.0005* 1 169 (1 145 , 1 194) 0.009 
Yes 424 (3.5%) 4 606 (4 110 , 5 103)  995 (858 , 1 131)  
Recovered renal function 
No  11 715 (97.1%) 7 270 (7 042 , 7 499) 0.127 1 178 (1 153 , 1 203) <0.0005* 
Yes 353 (2.9%) 6 241 (5 368 , 7 114)  664 (544 , 785)  
Myocardial infarction     
No  10 120 (85.1%) 7 185 (6 939 , 7 430) 0.033 1 183 (1 157 , 1 210) 0.019 
Yes 1 774 (14.9%) 7 872 (7 302 , 8 443)  1 101 (1 041 , 1 162)  
Congestive heart failure 
No  9 630 (81.0%) 7 085 (6 827 , 7 344) <0.0005* 1 187 (1 160 , 1 214) 0.010 
Yes 2 264 (19.0%) 8 145 (7 707 , 8 585)  1 105 (1 050 , 1 160)  
Peripheral vascular disease 
No  10 285 (86.5%) 7 104 (6 859 , 7 349) <0.0005* 1 170 (1 144 , 1 196) 0.854* 
Yes 1 609 (13.5%) 8 459 (7 888 , 9 030)  1 177 (1 107 , 1 248)  
Cerebrovascular disease 
No  10 812 (90.9%) 7 241 (7 002 , 7 480) 0.205 1 180 (1 154 , 1 205) 0.034 
Yes 1 082 (9.1) 7 749 (7 089 , 8 408)  1 087 (1011 , 1 164)  
Pulmonary disease     
No  10 293 (86.5%) 7 186 (6 937 , 7 435) 0.026 1 168 (1 142 , 1 194) 0.550* 
Yes 1 601 (13.5%) 7 938 (7 434 , 8 443)  1 192 (1 118 , 1 265)  
Liver disease      
No  11 785 (99.1%) 7 260 (7 035 , 7 484) 0.143* 1 169 (1 145 , 1 194) 0. 180* 
Yes 109 (0.9%) 10 263 (6 233 , 14 293)  1 379 (1 072 , 1 687)  
Diabetes      
No  7 846 (66.0%) 6 685 (6 415 , 6 956) <0.0005* 1 081 (1 051 , 1 110) <0.0005* 
Yes 4 048 (34.0%) 8 454 (8 049 , 8 858)  1 346 (1 303 , 1 389)  
Cancer      
No  10 885 (91.5%) 7 248 (7 010 , 7 487) 0.266 1 167 (1 142 , 1 193) 0.311 
Yes 1 009 (8.5%) 7 708 (7 045 , 8 370)  1 213 (1 119 , 1 307)  
Hypertension      
No  6 372 (53.6%) 7 525 (7 180 , 7 870) 0.024* 1 153 (1 122 , 1 184) 0.118 
Yes 5 522 (46.4%) 7 013 (6 734 , 7 291)  1 192 (1 154 , 1 230)  
 
*Unequal variances 
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Table 1b Peritoneal dialysis patient characteristics and mean inpatient and outpatient 
costs (excluding the costs of maintenance dialysis) during the first year of renal 
replacement therapy 
 n (%) 
Mean inpatient cost (£) 
(95% CI) 
p 
Mean outpatient cost (£)  
(95% CI) 
p 
Age group      
<50 years 1 395 (34.7%) 4 874 (4 463 , 5 286) 0.003 1 712 (1 642 , 1 782) <0.0005 
50-64 years 1 217 (30.3%) 5 266 (4 825 , 5 707)  1 748 (1 674 , 1 823)  
65-75 years 967 (24.1%) 4 762 (4 267 , 5 257)  1 600 (1 516 , 1 684)  
>75 years 439 (10.9%) 6 321 (5 587 , 7 055)  1 320 (1 195 , 1 444)  
Gender      
Male 2 505 (62.3%) 5 200 (4 878 , 5 522) 0.428 1 647 (1 595 , 1 699) 0.696 
Female 1 513 (37.7%) 4 998 (4 633 , 5 362)  1 664 (1 596 , 1 732)  
Death      
No  3 709 (92.3%) 4 755 (4 514 , 4 996) <0.0005* 1 694 (1 651 , 1 738) <0.0005 
Yes 309 (7.7%) 9 553 (8 380 , 10 725)  1 158 (1 022 , 1 294)  
Transplant      
No  3 643 (90.7%) 5 275 (5 010 , 5 540) <0.0005* 1 707 (1 663 , 1 751) <0.0005* 
Yes 375 (9.3%) 3 659 (3 316 , 4001)  1 130 (1 033 , 1 226)  
Recovered renal function 
No  3934 (97.9%) 5 158 (4 911 , 5 405) 0.060 1 673 (1 631 , 1 714) <0.0005* 
Yes 84 (2.1%) 3 528 (2 307 , 4 748)  745 (517 , 972)  
Myocardial infarction 
No  3 608 (90.8%) 5 057 (4 804 , 5 310) 0.021* 1 666 (1 622 , 1 710) 0.466 
Yes 367 (9.2%) 6 191 (5 261 , 7 120)  1 613 (1 492 , 1 734)  
Congestive heart failure 
No  3 577 (90.0%) 4 963 (4 704 , 5 221) <0.0005* 1 652 (1 609 , 1 695) 0.269* 
Yes 398 (10.0%) 6 951 (6 202 , 7 670)  1 743 (1 587 , 1 899)  
Peripheral vascular disease 
No  3 656 (92.0%) 5 063 (4 806 , 5 320)  0.008 1 647 (1 604 , 1 689) 0.046* 
Yes 319 (8.0%) 6 292 (5 500 , 7 084)  1 828 (1 655 , 2001)  
Cerebrovascular disease 
No  3 740 (94.1%) 5 043 (4 799 , 5 288) 0.006* 1 648 (1 605 , 1 690) 0.028* 
Yes 235 (5.9%) 7 044 (5 631 , 8 458)  1 873 (1 677 , 2 070)  
Pulmonary disease     
No  3605 (90.7%) 5 026 (4 770 , 5 282) 0.001* 1 647 (1 604 , 1 691) 0.054* 
Yes 370 (9.3%) 6 480 (5 641 , 7 319)  1 798 (1 651 , 1 945)  
Liver disease      
No  3 957 (99.6%) 5 152 (4 907 , 5 398) 0.275 1 661 (1 619 , 1 703) 0.794 
Yes 18 (0.4%) 7 187 (3 361 , 10 743)  1 743 (812 , 2 674)  
Diabetes      
No  2 829 (71.2%) 4 492 (4 215 , 4 770) <0.0005* 1 798 (1 453 , 1 543) <0.0005* 
Yes 1 146 (28.8%) 6 814 (6 321 , 7 307)  2 064 (1 976 , 2 152)  
Cancer      
No  3 810 (95.9%) 5 160 (4 907 , 5 413) 0.944 1 663 (1 621 , 1 706) 0.644 
Yes 165 (4.1%) 5 204 (4 288 , 6 120)  1 614 (1 432 , 1 796)  
Hypertension      
No  1 986 (50.0%) 5 200 (4 840 , 5 561) 0.757 1 720 (1 659 , 1 782) 0.005* 
Yes 1 989 (50.0%) 5 123 (4 790 , 5 456)  1 602 (1 546 , 1 658)  
 
*Unequal variances 
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Table 1c Transplant patient characteristics and mean inpatient and outpatient costs 
(excluding the costs of transplant surgery) during the first year of renal replacement 
therapy 
 n (%) 
Mean inpatient cost (£) 
(95% CI) 
P 
Mean outpatient cost (£)  
(95% CI) 
P 
Age group      
< 35 years 1 026 (25%)  3 941 (3 580 , 4 302) <0.0005  4 111 (3 978 , 4 246) 0.914 
36 - 45 years 1 110 (27%)  3 915 (3 568 , 4 263)   4 125 (3 996 , 4 254)  
46 - 55 years 973 (23%)  4 087 (3 716 , 4 458)   4 086 (3 948 , 4 224)  
> 55 years 1 040 (25%)  4 987 (4 628 , 5 346)   4 061 (3 928 , 4 195)  
Gender      
Male 2 589 (62.4%)  4 129 (3 908 , 4 350)  0.161*  4 073 (3 988 , 4 158) 0.373 
Female 1 560 (37.6%)  4 400 (4 092 , 4 707)   4 136 (4 027 , 4 244)  
Donor type  
Deceased 2 660 (64.1%)  4 540 (4 306 , 4 774) 
<0.0005
* 
 4 095 (4 015 , 4 176) 0.131* 
Living 1 367 (32.9%)  3 646 (3 373 , 3 919)   4 208 (4 086 , 4 331)  
Death      
No  4020 (96.9%)  4 160 (3 981 , 4 339) 0.004*  4 175 (4 108 , 4 241)  <0.0005 
Yes 129 (3.1%)  6 424 (4 906 , 7 942)   1 657 (1 292 , 2 023)  
Graft failure      
No  3 874 (93%)   4 211 (4 027 , 4 395) 0.484*  4 279 (4 213 , 4 345) <0.0005 
Yes 275 (7%)  4 508 (3 695 , 5 321)   1 526 (1 294 , 1 758)  
Myocardial infarction     
No  3 758 (91.0%)  4 015 (3 834 , 4 195) 
<0.0005
* 
 4 110 (4 040 , 4 179) 0.637* 
Yes 370 (9.0%)  6 666 (5 859 , 7 472)   4 170 (3 930 , 4 409)  
Congestive heart failure 
No  3 836 (93.9%)  4 051 (3 872 , 4 231) 
<0.0005
* 
 4 094 (4 026 , 4 163) 0.051* 
Yes 292 (7.1%)  6 892 (5 952 , 7 832)   4 385 (4 101 , 4 669)  
Peripheral vascular disease 
No  3 625 (87.8%)  3 862 (3 683 , 4 040) 
<0.0005
* 
 4 070 (4 000 , 4 139) 0.001* 
Yes 503 (12.2%)  7 067 (6 372 , 7 762)   4 443 (4 230 , 4 655)  
Cerebrovascular disease 
No  3 848 (93.2%)  4 082 (3 905 , 4 258) 
<0.0005
* 
 4 110 (4 041 , 4 179) 0.552 
Yes 280 (6.8%)  6 597 (5 534 , 7 661)   4 190 (3 937 , 4 443)  
Pulmonary disease     
No  3 562 (86.3%)  4 194 (4 002 , 4 385) 0.112  4 114 (4 042 , 4 186) 0.962 
Yes 566 (13.7%)  4 620 (4 087 , 5 153)   4 119 (3 946 , 4 292)  
Liver disease      
No  4 088 (99.0%)  4 220 (4 040 , 4400) 0.024*  4 115 (4 049 , 4 182) 0.919* 
Yes 40 (1.0%)  7 530 (4 677 , 10 384)   4 068 (3 143 , 4 994)  
Diabetes      
No  3 002 (72.7%)  3 626 (3 439 , 3 813) 
<0.0005
* 
 3 963 (3 890 , 4 036) 
<0.0005
* 
Yes 1 126 (27.3%)  5 921 (5 499 , 6 343)   4 520 (4 376 , 4 665)  
Cancer      
No  3 960 (95.9%)  4 255 (4 070 , 4441) 0.866  4 111 (4 043 , 4 179) 0.553 
Yes 168 (4.1%) 4 176 (3 381 , 4 972)   4 213 (3 876 , 4 550)  
Hypertension      
No  1 003 (24.3%)  3 300 (3 021 , 3 579) 
<0.0005
* 
 3 845 (3 722 , 3 968) 
<0.0005
* 
Yes 3 125 (75.7%)  4 558 (4 338 , 4 778)   4 202 (4 123 , 4 280)  
 
*Unequal variances 
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Table 2 Mean annual hospital costs by modality and number of years on renal 
replacement therapy (excluding the costs of maintenance dialysis and transplant surgery) 
Haemodialysis patients 
Year n 
Inpatient cost (£) 
Mean (SE) 
Outpatient cost (£)  
Mean (SE) 
Total cost (£) 
Mean (SE) 
1 12,068  7 240 (114)  1 163 (12)  8 403 (116)  
2 9,096  5 340 (95)  1 044 (13)  6 384 (98) 
3 7,614  4 844 (93)  1 069 (15)  5 913 (96) 
4 4,830  5 020 (105)  1 070 (20)  6 090 (111) 
5 2,452  5 325 (169)  1 091 (27)  6 416 (176) 
6 846  4 866 (231)  1 218 (62)  6 084 (248) 
Peritoneal dialysis patients 
Year n 
Inpatient cost (£) 
Mean (SE) 
Outpatient cost (£) 
Mean (SE) 
Total cost (£) 
Mean (SE) 
1 4,018  5 124 (124)  1 653 (21)  6 777 (129) 
2 2,897  4 140 (118)  1 407 (23)  5 547 (125) 
3 1,934  4 198 (147)  1 514 (30)  5 712 (157) 
4 1,000 4 830 (259)  1 541 (46)  6 371 (274) 
5 440 4 433 (329)  1 510 (72)  5 943 (358) 
6 137  4 859 (541)  1 484 (143)  6 343 (609) 
Transplant patients 
Year n 
Inpatient cost (£) 
Mean (SE) 
Outpatient cost (£) 
Mean (SE) 
Total cost (£) 
Mean (SE) 
1 4 149  4 231 (92)  4 097 (34)  8 327 (106) 
2 3 136  1 695 (77)  1 662 (21)  3 357 (88) 
3 2 307  1 334 (65)  1 403 (22)  2 738 (77) 
4 1 447  1 209 (77)  1 308 (27)  2 517 (91) 
5 759  1 368 (130)  1 234 (36)  2 603 (148) 
6 271  1 145 (205)  1 152 (53)  2 296 (225) 
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Table 3 Comparison of predicted inpatient and outpatient costs and renal replacement therapy costs by treatment modality over a four-year period for three 
hypothetical patients  
 
Patient 1: 25-year-old female patient with no comorbidities 
  
Haemodialysis (HD)  Peritoneal dialysis (PD)  Transplant (TX) 
  
Cost of 
HD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined HD 
and hospital 
costs (£) 
 Cost of 
PD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined PD 
and hospital 
costs (£) 
 Cost of TX 
surgery (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined TX 
and hospital 
costs (£) 
Year 1 24 804 6 204 1 295 32 303  20 440 4 250 1 745 26 435  14 832 3 452 4 019 22 302 
Year 2 24 804 4 335 1 148 30 287  20 440 3 190 1 481 25 112  0 1 206 1 472 2 678 
Year 3 24 804 3 750 1 162 29 716  20 440 3 223 1 626 25 289  0  995 1 228 2 223 
Year 4 24 804 3 699 1 202 29 705  20 440 3 417 1 673 25 530  0 908 1 139 2 047 
Total 99 216 17 989 4 807 122 011   81 760 14 080 6 526 102 366   14 832 6 561 7 858 29 251 
 
Patient 2: 50-year-old male patient with diabetes 
 Haemodialysis (HD)  Peritoneal dialysis (PD)  Transplant (TX) 
 Cost of 
HD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined HD 
and hospital 
costs (£) 
 Cost of 
PD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined PD 
and hospital 
costs (£) 
 Cost of TX 
surgery (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined TX 
and hospital 
costs (£) 
Year 1 24 804 6 739 1 504 33 047  20 440 5 677 2 140 28 257  14 832 3 637 4 319 22 788 
Year 2 24 804 4 811 1 359 30 974  20 440 4 463 1 877 26 780  0 1 223 1 770 2 993 
Year 3 24 804 4 197 1 379 30 380  20 440 4 501 2 022 26 963  0 1 013 1 526 2 539 
Year 4 24 804 4 144 1 422 30 370  20 440 4 703 2 070 27 213  0  940 1 437 2 377 
Total 99 216 19 891 5 664 124 771   81 760 19 344 8 109 109 213   14 832 6 813 9 052 30 697 
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Patient 3: 65-year-old male patient with peripheral vascular disease 
  
Haemodialysis (HD)  Peritoneal dialysis (PD)  Transplant (TX) 
  
Cost of 
HD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined HD 
and hospital 
costs (£) 
 Cost of 
PD (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined PD 
and hospital 
costs (£) 
 Cost of TX 
surgery (£)* 
Inpatient 
cost (£) 
Outpatient 
cost (£) 
Combined 
TX and 
hospital 
costs (£) 
Year 1 24 804 6 512 1 249 32 564  20 440 4 174 1 719 26 333  14 832 4 263 4 008 23 103 
Year 2 24 804 4 627 1 104 30 535  20 440 3 113 1 454 25 007  0 1 498 1 461 2 959 
Year 3 24 804 4 034 1 121 29 960  20 440 3 145 1 598 25 183  0 1 104 1 216 2 320 
Year 4 24 804 3 980 1 163 29 947  20 440 3 330 1 645 25 415  0 1 045 1 127 2 172 
Total 99 216 19 154 4 636 123 006   81 760 13 762 6 417 101 938   14 832 7 910 7 812 30 554 
 
*Fixed costs for renal replacement therapy were estimated using the following assumptions and sources: 
Haemodialysis: 2011-12 PbR tariff (HRG code LD06A = £159 per session) for satellite haemodialysis with access via arteriovenous fistula or graft 19 years and over = £159 x 3 times 
per week x 52 weeks = £ 24 804 per year 
Peritoneal dialysis:  2011-12 PbR tariff (HRG code LD12A = £56 per day) for automated peritoneal dialysis 19 years and over = £56 x 365 days = £ 20 440 per year 
Transplant surgery: NHS Reference Costs Spell Schedule 2011-12 (currency code LA02A) for kidney transplant, 19 years and over, from cadaver heart-beating donor = £ 14 832 
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APPENDIX 4: Final flexible parametric models for graft failure and waiting-list 
survival 
Table 1 Final fitted flexible parametric model for graft failure 
n = 12,289 
Scale: odds scale 
Degrees of freedom: 5 
c index = 0.61 
 
Baseline hazard (log odds scale) Coeff p-value 95% CI 
Restricted cubic spline 1 0.658 <0.001 0.630 - 0.686 
Restricted cubic spline 2 -0.149 <0.001 -0.169 - -0.128 
Restricted cubic spline 3 -0.124 <0.001 -0.136 - -0.112 
Restricted cubic spline 4 -0.041 <0.001 -0.055 - -0.027 
Restricted cubic spline 5 -0.028 <0.001 -0.039 - -0.016 
Constant -2.468 <0.001 -2.501 - -2.036 
Covariates Odds ratio p-value 95% CI 
Recipient age 18-29 Reference     
Age 30-39 0.680 <0.001 -0.586 - -0.184 
Age 40-49 0.592 <0.001 -0.717 - -0.332 
Age 50-59 0.558 <0.001 -0.781 - -0.384 
Age >=60 0.632 <0.001 -0.662 - -0.257 
HLA mismatch level 1 Reference     
Level 2  1.222 0.032 0.017 - 0.384 
Level 3  1.388 <0.001 0.148 - 0.507 
Level 4  1.485 <0.001 0.181 - 0.610 
Pre-emptive transplant       
No Reference     
Yes 0.721 0.001 -0.520 - -0.133 
Primary renal diagnosis other Reference     
Polycystic kidney disease 0.646 <0.001 -0.618 - -0.256 
Donor age <40 Reference     
40-49 1.588 <0.001 0.309 - 0.616 
50-59 1.885 <0.001 0.483 - 0.784 
> 60 2.579 <0.001 0.787 - 1.107 
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Table 2 Final fitted parametric model for death on waiting list 
n = 4366 
Scale: odds scale 
Degrees of freedom: 2 
c index = 0.67 
 
Baseline hazard (log odds scale) Coeff p-value 95% CI 
Restricted cubic spline 1 1.128 <0.001 1.080 - 1.176 
Restricted cubic spline 2 -0.155 <0.001 -0.195 - -0.115 
Constant -2.442 <0.001 -2.829 - -2.055 
Covariates Odds ratio p-value 95% CI 
Age 18-29 Reference     
Age 30-39 1.476 0.062 0.980 - 2.222 
Age 40-49 1.370 0.103 0.938 - 1.999 
Age 50-59 1.697 0.005 1.174 - 2.455 
Age >=60 2.093 <0.001 1.454 - 3.012 
Pre-emptive listing Reference     
Dialysis <1 year at activation 2.863 <0.001 2.214 - 3.253 
Dialysis 1-3 years at activation 3.523 <0.001 2.913 - 4.261 
Dialysis >3 years at activation 4.959 <0.001 3.921 - 6.273 
Male Reference     
Female 0.732 <0.001 0.642 - 0.835 
White Reference     
Asian 0.493 <0.001 0.412 - 0.591 
Black 0.366 <0.001 0.283 - 0.473 
Other 0.337 <0.001 0.223 - 0.510 
Primary renal diagnosis other Reference     
Diabetic nephropathy 2.405 <0.001 2.067 - 2.799 
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APPENDIX 5: Additional regression models to estimate health-state utility values 
 
This appendix contains a summary of additional OLS regression models to predict EQ-5D-
5L index scores in a combined population of waiting-list patients (constant, n = 1704) and 
transplant recipients at 6 months only (n = 512) from the ATTOM study. Eight different 
regression models were fitted with various combinations of predictor variables so that 
researchers undertaking cost-effectiveness analyses in ERF patients can select the 
appropriate model for their own needs based on data availability. 
 
 Coefficient 
Robust Std 
Error 
P-value 95% CI 
    
 
Model 1: transplant vs. waiting list     
     
Waiting list (constant) 0.773 0.005 <0.001 (0.762, 0.783) 
Transplant +0.054 0.011 <0.001 (0.032, 0.075) 
     
Model 2: transplant vs. waiting list, age   
    
 
Waiting list, aged 18-29 (constant)  0.814 0.015 <0.001 (0.784, 0.844) 
Age 
   
 
30-39 -0.046 0.019 0.015 (-0.084, -0.009) 
40-49 -0.049 0.018 0.008 (-0.084, -0.013) 
50-59 -0.057 0.018 0.001 (-0.092, -0.022) 
>60 -0.027 0.017 0.123 (-0.061, 0.007) 
Transplant  +0.053 0.011 <0.001 (0.032, 0.075) 
     
Model 3: transplant vs. waiting list, gender  
    
 
Waiting list, male (constant) 0.787 0.006 <0.001 (0.775, 0.800) 
Female -0.034 0.010 <0.001 (-0.052, -0.015) 
Transplant +0.053 0.011 <0.001 (0.031, 0.074) 
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Model 4: transplant vs. waiting list, diabetes 
 
 
    
 
Waiting list, non-diabetic (constant) 0.782 0.006 <0.001 (0.771, 0.793) 
Diabetic  -0.083 0.016 <0.001 (-0.115, -0.052) 
Transplant +0.054 0.011 <0.001 (0.033, 0.075) 
     
Model 5: transplant vs. waiting list, age, gender 
 
 
    
 
Waiting list, male aged 18-29 (constant) 0.829 0.016 <0.001 (0.798, 0.860) 
Age 
   
 
30-39 -0.047 0.019 0.014 (-0.084, -0.010) 
40-49 -0.048 0.018 0.008 (-0.083, -0.013) 
50-59 -0.058 0.018 0.001 (-0.093, -0.023) 
>60 -0.029 0.017 0.100 (-0.063, 0.006) 
Female -0.034 0.009 <0.001 (-0.052, -0.015) 
Transplant +0.053 0.011 <0.001 (0.031, 0.074) 
     
Model 6: transplant vs. waiting list, age, diabetes   
    
 
Waiting list, non-diabetic aged 18-29 
(constant) 
0.816 0.015 <0.001 (0.785, 0.846) 
Age 
   
 
30-39 -0.036 0.019 0.060 (-0.073, 0.002) 
40-49 -0.040 0.018 0.028 (-0.076, -0.004) 
50-59 -0.050 0.018 0.005 (-0.085, -0.015) 
>60 -0.019 0.017 0.273 (-0.053, 0.015) 
Diabetic -0.081 0.016 <0.001 (-0.113, -0.050) 
Transplant +0.054 0.011 <0.001 (0.032, 0.075) 
     
Model 7: transplant vs. waiting list, age, gender, diabetes  
    
 
Waiting list, male non-diabetic aged 18-
29 (constant) 
0.830 0.016 <0.001 (0.800, 0.861) 
Age 
   
 
30-39 -0.036 0.019 0.055 (-0.073, 0.001) 
40-49 -0.039 0.018 0.029 (-0.075, -0.004) 
50-59 -0.051 0.018 0.004 (-0.086, -0.017) 
>60 -0.021 0.017 0.233 (-0.055, 0.013) 
Diabetic -0.081 0.016 <0.001 (-0.112, -0.049) 
Female -0.033 0.009 <0.001 (-0.052, -0.015) 
Transplant +0.053 0.011 <0.001 (0.032, 0.074) 
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Model 8: transplant vs. waiting list, age, gender, diabetes, ethnicity  
    
 
Waiting list, male non-diabetic, non-
Asian aged 18-29 (constant) 
0.837 0.016 <0.001 (0.807, 0.868) 
Age 
   
 
30-39 -0.038 0.019 0.045 (-0.075, -0.001) 
40-49 -0.043 0.018 0.018 (-0.078, -0.007) 
50-59 -0.054 0.018 0.002 (-0.089, -0.020) 
>60 -0.025 0.017 0.152 (-0.059, 0.009) 
Female -0.033 0.009 <0.001 (-0.051, -0.015) 
Diabetic -0.078 0.016 <0.001 (-0.110, -0.046) 
Asian ethnicity -0.040 0.018 0.024 (-0.074, -0.005) 
Transplant +0.051 0.011 <0.001 (0.029, 0.072) 
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APPENDIX 6: Description of Visual Logic code in the simulation model 
SIMUL8, the software used to develop the kidney allocation model described in Chapter 5 
of this thesis, is based on its own proprietary internal programming language known as 
Visual Logic. For interested readers, this appendix contains a summary of how Visual 
Logic code has been used in the simulation model. Rather than reproducing all of the 
Visual Logic code here (which would be over 100 pages and not very informative without 
the model and data inputs to hand), this appendix provides a summary of the comments 
that were documented to describe how the model was constructed and the purpose of 
each section of code. The figure on the following page indicates where each section of 
Visual Logic code has been applied in the model.  
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SIMUL8 model of kidney allocation schemes indicating where Visual Logic code applies 
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1. Load prevalent patients Route In After Logic 
 
 ‘At the beginning of the simulation run, load 5500 patients from spreadsheet 
containing one patient per row with labels in columns for each characteristic 
 ‘For each patient record waiting time at start 
 ‘For each patient record time on dialysis at start 
 ‘For each patient record age at start 
 
2. Kidney for allocation On Entry Logic  
 
 'Obeyed just after a work item (kidney) enters the Queue 
 'Capacity of queue is 1 so that only one kidney is allocated at a time 
 IF gbl_allocation_scheme  =  1 
o 'Random allocation 
o CALL Proc_hla_matching 
o CALL Proc_blood_group_matching 
o CALL Proc_location_matching 
o CALL Proc_all_scheme1 (see section 2.1) 
 IF gbl_allocation_scheme  =  2 
o 'Waiting time 
o CALL Proc_hla_matching 
o CALL Proc_blood_group_matching 
o CALL Proc_location_matching 
o CALL Proc_all_scheme2 (see section 2.2) 
 IF gbl_allocation_scheme  =  3 
o 'Current national kidney allocation scheme 
o CALL Proc_hla_matching 
o CALL Proc_blood_group_matching 
o CALL Proc_location_matching 
o CALL Proc_hla_age_combined 
o CALL Proc_age_difference 
o CALL Proc_all_scheme3 (see section 2.3) 
 IF gbl_allocation_scheme  =  4 
o 'Longveity matching (top 20% KDRI restricted to top 20% EPTS) 
o CALL Proc_hla_matching 
o CALL Proc_blood_group_matching 
o CALL Proc_location_matching 
o CALL Proc_hla_age_combined 
o CALL Proc_age_difference 
o CALL Proc_epts_calculation (see section 2.4a) 
o CALL Proc_all_scheme4 (see section 2.4b) 
 IF gbl_allocation_scheme  =  5 
o 'QALY maximisation 
o CALL Proc_hla_matching 
o CALL Proc_blood_group_matching 
o CALL Proc_qaly_max_calculation (see section 2.5a) 
o CALL Proc_all_scheme5 (see section 2.5b) 
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2.1  Proc_all_scheme1 (random) 
 'Loop through all patients on the waiting list to identify which patients are 
eligible for matching based on HLA and blood group compatibility 
 'Set priority based on combination of HLA mismatch level and location 
 'If patient is blood group incompatible (0) and/or hla incompatible (1), set 
priority to 0 (not eligible to receive kidney) 
 'Exclude Level 4 HLA mismatches (NHSBT) 
 'Identify the number of patients with the highest score and store this in a global 
variable 
 'For patient(s) with highest score, set lbl_match = 1 
 'In the event that no match on the waiting list is found (e.g. rare blood or HLA 
type), move kidney to “No match identified” 
 'Otherwise create a distribution in which all patients with highest score have 
equal probability of receiving the kidney 
 'Create a spreadsheet with list of all eligible recipient ids based on current 
allocation scheme and number rows consecutively 
 'Sample from distribution and match to row number in spreadsheet to select 
one patient from all eligible patients to receive kidney 
 'Loop through waiting list and change lbl_match_select = 1 for the patient who 
will receive the kidney; this label is used to match recipient and donor kidney 
2.2  Proc_all_scheme2 (waiting time) 
 'Identify all patients who are eligible for matching based on HLA and blood 
group compatibility 
 'Set priority based on combination of HLA mismatch level and location 
 'If patient is blood group incompatible (0), hla incompatible (1), set priority to 0 
(not eligible to receive kidney) 
 'Exclude Level 4 HLA mismatches (NHSBT) 
 'Identify the number of patients with the highest score (lbl_priority) and longest 
waiting time (lbl_rwait) store this in a global variable 
 'For patient(s) with highest priority, set lbl_match = 1 
 'Identify the longest waiting time for patients with lbl_match = 1 
 'Identify all patients that have the maximum value for waiting time 
 'In the event that no match on the waiting list is found (e.g. rare blood or HLA 
type), move kidney to “No match identified” 
 'Otherwise create a distribution in which all patients with highest score have 
equal probability of receiving the kidney 
 'Create a spreadsheet with list of all eligible patients based on current 
allocation criteria and number rows consecutively 
 'Sample from distribution and match to row number in spreadsheet to select 
one patient from all eligible patients to receive kidney 
 'Loop through waiting list and change lbl_match_select = 1 for the patient who 
will receive the kidney; this label is used to match recipient and donor kidney 
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2.3 Proc_all_scheme3 (current national kidney allocation scheme) 
 'Assign indicator for HSP and/or HLA-DR homozygosity 
 'Assign 500 points for HLA-DR homozygosity but not 000 mismatch 
 'Assign 100 points for HLA-B homozygosity but not 000 mismatch 
 'Create tiers C to E (no paediatric patients) 
 'Assign lbl_priority = 3 to patients in Tier C (000 mismatch, HSP or HLA-DR 
homozygous) 
 'Assign lbl_priority = 2 to patients in Tier D (000 mismatched other) 
 'Assign lbl_priority = 1 to all other patients in Tier E 
 'Assign lbl_priority = 0 to patients who are blood group and/or HLA 
incompatible 
 'Exclude Level 4 HLA mismatches (NHSBT) 
 'Calculate total points for each patient within each tier 
 'Identify most favourable tier and highest points 
 'Loop through all patients on the waiting list to identify those in preferred tier 
with maximum score and set lbl_match = 1 
 'In the event that no match on the waiting list is found (e.g. rare blood or HLA 
type), move kidney to “No match identified” 
 'Otherwise create a distribution in which all patients with highest score have 
equal probability of receiving the kidney 
 'Create a spreadsheet with list of all eligible patients based on current 
allocation criteria and number rows consecutively 
 'Sample from distribution and match to row number in spreadsheet to select 
one patient from all eligible patients to receive kidney 
 'Loop through waiting list and change lbl_match_select = 1 for the patient who 
will receive the kidney; this label is used to match recipient and donor kidney 
2.4a  Proc_epts_calculation 
 'Convert donor age into categorical variable 
 'Copy current donor characteristics to EPTS calculation spreadsheet 
 'Calculate linear predictor for donor variables to use in regression to predict 
EPTS for each patient on the waiting list 
 'Calculate EPTS score for each patient on the waiting list and store in separate 
spreadsheet 
 'Calculate linear predictor for each patient according to flexible parametric 
post-transplant survival regression model 
 'After looping through all waiting list patients for a given kidney, determine 
which recipients have top 20% EPTS scores and reassign lbl_epts20 = 1 
2.4b Proc_all_scheme4  
 'If donor kidney is in the top 20% KDPI, only allocate to waiting list patients 
with top 20% EPTS 
o CALL Proc_all_scheme4_kdri20_yes (see section 2.4b.1) 
 'If donor kidney is not in top 20% KDPI (or if no match can be found in patients 
with top 20% EPTS), consider all patients irrespective of EPTS score 
o CALL Proc_all_scheme4_kdri20_no (see section 2.4b.2) 
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2.4b.1  Proc_all_scheme4_kdri20_yes   
 'Assign indicator for HSP and/or HLA-DR homozygosity 
 'Assign 500 points for HLA-DR homozygosity but not 000 mismatch 
 'Assign 100 points for HLA-B homozygosity but not 000 mismatch 
 'Create tiers C to E (no paediatric patients) 
 'Assign lbl_priority = 3 to patients in Tier C (000 mismatch, HSP or HLA-
DR homozygous) 
 'Assign lbl_priority = 1 to all other patients in Tier E 
 'Assign lbl_priority = 0 to patients who are blood group and/or HLA 
incompatible and/or who do not have top 20% EPTS score 
 'Exclude Level 4 HLA mismatches (NHSBT) 
 'Only allow patients with top 20% EPTS score to receive kidney 
 'Identify most favourable tier and highest points 
 'Loop through all patients on the waiting list to identify those in preferred 
tier with maximum score and set lbl_match = 1 
 'In the event that no match among patients with top 20% is found on 
waiting list, expand to all patients 
 'Otherwise create a distribution in which all patients with highest score 
have equal probability of receiving the kidney 
 'Create a spreadsheet with list of all eligible patients based on current 
allocation criteria and number rows consecutively 
 'Sample from distribution and match to row number in spreadsheet to 
select one patient from all eligible patients to receive kidney 
 'Loop through waiting list and change lbl_match_select = 1 for the patient 
who will receive the kidney; this label is used to match recipient and donor 
kidney 
 2.4b.2 Proc_all_scheme4_kdri20_no 
 'Assign indicator for HSP and/or HLA-DR homozygosity 
 'Assign 500 points for HLA-DR homozygosity but not 000 mismatch 
 'Assign 100 points for HLA-B homozygosity but not 000 mismatch 
 'Create tiers C to E (no paediatric patients) 
 'Assign lbl_priority = 3 to patients in Tier C (000 mismatch, HSP or HLA-
DR homozygous) 
 'Assign lbl_priority = 2 to patients in Tier D (000 mismatched other) 
 'Assign lbl_priority = 1 to all other patients in Tier E 
 'Assign lbl_priority = 0 to patients who are blood group and/or HLA 
incompatible 
 'Exclude Level 4 HLA mismatches (NHSBT) 
 'Set one label value for each patient to reflect score in any tier 
 'Identify most favourable tier and highest points 
 'Loop through all patients on the waiting list to identify those in preferred 
tier with maximum score and set lbl_match = 1 
 'In the event that no match on the waiting list is found (e.g. rare blood or 
HLA type), move kidney to “No match identified” 
 197 
 
 'Otherwise create a distribution in which all patients with highest score 
have equal probability of receiving the kidney 
 'Create a spreadsheet with list of all eligible patients based on current 
allocation criteria and number rows consecutively 
 'Sample from distribution and match to row number in spreadsheet to 
select one patient from all eligible patients to receive kidney 
 'Loop through waiting list and change lbl_match_select = 1 for the patient 
who will receive the kidney; this label is used to match recipient and donor 
kidney 
2.5a Proc_qaly_max_calculation  
 'Convert donor age into categorical variable 
 'Copy current donor characteristics to transplant QALY calculation 
spreadsheet 
 'Calculate linear predictor for donor variables to use in regression to predict 
QALYs for each patient  
 'Loop through each potential recipient on waiting list 
o 'Calculate linear predictor for each patient according to flexible 
parametric post-transplant survival regression model 
o 'Calculate health state utility for each patient according to transplant 
regression model 
o 'Calculate expected QALYs following transplant for each patient 
o 'Calculate linear predictor for each patient according to flexible 
parametric waiting list survival regression model 
o 'Calculate health state utility for each patient according to waiting list 
regression model allowing utility to change with time on dialysis 
 'For each patient, calculate QALY gain from transplant vs. remaining on 
waiting list and output to a separate spreadsheet 
 
2.5b Proc_all_scheme5 
 'This version of the QALY maximisation scheme prioritises Level 1 (000) 
mismatches vs all other levels  
 'If patient is blood group incompatible (0), hla incompatible (1), set priority to 0 
(not eligible to receive kidney) 
 'Exclude Level 4 HLA mismatches (NHSBT) 
 'Identify the top tier with patients who are potential matches 
 'Identify value of maximum QALY gain for each tier 
 'Loop through all patients on the waiting list to identify those in preferred tier 
with maximum QALY gain and set lbl_match = 1 
 'Create a distribution in which all patients with highest score have equal 
probability of receiving the kidney 
 'Create a spreadsheet with list of all eligible patients based on current 
allocation criteria and number rows consecutively 
 'Sample from distribution and match to row number in spreadsheet to select 
one patient from all eligible patients to receive kidney 
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 'Loop through waiting list and change lbl_match_select = 1 for the patient who 
will receive the kidney; this label is used to match recipient and donor kidney 
 
3.  Active waiting list On Exit Logic 
 
 'Obeyed just after a work item exits the Queue but before it begins travelling to the 
next object 
 'Each time a patient on the waiting list receives a kidney, add one new patient 
selected at random (with waiting time set to zero) 
 
4.  Post transplant outcome Route In After Logic 
 
 'Recipient and donor characteristics now combined into single work item 
 'Record running total of number of transplants 
 'Record patient age at time of transplant 
 'Record cost of surgery 
 'Record HLA mismatch level 
 'Calculate time to next event (graft failure or death) 
o CALL Proc_post_tx_competing_risk (see section 4.1) 
4.1   Proc_post_tx_competing_risk  
 'Generate patient-specific survival curves for graft failure and death events to 
sample from in order to determine which event will happen first 
 'Calculate linear predictor for each time point on the graft failure survival curve 
(proportional odds scale) 
 'Calculate linear predictor for each time point on the patient death survival 
curve (proportional hazards scale) 
 'Sample from uniform distribution for graft failure event 
 'Loop through survival probabilities for graft failure event until the sample value 
is less than or equal to survival probability; take corresponding time as the 
time to graft failure event 
 'Sample from uniform distribution for patient death event 
 'Loop through survival probabilities for patient death event until the sample 
value is less than or equal to survival probability; take corresponding time as 
the time to patient death 
 'Determine which event occurs first (graft failure or death) and route patient 
accordingly 
 
5.  Queue graft failure On Entry Logic  
 
 'If patient experiences graft failure, assume patient returns to dialysis / waiting list 
(in absence of robust model to estimate death after graft failure) 
 ‘Calculate survival after graft failure by sampling from waiting list (dialysis) survival 
curve; compare this to previously sampled estimate of transplant to death and use 
the smaller of the two values 
o 'Calculate patient age at time of graft failure (lbl_rage only updated while 
patient remains in Waiting List Queue) 
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o 'Re-categorise into age groups based on age updated at time of graft 
failure 
o 'Assume all patients equivalent to having been on dialysis >3 years 
 'Sample from uniform distribution for death after graft failure 
 'Loop through survival probabilities for patient death on waiting list until the sample 
value is less than or equal to survival probability; take corresponding time as the 
time to patient death 
 'Calculate discounted life years (using continuous discounting assuming utility 
equivalent to >3 years on dialysis) 
 'Calculate QALYs and discounted QALYs for period between graft failure and 
death 
 
6.  Graft failure Route In After Logic  
 
 'Calculate QALYs and discounted QALYs prior to transplant 
o CALL Proc_qalys_pre_tx (see section 8.1) 
 'Calculate QALYS and discounted QALYs between transplant and graft failure 
 'Calculate costs and discounted costs prior to transplant 
o CALL Proc_cost_pre_tx (see section 8.2) 
 'Calculate costs and discounted costs after transplant but before graft failure 
o CALL Proc_cost_tx_graft (see section 8.3) 
 'Calculate costs and discounted costs after graft failure until death 
o CALL Proc_cost_post_graft (see section 8.4) 
 
7.  Queue post transplant survival On Entry Logic  
 
 'Calculate QALYs and discounted QALYs for period on dialysis prior to transplant 
o CALL Proc_qalys_pre_tx (see section 8.1) 
 'Calculate QALYs and discounted QALYs for period between transplant and death  
 'Calculate costs and discounted costs for period on dialysis prior to transplant 
o CALL Proc_cost_pre_tx (see section 8.2) 
 'Calculate costs and discounted costs for period between transplant and death 
o CALL Proc_cost_post_tx (see section 8.5) 
 
8.1 Proc_qalys_pre_tx  
 'Calculate time spent on waiting list prior to transplant 
 'Calculate time spent on dialysis prior to transplant 
 'Quality adjust time while on the waiting list prior to transplant using health state 
utility regression model 
 'Calculate total QALYs and discounted QALYs prior to transplant 
8.2  Proc_cost_pre_tx  
 'Use two-part models to estimate hospital costs while on waiting list prior to 
transplant (for all transplant recipients) 
 'Create label to increment age for calculating costs during pre-transplant period 
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 'Calculate non-varying components of linear predictor using logistic regression for 
inpatient costs 
 'Calculate non-varying components of linear predictor using glm for inpatient costs 
 'Calculate non-varying components of linear predictor using logistic regression for 
outpatient costs 
 'Calculate non-varying components of linear predictor using glm for outpatient 
costs 
 'Determine modality for calculating annual dialysis costs 
 'If time on waiting list prior to transplant is less than 1 year, calculate portion of 
year alive 
o 'If patient has not yet started dialysis, set pre-transplant cost multiplier = 0 
o 'Calculate time on dialysis component of linear predictor 
o 'Categorise age into groups using age at entry to waiting list 
o 'Calculate total pretx inpatient costs (assuming patient receives transplant 
the same year) 
o 'Calculate total pretx outpatient costs (assuming patient receives 
transplant the same year) 
o 'Write local variable values to spreadsheet 
o 'Calculate costs and discounted costs during pretx period 
 'If time on waiting list is more than one year, create one row to estimate costs for 
each year prior to transplantation 
o 'If patient has not yet started dialysis, set pre-transplant cost multiplier = 0 
o 'Calculate time on dialysis component of linear predictor 
o 'Categorise age into groups using age at entry to waiting list 
o 'Calculate age component of linear predictor 
o 'Calculate total pretx inpatient costs 
o 'Calculate total pretx outpatient costs 
o 'Write local variable values to spreadsheet 
o 'Calculate costs for each row (year) 
o 'Calculate discounted costs for each row (year) 
o 'Before calculating utility for next row (year), increment time on dialysis by 
365 days 
o 'Before calculating utility for next row (year), increment recipient age by 1 
year 
o 'In the final row, calculate costs for the portion of the year before transplant 
o 'Calculate costs and discounted costs during pretx period 
8.3 Proc_cost_tx_graft  
 'Use two-part models to estimate hospital costs between transplant and graft 
failure 
 'Set age to age at time of transplant and then increment this label with each year 
 'Calculate non-varying components of linear predictor using logistic regression for 
inpatient costs 
 'Calculate non-varying components of linear predictor using glm for inpatient costs 
 'Calculate non-varying components of linear predictor using logistic regression for 
outpatient costs 
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 'Calculate non-varying components of linear predictor using glm for outpatient 
costs 
 'If patient experiences graft failure less than 1 year after transplant, calculate 
portion of year 
o 'Calculate age component of linear predictor 
o 'Calculate inpatient costs (assuming graft failure occurs that year) 
o 'Calculate outpatient costs (assuming graft failure occurs that year) 
o 'Write local variable values to spreadsheet 
o 'Calculate costs and discounted costs between transplant and graft failure 
 'If time to graft failure is more than one year, create one row to estimate costs for 
each year until graft failure 
o 'Calculate time since transplant component of linear predictor 
o 'Categorise age into groups using age at time of transplant 
o 'Calculate post-transplant inpatient costs for the year 
o 'Write local variable values to spreadsheet 
o 'Calculate costs for each row (year) 
o 'Calculate discounted costs for each row (year) 
o 'Before calculating costs for next row (year), increment recipient age by 1 
year 
o 'In the final row, calculate costs for the portion of the year before death 
o 'Add in the graft failure component of the linear predictor to the final full 
year of costs 
o 'Calculate costs and discounted costs between transplant and graft failure 
8.4  Proc_cost_post_graft  
 'Use two-part models to estimate hospital costs between graft failure and death 
 'Use expected post-graft failure time to death to calculate costs by year 
 'Set age to age at time of transplant and then increment this label with each year 
 'Calculate non-varying components of linear predictor using logistic regression for 
inpatient costs 
 'Calculate non-varying components of linear predictor using glm for inpatient costs 
 'Calculate non-varying components of linear predictor using logistic regression for 
outpatient costs 
 'Calculate non-varying components of linear predictor using glm for outpatient 
costs 
 'Determine modality for calculating annual dialysis costs 
 'If patient dies less than 1 year after graft failure, calculate proportion of year alive 
o 'Following graft failure, assume all patients incur costs equivalent to the 
greatest number of years on dialysis in the regression model 
o 'Categorise age into groups using age at time of graft failure 
o 'Calculate total inpatient costs (assuming patient dies the same year) 
o 'Calculate total outpatient costs (assuming patient dies the same year) 
o 'Write local variable values to spreadsheet 
o 'Calculate costs and discounted costs between graft failure and death  
 'If time to death is more than one year, create one row to estimate costs for each 
year until death 
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o 'Following graft failure, assume all patients incur costs equivalent to the 
greatest number of years on dialysis in the regression model 
o 'Categorise age into groups using age at time of graft failure 
o 'Calculate total post-graft failure inpatient costs 
o 'Calculate total post-graft failure outpatient costs 
o 'Write local variable values to spreadsheet 
o 'Calculate costs for each row (year) 
o 'Calculate discounted costs for each row (year) 
o 'Before calculating costs for next row (year), increment recipient age by 1 
year 
o 'In the final row, calculate costs for the portion of the year before death 
o 'Add in the death component of the linear predictor to the final full year of 
costs 
o 'Calculate costs and discounted costs between graft failure and death 
8.5  Proc_cost_post_tx  
 'Use two-part models to estimate hospital costs between transplant and death (for 
patients who do not experience graft failure) 
 'Set age to age at time of transplant and then increment this label with each year 
 'Calculate non-varying components of linear predictor using logistic regression for 
inpatient costs 
 'Calculate non-varying components of linear predictor using glm for inpatient costs 
 'Calculate non-varying components of linear predictor using logistic regression for 
outpatient costs 
 'Calculate non-varying components of linear predictor using glm for outpatient 
costs 
 'If patient dies less than 1 year after transplant, calculate portion of year alive 
o 'Categorise age into groups using age at time of transplant 
o 'Calculate age component of linear predictor 
o 'Calculate inpatient costs (assuming patient dies the same year) 
o 'Calculate outpatient costs (assuming patient dies the same year) 
o 'Write local variable values to spreadsheet 
o 'Calculate costs and discounted costs between transplant and death 
 'If time to death is more than one year, create one row to estimate costs for each 
year until death 
o 'Categorise years since transplant as dummy variables 
o 'Categorise age into groups using age at time of transplant 
o 'Calculate post-transplant inpatient costs for the year 
o 'Calculate post-transplant outpatient costs for the year 
o 'Write local variable values to spreadsheet 
o 'Calculate costs for each row (year) 
o 'Calculate discounted costs for each row (year) 
o 'Before calculating costs for next row (year), increment recipient age by 1 
year 
o 'In the final row, calculate costs for the portion of the year before death 
o 'Add in the death component of the linear predictor to the final full year of 
costs 
o 'Calculate costs and discounted costs between transplant and death 
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9. Queue for Death On Entry Logic 
 
 'Obeyed just after a work item enters the Queue 
 'For each transplant recipient, record individual patient characteristics to 
spreadsheet to facilitate checks and report results 
 'For each transplant recipient, calculate total pathway life years, costs and QALYs  
 
10.  End Run Logic  
 
 'Obeyed when the simulation reaches end of "Results Collection Period" 
 'Calculate QALYs for patients who remain on the waiting list at the end of the 
model 
 'Calculate costs for patients who remain on the waiting list at the end of the model 
o CALL Proc_cost_no_tx (see section 10.1) 
 ‘For each patient who did not receive a transplant, record individual patient 
characteristics to spreadsheet to facilitate checks and report results  
 ‘For each patient who did not receive a transplant, calculate life years, costs and 
QALYs 
 'Generate KPIs, life years, QALYs and costs for patients who received a transplant 
o CALL Proc_results_tx (see section 10.2) 
 'Generate KPIs, life years, QALYs and costs for patients who did not receive a 
transplant 
o CALL Proc_results_no_tx (see section 10.3) 
 'Generate combined life years, QALYs and costs for tx and no tx patients 
 
10.1  Proc_cost_no_tx  
 'Use two-part models to estimate hospital costs for patients who remain on the 
waiting list 
 'Create label to increment age for calculating costs until death 
 'Calculate non-varying components of linear predictor using logistic regression for 
inpatient costs 
 'Calculate non-varying components of linear predictor using glm for inpatient costs 
 'Calculate non-varying components of linear predictor using logistic regression for 
outpatient costs 
 'Calculate non-varying components of linear predictor using glm for outpatient 
costs 
 'Determine modality for calculating annual dialysis costs 
 'If time to death is less than 1 year 
o 'If patient has not yet started dialysis, set pre-transplant cost multiplier = 0 
o 'Calculate time on dialysis component of linear predictor 
o 'Categorise age into groups using age at entry to waiting list 
o 'Calculate age component of linear predictor 
o 'Calculate total inpatient costs (assuming the patient dies the same year) 
o 'Calculate total outpatient costs (assuming patient dies the same year) 
o 'Write local variable values to spreadsheet 
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o 'Calculate costs and discounted costs assuming patient never receives 
transplant 
 'If time to death is more than one year, create one row to estimate costs for each 
year prior to death 
o 'If patient has not yet started dialysis, set pre-transplant cost multiplier = 0 
o 'Calculate time on dialysis component of linear predictor 
o 'Categorise age into groups using age at entry to waiting list 
o 'Calculate age component of linear predictor 
o 'Calculate total pretx inpatient costs 
o 'Write local variable values to spreadsheet 
o 'Calculate costs for each row (year) 
o 'Calculate discounted costs for each row (year) 
o 'Before calculating utility for next row (year), increment time on dialysis by 
365 days 
o 'In the final row, calculate costs for the portion of the year before transplant 
o 'Add in the death component of the linear predictor to the final full year of 
costs 
o 'Calculate costs and discounted costs assuming patient never receives 
transplant 
10.2 Proc_results_tx 
 'Record summary characteristics for all patients who received a transplant in a 
spreadsheet 
o 'Average recipient age 
o 'Recipient blood group 
o ‘Recipient ethnicity 
o 'Proportion recipient HSP 
o 'Proportion recipient diabetic (PRD) 
o 'Proportion top 20% EPTS (allocation scheme 4 only) 
o 'Average QALY gain (allocation scheme 5 only) 
o 'Average waiting time 
o 'Average time on dialysis 
o 'Proportion HLA mismatch level 1 
o 'Proportion HLA mismatch level 2 
o 'Proportion HLA mismatch level 3 
o 'Proportion HLA mismatch level 4 
o 'Proportion pre-emptive transplant 
o 'Proportion graft failure 
o 'Average time to transplant within simulation time 
o 'Average time to graft failure 
o 'Average graft failure to death 
o 'Average time to death 
o 'Average inpatient cost 
o 'Average outpatient cost 
o 'Average dialysis cost 
o 'Average drug cost 
o 'Average total cost 
o 'Average total life years 
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o 'Average total QALYs 
o 'Total life years 
o 'Total QALYs 
o 'Total costs 
o 'Total discounted life years 
o 'Total discounted QALYs 
o 'Total discounted costs 
10.3  Proc_results_no_tx  
 'Record summary characteristics for all patients who did not receive a not receive 
a transplant in a spreadsheet 
o ‘Average recipient age 
o 'Recipient blood group 
o 'Recipient ethnicity 
o 'Proportion recipient female 
o 'Proportion recipient HSP 
o 'Proportion recipient diabetic (PRD) 
o 'Average waiting time 
o 'Average time on dialysis 
o 'Average inpatient cost 
o 'Average outpatient cost 
o 'Average dialysis cost 
o 'Average total costs 
o 'Average life years 
o 'Average total QALYs 
o 'Total life years 
o 'Total QALYs 
o 'Total costs 
o 'Total discount life years 
o 'Total discounted QALYs 
o 'Total discounted costs 
 
11.  Time Check Logic  
 
 'For all patients on the waiting list, increment waiting time and time on dialysis 
each day 
 'For all patients on the waiting list, increment age by 1 year after 365 days 
 
